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The failure of mammalian CNS neurons to regenerate their axons derives from a 
combination of intrinsic deficits and extrinsic obstacles. Following injury, chondroitin sulfate 
proteoglycans (CSPGs) accumulate within the glial scar that forms at the lesion site in 
response to the insult. CSPGs inhibit axonal growth and regeneration, an action mediated by 
their sulfated glycosaminoglycan (GAG) chains, especially those with 4-sulfated (4S) sugars. 
Arylsulfatase B (ARSB) selectively cleaves 4S groups from the non-reducing ends of GAG 
chains without disrupting other, potentially growth-permissive motifs. In this thesis, 
“Modifying Chondroitin Sulfation Enhances Retinal Ganglion Cell Axon Regeneration,” I, 
Craig Pearson, seek to determine the time course and spatial distribution of CSPG 
accumulation in the glial scar following acute injury, and then to demonstrate that ARSB is 
effective in reducing the inhibitory actions of CSPGs. I examine the effects of ARSB in an in 
vitro model of the glial scar and in vivo, using optic nerve crush (ONC) in adult mice. ARSB 
is clinically approved for replacement therapy in patients with mucopolysaccharidosis VI and 
therefore represents an attractive candidate for translation to the human CNS. My findings 
illustrate the importance of CSPGs as a barrier to axon extension following injury, and show 
compelling evidence that selective modification of the sulfation pattern on GAG chains 
results in significant enhancement of RGC axonal regeneration. Finally, I combine ARSB 
treatment with a host of intrinsic pro-regenerative stimuli and show robust, long-distance 
regeneration of RGC axons through the optic chiasm and into the optic tract. Taken together, 
the results of this thesis argue for the therapeutic potential of modifying the extracellular 
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I don’t remember any of the wishes I’ve made over birthday cakes. I toss coins into 
fountains and watch meteors skim the edge of the atmosphere, and then, as soon as the 
moment passes, I forget whatever it was I wanted. These wishes are fleeting, not fixed. So 
when, on a recent visit to Tokyo, I came across hundreds of prayer tablets hanging in neat 
rows around a camphor tree at the Meiji Jingu shrine, I was captivated. I spent an hour 
reading them. What struck me was the language—how people ask for the things they want 
most deeply. It felt like hearing someone’s whispered thoughts the moment before the 
candles are blown out. 
The prayers were all personal, and, at first glance, rather generic. Everyone wanted 
love, health, and happiness; nobody asked the gods to end climate change or resolve 
international conflicts. But between the lines, they bristled with unexpected details. One 
person wrote: “I wish my vitiligo would slowly disappear.” Another, in a brisk scrawl: “I 
wish to grow old with Linda. I wish for Philip to one day get his vision back.” Slowly. One 
day. Here, I thought, are people who don’t want to ask for too much. They’re hopeful, but 
patient. They’re willing to wait. 
As someone whose research explores how we might someday regenerate cells in the 
visual system to restore people’s sight, I read that second wish with a pang. I thought about 
the work that comprises my doctoral dissertation and asked myself: have my efforts brought 
that “one day” any closer? It’s impossible to know. 
This thesis represents the work of four years, and in a way, it is also the fulfillment of 
a wish. Shortly after I moved to Washington, DC, for the second half of my PhD, a lab 
colleague took us to a New Year festival hosted by the local Japanese cultural society. We 
played traditional games and ate food while taiko drummers performed on the main stage. I 
noticed next to the stage a large round doll with a bushy beard and blank white eyes. When I 
asked what it represented, Sayuri told me it was a daruma, a totem that reminds you of a 
commitment you’ve made. You color in his left eye when you set the goal and fill in the right 
eye once you’ve achieved it. I bought a miniature daruma for a few dollars. Later, at my desk 
in the lab, I drew in the left eye. 
My goal was straightforward: to publish my research in a reputable scientific journal. 
Anything more ambitious—curing blindness, changing lives—would have felt absurd. When 
I bought my daruma doll, I’d already spent more than two years learning techniques and 
acquiring preliminary data for a set of experiments that might, if successful, move the needle 
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of knowledge by a fraction of a degree. The progress of science often feels geologically slow. 
Setting and celebrating achievable goals along the way makes it possible to keep going. And 
yet, behind all that, there are people like Phillip, whoever he is, living out there in the wider 
world, aware—perhaps acutely, perhaps only vaguely—that people like me are working to 
develop technologies that might change the way they see. Something tells me he wouldn’t be 
particularly concerned with which journal my work gets published in. 
In May, I attended the annual meeting of the Association for Research in Vision and 
Ophthalmology to present my findings. In addition to meeting fellow researchers and 
physicians, I spoke with several patients living with eye disease and low vision. “Keep doing 
what you’re doing,” some of them told me. Also: “Work harder.” A week later I was in 
Tokyo, exchanging revisions of a paper with my supervisor twelve time zones away. We had 
calls in the morning and evening, and in between, I wandered museums taking notes on my 
phone and walked through parks eavesdropping on conversations I couldn’t understand. A 
few hours before my flight home, I stopped by the Meiji Jingu shrine and read the wishes at 
the camphor tree. Not long after I landed, I got an email that our paper had been accepted. 
At my desk, I filled in the right eye of the daruma doll and thought. There, I thought. 
Your sight has been restored. Now what? 
At the New Year, daruma dolls are burned alongside prayer tablets and other 
talismans in a ceremonial fire, whether or not the goal they carry has been met. It’s a 
cleansing and a renewal. I’ve been thinking about this recently, about what I’ll wish for if I 
happen to pick up another daruma doll, or the next time I pass a fountain or see a shooting 
star. I understand, now, the value of thinking on a different scale. I can imagine coloring in an 
eye and setting the daruma on my desk, as before. And maybe next year I’ll throw it into the 
fire unfulfilled—and again the next year, and the next, and the next. Somehow, this doesn’t 
feel like failure. 
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beneficiary; together, they have made my PhD an intellectually stimulating and enjoyable 
experience. I am forever grateful for their commitment to me and to this project. They have 
gone above and beyond to provide me with opportunities for scientific and professional 
development, and I hope to do them proud as I move forward with my career. Keith’s 
example has shown me that it is possible to balance meaningful scientific research with 
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CHAPTER 1: INTRODUCTION 
 
1.1  |  OVERVIEW 
 
The sense of sight enables people to perceive and respond to their surroundings, and 
is profoundly connected to many aspects of the human experience. Conditions that affect the 
visual system are a major global health concern, afflicting hundreds of millions of people 
worldwide. Degenerative diseases of the retina and optic nerve that lead to permanent visual 
impairment or blindness can severely reduce quality of life and have an enormous economic 
and emotional impact on patients, their caregivers, and society at large. Vision loss often 
occurs after retinal ganglion cell (RGC) axons, which connect the eye to the brain via the 
optic nerve, are damaged. Currently, no therapies exist that effectively promote regeneration 
of RGC axons to reconnect with their targets in the brain and restore vision. RGCs fail to 
regrow after injury for two primary reasons: 1) they lack the intrinsic growth factors 
necessary for regeneration, and 2) the extracellular environment in the optic nerve impedes 
axon regrowth. Previous work has shown that axon regeneration can be stimulated by altering 
the intrinsic growth state of RGCs, but few studies have adequately addressed the inhibitory 
factors in the optic nerve environment. A key aspect of this extracellular environment is the 
glial scar, which forms when astrocytes become reactive after injury and also includes 
activated microglia, macrophages, and extracellular matrix (ECM) molecules such as 
chondroitin sulfate proteoglycans (CSPGs). CSPGs are inhibitors of neuron growth that serve 
important roles as repulsive guidance cues during development and restrict plasticity in the 
brain during adulthood. CSPGs are also expressed following injury to central nervous system 
tissue, and in this context, they act as a barrier to regenerating axons. Removing or modifying 
CSPGs has the potential to reduce this inhibition and enable more robust axon regeneration 
following injury. The aims of this PhD were to investigate the cellular and molecular 
responses to optic nerve injury with a specific focus on CSPGs, and to develop an enzyme-
based therapy that targets CSPGs to enhance RGC axon regeneration in the presence of an 
intrinsic growth-promoting stimulus. Answering these questions will enable future therapies 
to overcome both intrinsic and extrinsic barriers to axon growth in the optic nerve, paving the 




1.2  |  ANATOMY OF THE VISUAL SYSTEM 
 
 The visual system evolved to enable organisms to detect and respond to their 
environment. This intricate apparatus transforms patterns of light into information encoded in 
neural circuits. The anatomy of the mammalian visual system has several common features: 
the eye, which captures and focuses light via the lens; the retina, where energy from photons 
is converted into neural signals and which performs early-level processing of such visual 
features as orientation and movement; the optic pathway, which consists of nerve fibers that 
organize and transmit information from the retina; and the brain, where visual information is 
processed and perception is produced. The structure of these systems naturally underpins 
their functions, and an understanding of visual system anatomy is therefore vital to studies of 
disease, injury, and repair. 
 
1.2.1  |  Retina 
 
 The retina is a thin sheet of transparent neural tissue that lines the back of the eye. It 
consists of three primary cell layers (Figure 1.1): the outer nuclear layer (ONL), which 
contains light-sensing photoreceptors; the inner nuclear layer (INL), which contains bipolar, 
amacrine, and horizontal cells, and the ganglion cell layer (GCL), which contains RGCs. The 
cornea and lens focus light onto the retina, where photons pass through the GCL and INL 
before arriving at the ONL. Photoreceptors contain proteins called opsins, which are bound to 
the photosensitive molecule 11-cis-retinal. When a photon encounters this complex, its 
energy causes the double bond in 11-cis-retinal to isomerize, producing all-trans-retinal. This 
induces a conformational shift in the opsin protein, which leads to a cascade of second 
messenger signals that ultimately causes the photoreceptor to hyperpolarize, a process termed 
phototransduction. This series of events enables photoreceptors to respond to individual 
photons, making them highly sensitive detectors of light. The shift from a steady state of 
depolarization, in which photoreceptors produce what is called “dark current,” to a 
hyperpolarized state, transforms light into a neural code, which is passed from photoreceptors 
to bipolar cells and subsequently to RGCs. Information is integrated as it passes from one cell 
layer to the next, with multiple photoreceptors often converging on a single bipolar cell, and 
likewise multiple bipolar cells signaling to a single RGC. Information can be further modified 
by interneurons called horizontal cells whose processes extend into the outer plexiform layer 
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(OPL) between photoreceptors and bipolar cells, and by neurons called amacrine cells that 
extend into the inner plexiform layer (IPL) between bipolar cells and RGCs, as well as by 
glial cells such as Muller glia, which span the entire retina. Ultimately, the flow of 
information from the incident photon to the RGC enables the retina to encode a remarkably 
complex set of features in an extremely short amount of time. Numerous subtypes of 
specialized RGCs have evolved to convey information about these sets of features to the 
brain, where it undergoes further processing so that the organism can respond appropriately 
to a dynamic environment. 
 
 
Figure 1.1. Neural cell types in the retina. The retina contains five neuronal cell types. The 
outer nuclear layer (ONL) is composed of light-sensitive photoreceptors. The inner nuclear 
layer (INL) contains bipolar cells that connect photoreceptors with the retinal ganglion cells 
(RGCs) of the ganglion cell layer (GCL). Also located in the INL are horizontal cells and 
amacrine cells, which modulate signal transmission through the other layers. RGC axons 
project from the retina through the optic disc and into the optic nerve. Figure adapted from 
Sanes & Masland 2015. 
 
Our understanding of RGC subtypes has seen dramatic progress in recent years, with 
more than 30 subtypes identified (Sanes & Masland 2015). Many tools have emerged for 
classifying and labeling these distinct subpopulations so they can be more comprehensively 
studied. RGCs are primarily classified by four criteria: morphology, gene expression, spacing 
in the retina, and physiological properties (Figure 1.2) (Sanes & Masland 2015). They can 
also be understood by their function. For instance RGCs that respond to a stimulus moving in 
a particular direction are termed directionally selective (dsRGCs); another subtype are α-
RGCs, which have larger somas and branching dendrites; some RGCs contain the pigment 
melanopsin, making them intrinsically photosensitive (ipRGCs); others respond most 
strongly to light-dark edges (local edge detectors, or LEDs); each of these subtypes can be 
further subdivided based on the four features described above (Sanes & Masland 2015). 
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Naturally, the fact that RGCs respond preferentially to different types of stimuli affects their 
projections to the brain. Different RGC subtypes send their axons to different central targets 
for processing (Dhande et al. 2015). In recent years, unique genetic markers for different 
RGC subtypes have been identified, making it possible to isolate and examine these cells 
with greater scrutiny (Dhande et al. 2015). 
 
 
Figure 1.2. RGC subtypes shown in lateral cross-section. RGC subtypes can be classified 
by their differing morphologies. The number of each cell type shown above approximately 
matches their frequency in the mouse retina. Abbreviations: DSGC, directionally selective 
ganglion cell; J-RGC, junctional adhesion molecule B–positive RGC; LED, local edge 
detector; RGC, retinal ganglion cell. Figure adapted from Sanes & Masland 2015. 
  
1.2.2  |  Optic pathway 
 
 RGCs send their axons toward the central retina, where they pass through the optic 
disc and enter the optic nerve (Figure 1.3). The transitional region between the retina and 
optic nerve is called the optic nerve head (ONH), and its anatomy differs widely, even among 
mammals. In humans, a network of collagen fibers forms the lamina cribrosa, a dense matrix 
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that also contains astrocytic processes and forms a series of canals roughly 40-220 μm in 
diameter, through which RGC axons project (Elkington et al. 1990). The lamina cribrosa is of 
particular interest in the study of glaucoma, where deformation and displacement of the 
lamina cribrosa, often associated with elevated intraocular pressure (IOP), exerts a physical 
stress on the RGC axons and potentially contributes to their progressive degeneration. While 
other primates such as monkeys also possess the lamina cribrosa, it is absent in mice and rats, 




Figure 1.3. Anatomy of the visual pathway in humans. RGCs respond to information from 
the left and right visual fields according to their location in the retina. RGCs send their axons 
to the central retina, where they pass through the optic disc to form the optic nerve. The two 
nerves cross at the optic chiasm, where RGC axons decussate and project into the brain. 
Figure adapted from California State University Sacramento. 
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 The optic nerve is considered part of the central nervous system (CNS). RGC axons 
are myelinated, except for a brief region at the optic nerve head, by oligodendrocytes, as 
opposed to the Schwann cells that myelinate peripheral nerve axons. RGC axons project in 
parallel through the optic nerves until they reach the optic chiasm. In binocular animals, 
visual information from the two hemifields is processed separately, on opposing side of the 
brain. Therefore, RGCs whose receptive fields encode information from the right visual 
hemifield project to the left hemisphere of the brain, and vice versa (Figure 1.3). To 
accomplish this patterning, axons must decussate at the optic chiasm according to their 
origins in the retina. In highly binocular animals, such as humans, about 60% of RGCs cross 
at the chiasm; in species where the eyes are positioned at the sides of the head, such as mice, 
about 95-97% cross (Petros et al. 2008). Axons then travel through the optic tracts and enter 
the brain. 
 The RGC axons are the only neuronal tissue in the optic nerves; however, many glial 
cell types are also present. In addition to oligodendrocytes, astrocyte processes are found 
throughout the optic pathway, as are resident microglia. These cells perform an array of 
structural and maintenance functions, and become reactive after injury and undergo 
progressive changes over the course of neurodegenerative diseases. The optic nerve is 
surrounded by meninges, including the three layers of the dura, arachnoid, and pia mater. The 
meninges contain fibroblasts which, like astrocytes and microglia, respond to acute injury by 
forming a scar to limit the spread of inflammatory damage. The optic pathway forms early in 
development, with RGC axons fully extended prior to birth, and remains relatively 
unchanged in adulthood. As mentioned above, mammalian RGC axons damaged by injury or 
degeneration do not naturally regenerate. 
 
1.2.3  |  Brain targets 
 
 Visual information arrives at the brain via synapses formed by RGC axons at several 
key target regions. At least 46 discrete targets have been proposed as part of the retinofugal 
pathway (Morin & Studholme 2014). These can be grouped under broad categories, such as 
visual circuits that govern general physiology, circuits that drive reflexive behaviors, and 
circuits that encode higher order visual features and contribute to conscious perception 
(Dhande et al. 2015). It is worth noting that different target regions receive axons from 
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different, often overlapping groups of RGC subtypes, indicating specialized networks for 
processing information from discrete types of stimuli (Figure 1.4). 
 
Figure 1.4. Different RGC subtypes project to distinct target regions in the brain. 
Retinal neurons facilitate a variety of functions, ranging from the maintenance of an 
organism’s physiological state to the conscious perception of visual features in the 
environment. These functions require different sets of encoded information, which is 
transmitted by different RGC subtypes. Abbreviations: dLGN, dorsal lateral geniculate 
nucleus; DSGCs, direction-selective ganglion cells; IGL, intergeniculate leaflet; ipRGCs, 
intrinsically photosensitive retinal ganglion cells; mdPPN, medial division of the posterior 
pretectal nucleus; MTNd, dorsal medial terminal nucleus; MTNv, ventral medial terminal 
nucleus; NOT/DTN, nucleus of the optic tract/dorsal terminal nucleus; OPN, olivary pretectal 
nucleus; SC, superior colliculus; SCN, suprachiasmatic nucleus; s-Off, Off-sustained; t-Off, 
Off-transient; vLGN, ventral lateral geniculate nucleus. Figure adapted from Dhande et al. 
2015. 
 
 The majority of retinofugal axons project to the dorsal lateral geniculate nucleus 
(dLGN) and superior colliculus (SC). The LGN integrates sensory information and relays it 
along what is termed the optic radiation to the primary visual cortex, where higher order 
processing occurs. Inputs to the LGN are organized retinotopically, which means that the 
spatial relationships of RGC cell bodies in the retina are preserved. The structure of the 
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dLGN varies widely across species, with primates exhibiting a six-layered structure that 
provides for a preliminary segregation of inputs, whereas rodents do not exhibit the same 
degree of lamination (Reese 1988). The LGN also receives input from visual cortex along the 
corticogeniculate pathway, creating a feedback loop. The SC, known as the tectum in non-
mammals, also exhibits retinotopy and is considered an important map of visual space. It 
facilitates the organism’s responses to orientation and body position. The SC also initiates 
motor commands that control the orientation of the gaze, and has been implicated in 
functions including tracking of moving stimuli, pursuit, and attention, as well as defense 
mechanisms such as the freezing and looming responses. Its relative size is much smaller in 
mammals than in other species, corresponding to larger regions associated with visual cortex. 
 The earliest visual target reached by RGC axons is the suprachiasmatic nucleus 
(SCN), which controls circadian rhythm. It is located directly above the optic chiasm, and 
receives input from melanopsin-containing ipRGCs. It has been proposed that light-sensing 
RGCs drive photoentrainment and facilitate the setting of the biological clock (Berson et al. 
2002; Foster et al. 1991). While this appears to be true, it has been demonstrated that 
circadian rhythm is not abolished even in melanopsin knockout mice, suggesting that ipRGCs 
do not signal exclusively through their intrinsically photosensitive properties, but also receive 
inputs from photoreceptors in the “traditional” sense (Dhande et al. 2015). Knocking out 
ipRGCs entirely leads to a complete loss of photoentrainment, indicating that these cells are 
essential to the process (Hatori et al. 2008; Göz et al. 2008; Güler et al. 2008). The SCN is 
also innervated by pathways arising in the thalamus, suggesting indirect mechanisms of 
entrainment. The dLGN, ventral LGN (vLGN), and intergeniculate leaflet (IGL) are the main 
retinorecipient regions of the thalamus. Studies have shown that the vLGN and IGL are vital 
for the process whereby daily exposure to light entrains diurnal behaviors. 
 An essential adaptive function of the visual system is its ability to accommodate a 
wide range of luminance levels, from bright sunlight to the darkness of night. One element of 
this accommodation arises from adjusting the aperture of the pupil, thereby reducing the 
amount of light that enters the eye. The automatic process by which the pupil dilates and 
contracts is known as the pupillary light reflex (PLR). The PLR is controlled by both ipRGCs 
and photoreceptors. ipRGCs project to the olivary pretectal nucleus (OPN), which resides 
between the dLGN and the SC. Elevation of light levels stimulates contraction of the pupil 
via connections through the OPN, and low light levels lead to pupil dilation, enabling the 
visual system to respond dynamically to varying light levels. 
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 Another important set of reflexes in the visual system facilitate small changes in head 
and eye position that serve to stabilize the image on the retina by accommodating for 
movement or changes in body, head, or eye position. The optokinetic reflex (OKR) and 
vestibuloocular reflex (VOR) work together to make fast, image-stabilizing compensatory 
movements that streamline the intake of visual information. It appears that dsRGCs are the 
primary drivers of these reflex circuits, responding rapidly to changes in the orientation and 
motion of visual stimuli. Brain regions essential to these reflexes include the nucleus of the 
optic tract and the dorsal, medial, and lateral terminal nuclei, which receive their primary 
inputs from dsRGCs. 
 Once RGC axons reach these central targets, they must form functional synapses. 
Significant effort has been dedicated toward understanding how these connections are 
formed, and emerging work suggests that a high degree of complexity governs these synaptic 
contacts. For instance, connections between RGCs and thalamocortical cells (TCs) have been 
observed to consist of mixed synapses with multiple RGC types and morphologically diverse 
TCs, with no apparent set of rules dictating which cells were found together (Morgan et al. 
2016). It has been demonstrated that axons form early, weak synapses upon first encountering 
their targets during development, and that these connections are refined and strengthened 
based on visual experience, until the conclusion of a critical period after which plasticity 
sharply declines and networks become stabilized. The incredible complexity seen in the 
wiring of RGCs to their central targets has led to questions of whether regenerated axons 
could ever come close to restoring functional, healthy vision. Evidence suggests that 
regenerated RGCs do form functional synapses (Bei et al. 2016), but how these connections 
contribute to visual perception remains unknown. These topics are addressed in greater detail 
in later sections. 
 
1.3  |  VISUAL PATHWAY DEVELOPMENT 
 
 The optic pathway arises from the mesoderm and ectoderm. Early in embryonic 
development, two optic vesicles develop on either side of the forebrain. Each optic vesicle 
subsequently forms an optic cup, with the inner layer of the optic cup eventually maturing 
into the retina, and the outer layer maturing into the retinal pigment epithelium. The neuronal 
population of the retina arises from multipotent retinal progenitor cells, which differentiate 
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into different retinal neurons according to a precise ordering mechanism (Reese 2011). The 
fate of retinal progenitor cells depends on intrinsic cell-autonomous mechanisms as well as 
environmental signals, including paracrine signaling from nearby developing cells. Subsets of 
retinal precursor cells produce key transcription factors at different periods of development, 
which can dictate cell fate (Figure 1.5). For instance, RGC differentiation is associated with 
early expression of the Math5 gene, and knockout of Math5 reduces the population of RGCs 
in the retina (Brown et al. 2001). However, this gene alone is not responsible for RGC 
differentiation, as Math5-expressing progenitor cells can also form other retinal neuronal 
cells, including horizontal cells, amacrine cells, and photoreceptors. Members of the Brn3 
family have been associated with generating RGCs during development (Badea et al. 2009). 
As RGC nuclei migrate to their final position in the retina, they extend small projections 
called radial processes, which will eventually become their axons (McLoon & Barnes 1989). 
RGCs ultimately migrate to form an evenly-spaced mosaic, comprised of distributions of 
different subtypes. As ongoing studies continue to investigate the subtle differences between 
RGC subtypes, our understanding of this patterning will continue to expand. 
 
 
Figure 1.5. Differentiation of retinal progenitor cells in to retinal neurons. Different 
retinal neurons arise from retinal progenitor cells in a specific order over the course of 
development, influenced by both intrinsic and extrinsic factors. Figure adapted from (Reese 
2011). 
 
 Developing RGC axons grow from the basal surface of the cell and extend into the 
optic fiber layer, where they project toward the optic disc in the central retina. The generation 
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and early extension of axons is influenced by both intrinsic factors, including integrins and 
cadherins, and extracellular factors in the neuroepithelium (Erskine & Herrera 2007). The 
directional growth of axons from the peripheral retina to the optic disc is guided, in part, by 
gradients of CSPGs, which inhibit neurite extension and thereby serve as a repulsive cue 
directing axons toward the central retina and optic nerve head (Brittis et al. 1992). The 
presence of Slit family proteins in the inner nuclear layer and their receptor Robo2 expressed 
on RGCs also contributes to the guidance of developing RGC axons (Erskine & Herrera 
2007). At the optic disc, the expression of netrin-1 by glial cells signals RGC axons to the 
exit the eye (Deiner et al. 1997). It should be noted that different RGC axons arise and extend 
at different times, with the earliest, termed “pioneer axons,” helping establish mature axon 
tracts (Brittis & Silver 1995). Axons that arise later in development fasciculate around these 
pioneer axons with the aid of cell-surface molecules. After exiting the eye, RGC axons 
populate the optic stalk, through which they extend toward the brain. Numerous tightly-
regulated signaling molecules prevent axons from undertaking aberrant paths, including the 
inhibitory Sema5A, which constrains axons within the developing optic pathway (Oster 
2003). 
 When growing axons enter the ventral diencephalon, they decussate, forming the 
optic chiasm. Much energy has been dedicated to understanding the mechanisms of RGC 
axon decussation at the developing optic chiasm, as it is an incredibly complex phenomenon 
and has provided many instructive insights regarding axon guidance and spatiotemporal 
signaling. In its simplest form, the process of axon crossing can be considered to have three 
key stages (Figure 1.6) (Petros et al. 2008). In the early phase, RGC pioneer axons, which 
predominantly arise from the dorsocentral retina, enter the diencephalon and form two 
projections, one of which extends ipsilaterally and the other contralaterally. During the peak 
phase, axons from the ventrotemporal retina arrive at the midline and are repelled, entering 
the ipsilateral optic tract, whereas all other axons cross at the midline, entering the 
contralateral optic tract. Again, the extent to which axons arising from the ventrotemporal 
retina are repelled at the midline is dependent on the degree of binocularity of the animal. 






Figure 1.6. RGC axons decussate at the optic chiasm. RGC axons from different regions 
of the retina (D: dorsal, V: ventral, T: temporal, N: nasal) enter the chiasm at different times. 
Their crossing behavior is controlled by a variety of glial cells and associated signaling 
molecules. In the early and late phases, radial glia express RC2 and BLBP, whereas during 
the peak phase they predominantly express EphrinB2. The presence of EphB1 receptors on 
axons is partially responsible for whether they cross upon encountering EphrinB2 at the 
midline, with EphB1+ cells turning back from the midline while EphB1- cells cross the 
midline. Other important factors in optic chiasm development include NrCAM, which is 
essential for axon crossing, and CSPGs, which prevent axons from extending outside the 
optic pathway. Abbreviations: EphB1, Ephrin type-B receptor 1; NrCAM, Neuronal cell 
adhesion molecule; Islet2, Isl2 insulin related protein 2; Zic2, Zinc finger protein 2; BLBP, 
Brain lipid-binding protein; SSEA-1, Stage-specific embryonic antigen 1. Figure adapted 




 The midline of the developing optic chiasm is defined by radial glial cells (Marcus & 
Mason 1995). Once axons cross at the optic chiasm, they navigate through the diencephalon 
and along the telencephalon, with their paths constrained by inhibitory factors including 
CSPGs that limit aberrant growth into inappropriate regions. RGC axon fasciculation, 
mediated by integrins and cadherins, also reduces aberrant off-target navigation. It is worth 
noting the highly regulated spatiotemporal expression of extracellular guidance cues during 
development (Figure 1.6). Studies of optic nerve regeneration in adult animals have shown 
that successful navigation of regenerating RGC axons at the optic chiasm is rare, with many 
axons failing to cross appropriately into the contralateral optic tract (Luo et al. 2013; Pernet 
& Schwab 2014; Bray et al. 2017). The behavior of axons at key decision points in the optic 
pathway suggests that new environments strongly influence growth cone dynamics: when 
they reach the optic nerve head, the optic chiasm, and their terminal targets in the brain, RGC 
growth cones undergo cyclic expansion, pausing, and retraction (Holt 1989; Bovolenta & 
Mason 1987; Mason & Wang 1997). Therefore, expanding our understanding of the 
mechanisms responsible for decussation of developing RGC axons may contribute to new 
insights for facilitating regeneration after injury. These questions are addressed in more detail 
in Chapters 5 and 6. 
 After crossing at the optic chiasm and navigating through the optic tract, RGC axons 
must find their targets in the LGN and SC and form functional synapses. Crucially, the 
retinotopic map must be preserved at these target regions. As a general rule, axons arising 
from RGCs in the nasal retina project to the posterior areas of their targets, whereas those 
arising from the temporal retina project to anterior areas (Erskine & Herrera 2007). Dorsal 
and ventral RGCs are mapped to dorsal and ventral areas of targets, respectively. This 
mapping requires EphA/ephrinA signaling, with EphrinAs exhibiting a gradient in the LGN, 
and mice lacking EphrinA showing a loss of retinotopy (Erskine & Herrera 2007). Neural 
activity in the retina appears to influence the action of EphrinA, and the importance of 
“retinal waves” of spontaneous electrical activity during development has been extensively 
studied (Wong 1999). This suggests a role for visual activity in determining retinotopy, 
which adds to the evidence that early visual experience is necessary for higher-order visual 
functioning. Once RGC axons have terminated at the proper target region, they form 
synapses with neurons in these regions. Following closure of the critical period, these 
synapses are highly stable, with limited plasticity. Signals from RGCs are integrated in the 
thalamus and travel onward to the visual cortex for higher order processing. 
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1.4  |  OPTIC NERVE DAMAGE 
 
1.4.1  |  Progressive neurodegeneration 
 
 The most common form of optic nerve damage in humans is glaucoma. Glaucomatous 
optic neuropathies are a group of diseases characterized by changes in the structure of the 
optic nerve head and the progressive loss of RGCs. Glaucoma is the leading cause of 
irreversible blindness worldwide; its global prevalence is estimated to exceed 100 million 
people by 2040 (Tham et al. 2014). The main modifiable risk factor for glaucoma is elevated 
intraocular pressure (IOP), although not all glaucoma cases are associated with high IOP 
(Weinreb et al. 2014). Other risk factors include age and ethnic origin (Vidal-Sanz et al. 
2012). Elevated IOP is linked with dysfunction of the trabecular meshwork (TM) and 
increased resistance to outflow of aqueous from the anterior chamber of the eye. Aqueous 
humor drains from the eye via the TM, located in the angle between the iris and the cornea 
(Figure 1.7). The balance between aqueous production and outflow determines IOP (Goel 
2010). It is believed that the TM and Schlemm’s canal senses IOP fluctuation via mechanical 
signals and respond by altering their resistance to fluid flow (Acott et al. 2014; Acott & 
Kelley 2008; Keller et al. 2009; Titze et al. 2003). At least two mechanisms have been shown 
to contribute to this modulation of resistance: secretion of enzymes and extracellular matrix, 
and phagocytosis of debris, pigment, and other materials in the aqueous humor (Zhang et al. 
2007; Buller et al. 1990). Dysfunction of the aqueous outflow pathway often arises from 
decreased cellularity in the TM (Liton et al. 2005), which leads to excessive resistance, high 
IOP, and ultimately a heightened risk of developing glaucoma (Alvarado et al. 1981; 





Figure 1.7. The aqueous outflow pathway is dysfunctional or damaged in glaucoma. In 
the healthy eye, aqueous humor flows into the anterior chamber and exits through the 
trabecular meshwork. Occlusion of this pathway leads to elevated intraocular pressure and is 
a primary risk factor for glaucoma. Figure adapted from the National Eye Institute 
(nei.nih.gov). 
 
The biomechanical and physiological causes of optic nerve damage are not entirely 
understood. This is partly because anatomical differences between species make modelling 
glaucoma in animals difficult. For instance, the human optic nerve head possesses a lamina 
cribrosa, whereas mice and rats have a glia lamina. However, in both humans and rodents, it 
has been suggested that elevated IOP injures RGC axons at the optic nerve head via 
mechanical deformation of the lamina cribrosa or glia lamina (Figure 1.8). Further, studies 
have shown that astrocytes in the optic nerve head become reactive in response to glaucoma, 
indicating that the mechanical strain may stimulate changes in cell reactivity (Wang et al. 
2017). Others have demonstrated that elevated IOP is associated with a loss of retrograde 
axonal transport in rodents (Vidal-Sanz et al. 2012). The failure of axonal transport and 
passive diffusion in RGCs suggests that there are likely metabolic causes underlying the 
progressive degeneration observed in glaucoma. Following extended periods of high IOP, 
RGC axons, dendrites, and soma undergo Wallerian degeneration, a well-known feature of 
many neurodegenerative diseases. Expression of the WldS gene, which slows Wallerian 
degeneration, delayed axonal degeneration in a rat model of glaucoma (Beirowski et al. 
2008). Wallerian degeneration is irreversible, meaning that subsequent loss of vision is also 





Figure 1.8. Elevated intraocular pressure leads to RGC damage and degeneration. 
Accumulation of aqueous humor in the anterior chamber contributes to high intraocular 
pressure. High IOP causes mechanical strain at the optic nerve head, where, in humans, the 
lamina cribrosa deforms and distorts the axons of RGCs. Additionally, disruptions of axonal 
transport contribute to metabolic dysfunction of RGCs. These stressors cause degeneration of 
axons and atrophy of cell soma, and ultimately cell death. Figure adapted from (Weinreb et 
al. 2014). 
 
Current therapeutic approaches for human glaucoma patients consist mainly of self-
administered eye drops, surgery, or laser treatment to enhance aqueous outflow and lower 
IOP. However, in many cases IOP reduction does not successfully prevent the degeneration 
of RGCs, and poor patient adherence to prescribed treatment regimes can render them 
ineffective. Furthermore, symptomatic reduction in vision typically arises only late in the 
disease, after significant damage has been incurred. Thus, there is an urgent need for 
treatments which not only lower IOP and protect RGCs from dying, but also promote the 




 Degeneration of optic nerve axons is also associated with multiple sclerosis (MS). MS 
is an inflammatory disease characterized by multiple focal regions of demyelination and 
axonal damage in the brain, spinal cord, and optic nerve known as plaques (Compston & 
Coles 2008). While demyelinated axons in MS plaques may spontaneously remyelinate in the 
relapsing-remitting phase of the disease, the failure of remyelination in the progressive phase 
yields extensive neurodegeneration, leading to severe dysfunction and disability (Franklin 
2002). Human patients with MS commonly exhibit atrophy of the nerve fiber layer and 
ganglion cell layer in the retina. A related condition, neuromyelitis optica, involves 
inflammation and demyelination of the optic nerve and spinal cord, and produces some 
similar symptoms in the retina. Optic nerve damage and loss of RGCs in the retina have also 
been observed in Alzheimer’s disease (Sadun & Bassi 1990). 
 
1.4.2  |  Acute trauma 
 
 While less common than degenerative diseases such as glaucoma, traumatic injury to 
the optic nerve can also cause optic neuropathy, leading to loss of vision. The optic nerve 
may be injured by direct contact of an object, such as a bullet, knife, or fragments of broken 
orbital bone, as well as indirectly, following compressive injuries to the head. Tumors in and 
around the optic nerve can also compress and damage RGC axons. Indirect optic nerve 
damage can be caused by obstructing blood flow to the tissue, or, conversely, from 
hemorrhaging following a head injury. Extreme torsional rotation of the eye can strain and 
damage the nerve. In many cases, optic nerve atrophy is not apparent until weeks following 
the initial insult. The conditions can be unilateral, affecting one eye, or bilateral, affecting 
both eyes. Vision loss sustained in these conditions is typically irrecoverable, especially after 
direct injury of axon tracts. Treatments such as surgical decompression of the nerve and 
administering steroids have proved beneficial in some cases. However, a comprehensive 
study asserted that outcomes for patients treated with surgery or steroids were no better than 
those who received no treatment (Levin et al. 1999). Risk factors for traumatic optic 
neuropathies are not easily identified, although the same study reported that 85% of victims 
are male, and the average age was 34 (Levin et al. 1999). While the prevalence of traumatic 
optic neuropathies is far lower than that of degenerative diseases, many experimental models 
of optic nerve regeneration in animals rely on crush or transection of RGC axons, because the 
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injury is highly replicable and regenerating axons can be easily visualized and reliably 
quantified. 
 
1.5   |   AXON REGENERATION IN THE CNS 
 
1.5.1  |  Overview of nerve regeneration 
 
 The nervous system is essential for animal life, controlling the acquisition of 
information from the surrounding world and the conversion of that information into neural 
signals, and then processing those signals to determine the organism’s reactions and 
physiological state. Damage to the nervous system can lead to severe dysfunction across 
virtually all aspects of life. Millions of people each year suffer from traumatic brain injury, 
stroke, spinal cord injury, and other conditions affecting the CNS. In humans, as in other 
mammals, neurons in the CNS fail to regenerate their axons following injury or degeneration. 
This creates an urgent need for the discovery of therapies that protect nerve cells against 
damage and promote and sustain the regeneration of neural tracts and circuits. 
 The field of neuroregeneration research is informed by the successful regeneration of 
mammalian PNS neurons and non-mammalian CNS neurons. In these neurons, the Wallerian 
degeneration that follows injury is often succeeded by extension of axons and subsequent 
reinnervation of targets. These events do not occur in the mammalian CNS. The evolutionary 
basis for mammals’ loss of regenerative capacity remains unknown; one hypothesis is that the 
risks of partial regeneration or miswiring of regenerated circuits outweigh the potential 
benefits. It is known that poorly or improperly regenerated peripheral neurons can 
occasionally lead to neuropathies and neuropathic pain, lending credence to this theory. 
Conversely, it has been suggested that sustaining a CNS injury makes animals so vulnerable 
to attack or starvation that there is no chance of recovery, and therefore no selective pressure 
to maintain regenerative ability. While the origins of the differences between PNS and CNS, 
and between mammals and non-mammals, are not entirely clear, much can be learned from 
studying the regenerative competence of these systems (Figure 1.9). For instance, studies 
have compared the genetic profiles of non-mammalian CNS neurons with their mammalian 
counterparts to identify target genes for intervention. And autologous mammalian peripheral 
nerve grafts have been implanted at sites of CNS lesions, leading to measurable 
improvements in regeneration. While such experiments are limited in their ability to predict 
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successful translational therapies, they nonetheless provide valuable insight into the 
mechanisms and dynamics of neuroregeneration. 
 
 
Figure 1.9. Neurons exhibit differing degrees of regenerative competence. Key factors 
that determine a cell’s regenerative competence include its developmental stage, the presence 
of intrinsic and extrinsic growth-promoting and growth-inhibiting factors, and neuron-
specific gene expression. Generally, mammalian CNS neurons fail to regenerate whereas 
non-mammalian neurons and mammalian PNS neurons are regeneration competent. Figure 
adapted from (He & Jin 2016). 
 
Evidence that RGCs and other CNS neurons have a capacity for regeneration after 
injury was demonstrated as early as the 1980s, when Albert Aguayo and others showed that 
CNS axons will grow through a peripheral nerve graft following injury (Figure 1.10) (So & 
Aguayo 1985; Vidal-Sanz et al. 1987; Richardson et al. 1980; David & Aguayo 1981). This 
suggested that, when the extracellular environment was made more amenable to axonal 
growth, regeneration of injured CNS tracts was possible. Because nerve grafting poses 
substantial technical challenges and high levels of variability, this technique is rarely used in 
current studies. However, in the decades since Aguayo’s findings were first reported, a broad 
spectrum of approaches have been utilized to stimulate RGC axon regeneration after optic 
nerve injury. Most of these address the cells’ intrinsic state. Intrinsic approaches encompass 
breeding of transgenic animals or virally mediated gene therapy, including methods such as 
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cre-lox recombination or emerging technologies such as CRISPR-Cas9. Approaches that 
modify the environment are far less common, possibly due to the difficulty of directly 
targeting the optic nerve with therapeutic agents. These challenges are discussed below, and 
addressed directly in Chapter 3. 
 
 
Figure 1.10. Injured RGC axons extend into a peripheral nerve graft. Implanting a 
segment of peripheral nerve at the site of a puncture lesion in the retina enables injured RGC 
axons to extend from the retina into the graft. This evidence showed that CNS axons, 
including RGCs, are capable of regeneration given a permissive microenvironment. 
Abbreviations: ON, optic nerve; OC, optic chiasm; OT, optic tract. Figure adapted from (So 
& Aguayo 1985). 
 
1.5.2  |  Intrinsic and extrinsic obstacles to regeneration 
 
 To achieve robust regeneration of CNS axons, two primary obstacles must be 
overcome: neurons’ intrinsic failure to assume an active growth state, and a growth-inhibitory 
environment that prohibits the extension of new axons. Over the past decades, it has become 
apparent that therapies must address both intrinsic and extrinsic factors to facilitate axon 




 CNS neurons’ failure to regenerate is due in part to changes in gene expression 
between development and adulthood. Genetic programs active during the initial embryonic 
growth phase include axon associated genes that promote extension and formation of early 
nerve tracts. After this critical period of development, expression of growth-related genes is 
largely reduced. For instance, the growth rate of mammalian embryonic RGCs declines 
steeply after birth, with little to no spontaneous axon growth observed in adult systems 
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(Goldberg, Espinosa, et al. 2002). Reactivating developmental growth states by identifying 
key genetic pathways and manipulating specific gene expression has been demonstrated as a 
viable strategy for stimulating regeneration after injury. One common target of CNS 
regeneration therapies is the phosphatase and tensin homolog (PTEN) gene. PTEN is an 
upstream inhibitor of mammalian target of rapamycin (mTOR), the hub of a signaling 
pathway that controls cell growth and protein synthesis as well as metabolism  (Lipton & 
Sahin 2014). PTEN, by acting through the phosphoinositide 3-kinase (PI3K)-AKT-mTOR 
pathway, plays a central role in cell survival and proliferation (M. S. Song et al. 2012). 
Knocking down or suppressing PTEN activates this pathway, thereby promoting cell growth 
programs. Deletion of PTEN in a transgenic floxed mouse line led to enhanced survival and 
robust regeneration of RGC axons after optic nerve injury (Park et al. 2008). Suppression of 
PTEN expression using a short hairpin RNA improved regeneration of corticospinal tract 
neurons in mice after spinal cord injury (Zukor et al. 2013). Manipulating the expression of 
PTEN or other genes involved in signaling pathways that control cell growth and 
proliferation is thus a promising step toward resolving the intrinsic inability of CNS neurons 
to regenerate axon tracts after injury. 
Intrinsic control of axon regeneration has been reviewed extensively (Figure 1.11) 
(He & Jin 2016; Liu et al. 2011; Fischer & Leibinger 2012). Many relevant factors have been 
proposed and demonstrated. Neurons may lack sufficient neurotrophic factors in the adult 
CNS, limiting the much-needed support for undertaking new axon growth. It is known that 
inflammation stimulates regeneration in mature CNS neurons, and therefore it is possible to 
target elements of the inflammatory or immune response to promote regrowth of axons 
following damage or degeneration (Benowitz & Popovich 2011). Embryonic axon growth 
often relies on specific patterns of electrical stimulation, suggesting that coordinated neuronal 
activity may promote more effective axon growth and navigation (Goldberg, Espinosa, et al. 
2002). Successful therapeutic regeneration stimuli will likely combine multiple intrinsic 
approaches. In Chapter 5, I demonstrate the effectiveness of several intrinsic approaches and 





Figure 1.11. Intrinsic factors affecting CNS axon regeneration. The intrinsic failure of 
CNS neurons to regenerate their axons derives from both loss of intrinsic growth ability and 
the presence of extrinsic growth-inhibiting factors. Intrinsic regenerative ability can be 
enhanced by several methods, ranging from addition of growth factors and signaling 
molecules to genetic modulation of key cell proliferation pathways. Figure adapted from (He 




The ECM in the CNS occupies the spaces between neurons and glial cells and is 
composed primarily of proteins secreted by these cells. It performs active supportive 
functions which go beyond simply providing a structural framework for CNS cells. During 
development, the ECM plays a key role in directing the growth of new axon tracts via 
spatially and temporally controlled patterning of molecular guidance cues (Figure 1.12). 
These patterns are themselves mediated by tightly regulated gene expression in neurons and 
42 
 
glia. In adulthood, the ECM forms structures such as the perineuronal nets (PNNs), which 
include CSPGs, hyaluronan, link proteins and tenascin-R (Kwok et al. 2010; Köppe et al. 
1997) and surround neuronal cell bodies, stabilizing the synaptic connections between linked 
neurons (Pyka et al. 2011). The ECM undergoes substantial changes after CNS injury, 






Figure 1.12. The CNS microenvironment changes during development and after injury. 
The mammalian CNS possesses a growth-promoting environment early in development, but 
upon maturation of nervous circuits and tracts, the growth-promoting factors are scarce and 
the environment is less permissive. Following injury, the presence of myelin debris, 
oligodendrocytes, reactive astrocytes, and other components of the glial scar prevent axons 
from extending through the lesioned area. Figure adapted from (Yiu & He 2006). 
 
The glial scar forms as a response to CNS tissue damage. Many definitions and 
interpretations of the “glial scar” have been put forward, and many elements of the scar’s role 
with respect to injury and repair remain under debate. Here, we define the glial scar as a part 
of the local immune response following CNS injury, wherein glial cells and several other 
non-neuronal cells such as pericytes and meningeal cells at the lesion site become 
hypertrophic or reactive (Faulkner 2004; Silver et al. 2015). Reactive astrocytes can be 
detected by an increase in the cells’ expression of glial fibrillary acid protein (GFAP), and 
this technique is often used to visualize the glial scar using immunohistochemistry (Bignami 
& Dahl 1974). The consequences of glial scarring are manifold, and considerable 
disagreement remains regarding how damaged neurons interact with the cells and matrix 
proteins that make up the scar. It has been demonstrated that the glial scar acts to repair the 
blood-brain barrier (BBB) and sequester inflammation at the lesion site, thereby limiting 
damage to nearby cells (Faulkner 2004). Indeed, the degree of scarring appears linked to the 
level of BBB disruption and the influx of non-CNS components, including activated 
macrophages, into the lesion site (Preston et al. 2001). This suggests that the glial scar plays 
an important role in reducing the scope of tissue damage after CNS injury. However, the scar 
is also a potential physical and chemical barrier to the regeneration of axons. Acute injuries 
produce a core of reactive astrocytes, oligodendrocyte precursor cells (OPCs), microglia, 
fibroblasts, and activated macrophages (Figure 1.13) (Soderblom et al. 2013; Sabelstrom et 
al. 2013; Barnabé-Heider et al. 2010; Busch et al. 2010; Horn et al. 2008; Meletis et al. 
2008). When newly regenerating axons encounter this barrier, their active growth cones 
become dystrophic, forming the endbulbs first described by Ramon y Cajal. These endbulb 
structures signify the terminus of the regeneration path, as few if any axons successfully 
penetrate the scar. In addition to the scar itself, the area distal to the lesion where axons have 
degenerated is also highly inhibitory to growth. This is in large part due to the presence of 
myelin debris, which inhibits growing axons. Similarly, the presence of myelin-forming 
oligodendrocytes is deleterious to axon regeneration, mediated in large part by Nogo family 





Figure 1.13. Formation of the glial scar following different types of injury. Examples 
from the spinal cord show different types of CNS injury and the resulting morphologies and 
composition of the glial scar Reactive astrocytes and fibroblasts cluster around the lesioned 
area, preventing axons from extending beyond the lesion. Figure adapted from (Silver & 
Miller 2004). 
  
Within the glial scar, changes in the deposition of ECM molecules perform a central 
role in creating a growth-inhibitory CNS microenvironment (Figure 1.14). For injuries 
wherein the dura mater is spared, changes in ECM components are driven primarily by 
reactive astrocytes, which express heightened levels of tenascin-C and CSPGs (Burnside & 
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Bradbury 2014; Silver & Miller 2004). After injury, the accumulation of CSPGs in and 
around the glial scar contributes to the overall inhibitory effect of the local microenvironment 
toward new axons. As such, CSPGs have been widely studied in the context of injury and 
regeneration, and removing them from the ECM or modifying their post-translational 
structure to reduce their inhibitory influence can facilitate the growth of regenerating axons. 
Characterizing the accumulation of CSPGs within the glial scar and subsequently modifying 
their inhibitory structures to facilitate axonal regeneration is the primary focus of this thesis. 
 
 
Figure 1.14. Comparison of extrinsic and intrinsic factors. Extrinsic factors that limit 
axon regeneration include the CSPG family proteins, the presence of myelin debris from 
degenerating axons, the presence of NG2 which appears to entrap axons, loss of tissue, and 




1.6  |  THE GLIAL SCAR AND CSPGS 
 
Proteoglycans are composed of a protein core covalently joined to one or more 
glycosaminoglycan (GAG) chains. These linear, unbranched chains are assembled from 
repeating disaccharide units, the composition of which determines the GAG’s classification 
as chondroitin sulfate (CS), heparan sulfate (HS), keratan sulfate (KS), or dermatan sulfate 
(DS) (Figure 1.15). CSPGs are the most abundant proteoglycans in the mammalian CNS and 
can be inhibitory or permissive to neurons depending on their structural features, enabling 
these dynamic proteins to play flexible roles in axon growth and guidance during 
development, at synapses, and after injury. 
 
Figure 1.15. Structural diversity and classification of proteoglycans. A series of 
cooperative enzymes add sugars to the growing GAG chain. Up to 100 residues may be 
added. Sulfotransferase enzymes then add sulfate groups to a number of possible positions on 
the sugar rings. Epimerases can convert glucuronic acid to iduronic acid. Because the 
processes of chain extension and sulfation are not template driven, proteoglycans possess an 
incredible structural diversity. Sulfation does follow a set of common patterns, leading to 
several distinct classifications of the sulfation code. Abbreviations: CS, chondroitin sulfate; 
DS, dermatan sulfate; HS, heparan sulfate; Ser, serine; Asn, asparagine; Thr, threonine; 
GalNAc, N-acetyl-galactosamine, GlcNAc, N-Acetylglucosamine; Gal, galactose; Man, 
mannose; GlcA, glucuronic acid; IdoA, iduronic acid; Xyl, xylose; Fuc, fucose; Neu5Ac, N-




1.6.1  |  CSPG structure and classification 
 
The CSPG family comprises a diverse array of molecules that share several common 
structural elements (Figure 1.16). The lectican group encompasses molecules formed from a 
core protein to which are bound several CS-GAG chains composed of repeating disaccharide 
units made of N-acetyl-galactosamine (GalNAc) and glucuronic acid (GlcA) (Figure 1.17) 
(Siebert et al. 2014). Molecules in the lectican family, which include aggrecan, versican, 
neurocan and brevican, differ in the number of GAG chains attached to their core protein: 
aggrecan can have hundreds of GAG chains bound to a single core protein, whereas neurocan 
and brevican may have only a few, or none at all. Outside of the lectican family, phosphacan 
is a proteoglycan formed as a splice variant of receptor-type protein tyrosine phosphatase 
(RPTP), which contains binding regions for CS-GAG attachment. Chondroitin sulfate 
proteoglycan 4 (CSPG4, also known as neuron-glial antigen 2 or NG2) is a transmembrane 
protein expressed by OPCs, activated microglia, and macrophages, and contains relatively 
little sequence homology to other CSPGs. 
 
 
Figure 1.16. Types of CSPGs. The lectican family of CSPGs differ in the number of GAG 
chains attached to their core protein, and non-lectican CSPGs include phosphacan, an RPTP 
splice variant, and NG2, a transmembrane protein found in OPCs and immune cells. Figure 




CSPGs differ in the post-translational modifications that influence their respective 
functions in the CNS. For example, the number of GAG chains attached to the core protein, 
and the length of the core protein itself, are key determinants of the molecules’ biological 
activity. Experiments using chondroitinase ABC (ChABC) have demonstrated that the GAG 
chains, as opposed to the core protein, mediate the inhibitory effect of CSPGs on neurite 
growth. ChABC is a bacterial enzyme, produced by Proteus vulgaris, that removes 
disaccharide units from the terminal nonreducing end of the GAG chain (Habuchi 1967), 
effectively stripping the GAG chains from the CS core protein. Treating glial scar explants 
with ChABC rendered them permissive to neurite growth (Mckeon 1995). Administration of 
therapeutic ChABC doses in rats resulted in significant regeneration of cerebrospinal tract 
axons after spinal cord injury (Bradbury et al. 2002). Removal of CS GAGs appears to 
contribute to a more growth-permissive microenvironment and facilitate regeneration of 
damaged CNS axons. Precisely which features of GAG chains mediate this effect are not 
fully understood. A likely candidate is the “sulfation code,” the pattern of sulfate groups post-
translationally added to the carbons of GAG sugars. 
 
 
Figure 1.17. Structure of chondroitin disaccharide. Chondroitin GAG chains consist of 
repeating disaccharide units. Each disaccharide contains a glucuronic acid and an N-acetyl-
galactosamine. Sulfation groups can be added at several positions on these rings by 
sulfotransferase enzymes, leading to a diverse set of possible patterns. Figure adapted from 






1.6.2  |  CSPG sulfation 
 
The sulfation code has been observed to play an influential role in determining the 
biological actions of CSPGs. The addition of sulfate groups to the disaccharide units of CS 
GAG chains is performed by sulfotransferase enzymes. Sulfate can be added at carbon 4 (4S) 
or carbon 6 (6S) of the GalNAc unit, or carbon 2 (2S) of the GlcA unit. Combinations of 
these patterns result in several variants of sulfated GAG chains on individual proteins (Table 
1.1), and different variants exert different effects on neuronal growth. 4S has been found to 
be highly inhibitory toward axon growth in vitro (Wang et al. 2009), whereas 6S has been 
shown to be both inhibitory and permissive to axon growth in different experiments (Lin et 
al. 2011; Properzi et al. 2005). Modifying sulfation directly thus offers a targeted approach to 
reducing CSPG-mediated inhibition of regenerating axons in vivo. 
 
Sulfation Position Unit Name 
No sulfation 0S CS-O 
Chondroitin-4-O-sulfate 4S (R2) CS-A 
Chondroitin-6-O-sulfate 6S (R3) CS-C 
Chondroitin-2,4-O-sulfate 2S, 4S (R1, R2) CS-B 
Chondroitin-2,6-O-sulfate 2S, 6S (R1, R3) CS-D 
Chondroitin-4,6-O-sulfate 4S, 6S (R2, R3) CS-E 
Chondroitin-2,4,6-O-sulfate 2S, 4S, 6S (R1, R2, R3) CS-T 
Table 1.1. Nomenclature of chondroitin sulfate disaccharides. Several naming systems are 
used to distinguish CS GAGs with different sulfation code. Table adapted from (Yu et al. 
2017). 
 
Because of the lack of genetic knockout models, our knowledge of CS GAG chain 
function in the mammalian nervous system derives primarily from studies of the effects of 
GAG chains on neurite formation and neuronal polarization in culture (Miller & Hsieh-
Wilson 2015). Following the demonstration that GAG chains inhibit dorsal root ganglion 
neurites in culture (Carbonetto et al. 1983), many groups have used in vitro assays to evaluate 
how GAG chains with differing sulfate composition influence neurite growth. Unfortunately, 
it has not been possible to achieve a consistent standard for GAG composition in such 
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experiments. Efforts to synthesize CS GAG chains are still in their infancy, meaning that 
virtually all data have been collected using tissue-derived GAG chains whose composition 
varies depending on the source of the tissue; even GAGs from the same tissue exhibit batch-
to-batch variation (Rapp et al. 2005). Therefore, results of experiments studying GAG chain 
sulfation yield a wide range of results and interpretations, depending upon both the cell type 
used and the composition of the GAG chains. 
Because of these drawbacks, the overall picture of the role of GAG sulfation gleaned 
from in vitro experiments is somewhat confusing. For instance, one study showed that rat 
cerebral cortical neurons were inhibited by CS-C but not CS-A (Butterfield et al. 2010), and 
another that they were inhibited by CS-E (Karumbaiah et al. 2011). Chick dorsal root 
ganglion (DRG) neurons, on the other hand, were inhibited by CS-E (Brown et al. 2012), but 
not CS-A or CS-C, while another study showed that CS-C as well as DS were both inhibitory 
to chick DRGs (Verna et al. 1989). Our group has shown that CS-A, but not CS-C, is 
inhibitory to mouse cerebellar granule cell neurites, and that this inhibition is dependent on 
4S (Wang et al. 2008). The role of 4S appears to be outsized in mediating the inhibitory 
actions of CS: an antibody against 4S improves neurite outgrowth on aggrecan (Yang et al. 
2017) and selective removal of 4S specifically at the non-reducing end of GAG chains is 
sufficient to reduce CS-mediated inhibition of rat hippocampal neuron growth (Zhang et al. 
2014). For chick retinal neurites, CS-C, -D or -E, but not CS-A, were observed to be 
inhibitory (Shimbo et al. 2013), while chick trigeminal neurites were inhibited by CS-A, CS-
C and dermatan sulfate (DS) (Schwend et al. 2012). In contrast, rat hippocampal neurite 
outgrowth was generally promoted by CS-D and CS-E as well as several different 
oversulfated DS saccharides (Clement et al. 1998; Clement et al. 1999; Bao et al. 2004; 
Hikino et al. 2003). The Hsieh-Wilson lab has produced GAG mimetics with pure sulfation 
patterns. And yet, even among these purified samples, the results are inconsistent, with CS-E 
mimetics both inhibiting (Rawat et al. 2008) and promoting (Tully et al. 2004) hippocampal 
neurite outgrowth. 
There are several possible explanations for the heterogeneous responses to CS GAG 
chains in culture. One is that each laboratory uses its own strategy for creating substrates, as 
well as its own tissue source and culture conditions: some studies compare growth on poly-
amino acids with growth on CS GAGs, while others evaluate GAG actions on neurons plated 
on laminin or fibronectin, both of which depend on integrin receptor activation for their 
growth-promoting activity. Different types of neurons may express specific complements of 
receptors for the growth promoting substrate or for CS GAG chains, and they may also 
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produce distinct types of ECM molecules that interact with GAGs, altering the outcome. 
Some of these effects are due to direct interactions with the neurons, while others, especially 
using the more highly-sulfated GAGs, may be through GAG chain interactions with growth 
factors such as pleiotrophin and contactin-1, which promote growth (Hashiguchi et al. 2010; 
Mikami et al. 2009), and semaphorins, which inhibit growth (Dick et al. 2013). Furthermore, 
methods of measuring effects may fail to detect subtle differences: while both CS-D and CS-
E each promoted the outgrowth of embryonic mouse hippocampal neurites, there were 
differences in the morphology of the cells on the different GAGs (Hikino et al. 2003). The 
future availability of defined CS GAG chains along with more consistent experimental 
protocols and molecular probes for different classes of neurons may help resolve these 
inconsistencies. 
The critical role of CS sulfation is also supported by in vivo evidence. For instance, 
the sulfate composition of CS GAG chains has been shown to change with age. In the mouse 
cerebellum, the percentage of CS-A units rises from 50% at birth to 85% in the young adult, 
with a corresponding decrease in CS-C units from 35% to 5%, and O units from 9% to 3% 
(Ishii & Maeda 2008b). siRNA-mediated knockdown of sulfotransferases reduced cortical 
neuronal migration, indicating that sulfation is essential to this developmental process (Ishii 
& Maeda 2008a). Other experiments using knockout animals suggest that 6S on CS-C may 
promote growth (Lin et al. 2011), and that an age-associated increase in the ratio of 4S GAG 
to 6S GAG in perineuronal nets may decrease synaptic plasticity (Foscarin et al. 2017). This 
is supported by the observation that overexpression of chondroitin 6-O-sulfotransferase-1, 
which decreases the ratio of 4S to 6S in perineuronal nets, increases seizure susceptibility 
(Yutsudo & Kitagawa 2015). These studies emphasize the urgent need for genetic 
manipulation of other chondroitin sulfotransferases to illuminate their biological functions 
and generate a clearer picture of the role sulfation plays in development and aging. 
 
1.6.3  |  CSPG signaling 
 
 Signaling pathways downstream of CSPG binding to neuronal receptors have been 
widely studied. The diversity of species, neuronal subtypes, and culture conditions used make 
these findings difficult to compare directly. However, several important pathways have 






The Rho GTPase family (Cdc42, Rac1, and RhoA (Jain et al. 2004)) and their 
downstream effector ROCK are activated by aggrecan, impeding neurite outgrowth and 
inducing growth cone collapse (Chan et al. 2008). Pharmacologically suppressing ROCK 
enhances axon growth on aggrecan substrates (Borisoff et al. 2003). Likewise, directly 
inhibiting Rho reverses CSPG-mediated inhibition (Monnier et al. 2003). Inhibiting Rho 
GTPase family members Cdc42 and Rac1 also overcomes CSPG-dependent inhibition of 




ROCK pathway activation acts through downstream effectors related to cytoskeletal 
dynamics, including cofilin, which disassembles actin filaments (Gopalakrishnan et al. 2008). 
Inhibition of nonmuscle myosin II causes actin and microtubule reorganization, which 
accelerates axon extension and enables axons to cross boundaries with inhibitory CSPG 
substrates (Yu et al. 2012; Hur et al. 2011). When actin filament formation was inhibited in 
DRGs in vitro, microtubule realignment upon contact with a CSPG boundary was limited and 
growth cone turning prevented (Challacombe et al. 1996). Suppressing microtubule dynamics 
produced a similar effect, with limited growth cone turning at a CSPG boundary 




Activation of this cell cycle regulatory pathway overcomes CSPG inhibition of axon 
extension (Silver & Silver 2014). The CSPG-binding receptors PTPσ and LAR share 
common signaling pathways, including RhoA, Akt and Erk (Ohtake et al. 2016). An 
antagonist of the PI3K-Akt-mTOR pathway, GSK-3β, is activated by CSPGs, and its 
inactivation leads to neurite growth in vitro and axon sprouting and functional recovery in 








Suppressing EGFR’s kinase function enhances regeneration of neurons (Koprivica et 
al. 2005). Downstream of EGFR, MAPK signaling mediates CSPG inhibition of neurite 
growth from cerebellar granule neurons (Kaneko et al. 2007). Blocking EGFR promotes 
growth and migration of human neural precursor cells (Novozhilova et al. 2015). Survival of 
neural stem cells is promoted by CSPGs acting through EGFR pathways as well as 




Young embryonic neurons can adapt to inhibitory environments, growing more 
readily than mature neurons across CSPG surfaces; this may be due to upregulation of 
integrin (Lemons et al. 2005). In hostile growth conditions, young neurons express integrin 
family receptors (Condic 2001), whereas adult neurons lack the growth-promoting α9 
integrin subunit (Andrews et al. 2009). Induced expression of alpha-integrins in adult neurons 
enhances growth and regeneration of axons (Condic 2001; Andrews et al. 2009; Cheah et al. 
2016). Aggrecan and Nogo-A both inactivate integrins. Aggrecan decreases levels of 
phosphorylated FAK and pSrc without directly affecting surface integrins. Activating 
integrins directly reverses the inhibitory effects (Tan et al. 2011). In melanoma cells, CSPGs 
bind alpha-4-beta-1 integrin to inhibit cell adhesion, mediated by a CS-GAG binding site on 
alpha-4 integrin (Iida et al. 1998). Neuronal precursor cells respond to cleavage of CSPGs by 
ChABC with enhanced proliferation, differentiation, and migration, mediated by integrin 




Intracellular calcium regulates growth cone dynamics during axon extension (Gomez 
& Spitzer 2000). In culture, neurons encountering a CSPG substrate display a rise in 
intracellular calcium, dependent on influx through non-voltage-gated calcium channels 
(Snow et al. 1994). However, growth cone avoidance of CSPG surfaces occurs regardless of 
a transient rise in intracellular calcium, suggesting that this behavior is not dependent on 
elevated intracellular calcium (Snow et al. 1994). The transient calcium influx provoked by 
CSPGs is similar to that elicited by AMPA and kainate, and antagonizing AMPA and kainate 
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receptors blocked CSPG-mediated calcium influx (Maroto et al. 2013). This suggests that 




Blocking PKC activity reduces inhibition from CSPGs, and inhibiting PKC in vivo led 
to enhanced axon regeneration after spinal cord injury in rats (Sivasankaran et al. 2004). 
Downregulating or inhibiting PKC in vitro increased neurite crossing on non-permissive 
astrocytes, suggesting that astrocyte-derived matrix molecules such as CSPGs signal through 
PKC to influence neurite growth (Powell et al. 2001). 
 
Local protein synthesis 
 
Depletion of intra-axonal RhoA synthesis enhanced growth of neurons in CSPG-rich 
media (Walker et al. 2012). Increased protein translation was confirmed by an increase in 
phosphorylated 4E-BP1 levels (Walker et al. 2012). Sema3A, a negative guidance cue, also 
stimulates local translation of RhoA mRNA in axons (Wu et al. 2005). 
 
1.6.4  |  CSPGs in the healthy CNS 
 
 The CNS is particularly rich in proteoglycans, which are distributed widely 
throughout the brain, spinal cord, and optic nerves (Novak & Kaye 2000). CSPGs are the 
most abundant proteoglycans in the mammalian CNS. Historically, CSPGs and other ECM 
components were primarily thought to play a structural role, filling the gaps between cells 
and supporting complex neuronal structures. CSPGs are now known to perform a diversity of 
additional functions in the CNS. These include growth factor regulation, as the GAG chains 
of CSPGs are known to bind both growth promoting factors (Deepa et al. 2002; Deepa et al. 
2004) and growth inhibiting factors (Kantor et al. 2004). By binding growth-related factors, 
CSPGs facilitate ligand-receptor signaling, localize key molecules to sites of growth during 
development, and build reservoirs of growth-related molecules that can later be mobilized 
when needed (Galtrey & Fawcett 2007). They can also function as receptors that modulate 
cell signaling (Oohira et al. 2000). CSPGs play wide-ranging roles in nervous system 
development. They are present at early sites of cell proliferation in the brain and spinal cord 
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(Engel et al. 1996). Because their GAG chains generally inhibit axonal growth, CSPGs often 
function as repulsive guidance cues. The axon guidance function of CSPGs is particularly 
well studied in the visual system, as described below. Another critical domain for CSPGs in 
the CNS is neural plasticity, implicating CSPGs in learning and memory. The composition 
and sulfation code of CSPGs in the CNS changes with age, which supports the notion that 
CSPGs are dynamic molecules whose diverse roles change flexibly over time and in different 
regions of the CNS, making them an object of interest and extensive study. 
 
1.6.5  |  CSPGs after CNS injury 
 
 CNS injuries induce reactive gliosis, as described above. CSPGs are synthesized by 
multiple cell types in this response, including astrocytes, which when reactive produce 
brevican, neurocan, and phosphacan (Jones et al. 2003), as well as microglia and 
oligodendrocyte precursor cells (OPCs), which are known to produce NG2 and versican 
(Asher et al. 2002). The precise temporal and spatial expression of CSPGs in the glial scar 
varies among different core proteins (Siebert et al. 2014). For instance, following spinal cord 
injury, aggrecan expression is reduced (Lemons et al. 2001), and phosphacan is transiently 
reduced before increasing (Morgenstern et al. 2002). In addition to changes in core proteins, 
the abundance of differentially sulfated GAG chains may also change following CNS injury. 
It has been shown that 4S GAGs are strongly upregulated at the lesion site following brain 
injury (Yi et al. 2012). The dynamic regulation of CSPG deposition and changes in sulfation 
has yet to be fully characterized, and subtle differences exist in different systems, species, 
and types of injury. 
The time course of CSPG expression in chronic neurodegenerative diseases is more 
difficult to study than controlled acute injuries, particularly in human patients where tissue is 
generally available only in the late phase of the disease. Evidence suggests that Alzheimer’s 
disease progression includes reactive gliosis, implying that CSPGs are upregulated in affected 
CNS tissue (McGeer & McGeer 1995). CSPGs have also been detected in the white matter of 
MS patients (Sobel & Ahmed 2001). Changes in CSPG expression have been linked to 
seizures in a rat model of epilepsy (Okamoto et al. 2003), and to plasticity in brain areas 
damaged by stroke (Galtrey & Fawcett 2007). Treating lesioned areas with ChABC often 
improves axonal sprouting and plasticity, although the extent to which such therapies 
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promote functional recovery, and their viability as clinical treatments in humans, remains a 
topic of debate (Zhao & Fawcett 2013; Burnside & Bradbury 2014; Bradbury & Carter 
2011). 
 
1.6.6  |  CSPGs in the visual system 
 
 CSPGs in the visual system direct the patterning of RGCs in the developing retina and 
facilitate the extension and navigation of their axons and, in adulthood, stabilize their 
connections with visual targets in the brain. Understanding the factors responsible for the 
expression, distribution, and behavior of CSPGs is vital for studies of visual system 
development, damage, and repair. 
 
CSPGs in visual system development 
 
 In the visual system, CSPGs are predominantly found in nerve fiber layers. These 
include the optic nerve, the interphotoreceptor matrix (IPM), and the surface of retinal 
pigment epithelium (RPE) cells (Varner et al. 1987). Early histological studies identified 
neurocan and versican as the dominant proteoglycans in the developing retina of multiple 
species (Li et al. 2000; Zako et al. 1997; Inatani, Tanihara, Oohira, et al. 1999). In the chick 
retina, CSPGs were found in the optic fiber layer, corresponding to the onset and cessation of 
RGC growth (Ring et al. 1995). Specifically, neurocan was identified in chick retina as early 
as embryonic day 7 (Li et al. 2000). Another study found neurocan and versican throughout 
the embryonic chick retina, whereas aggrecan and brevican were not detected (Zako et al. 
1997). In rats, neurocan localizes to the inner retinal layers at birth (Inatani, Tanihara, Oohira, 
et al. 1999), and can be found in the IPL and OPL at postnatal stage P7-P14, after which its 
reactivity steadily declines. Neurocan inhibits the growth of rat RGCs in culture (Inatani et al. 
2001). Both 6S and 4S GAGs were observed in association with RGC axons in the 
developing chick visual system (McAdams & McLoon 1995). While CSPG-mediated 
inhibition of neurons is generally attributed to the GAG chains, digestion of the GAG chains 
with ChABC failed to abolish neurocan’s inhibition of neurite growth, suggesting that the 
core protein may be intrinsically inhibitory (Inatani et al. 2001). Various CSPGs have also 
been identified in bovine eyes, where an unidentified proteoglycan was found in the outer 
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plexiform layer and associated with horizontal cells (Williams et al. 1998). CSPGs have been 
identified within the developing macaque retina (Peterson et al. 1995) and in the human 
retina and vitreous (Azuma et al. 1998). 
 The presence of axon-inhibiting CSPGs during development appears essential for the 
functional organization of retinal neurons. Early in vitro studies showed that RGC growth 
cones extend filopodia that repeatedly sample and respond to their extracellular environment, 
and that CSPG expression in the retina moves from the center to the periphery, maintaining a 
gradient that coincides with the edge of the developing axons (Snow et al. 1991). In a time-
lapse video-microscopy study, CSPG immunoreactivity was observed to recede in a wavelike 
motion toward the retinal periphery (Brittis & Silver 1995). This phenomenon was confirmed 
by another study showing the shift of CSPG expression from the central retina toward the 
periphery (K.-Y. Chung et al. 2000). RGCs near the edge of this receding wave send out 
minor processes, termed probing processes, which respond to the gradient of CSPG 
expression by extending toward regions of lower CSPG concentration, i.e. the central retina. 
The probing processes develop growth cones, enabling the axons to navigate toward the optic 
fissure to form the developing optic nerve. These early pioneer axons facilitate the 
subsequent guidance of later axons along the same path (Brittis & Silver 1995). Digesting CS 
GAG chains with ChABC leads to aberrant growth of RGC axons toward the retinal 
periphery, indicating that CSPGs are required to direct axonal growth toward the optic nerve 
head (Brittis et al. 1992). 
 In binocular animals, optic nerve fibers decussate at the optic chiasm. The boundary-
forming properties of CSPGs are critical for this process. When RGC axons first enter the 
chiasm, CSPG levels are low in the optic fiber layer but robust in the caudal parts of the 
ventral diencephalon (K. Y. Chung et al. 2000). Where axons cross the midline toward the 
optic tract, CSPGs were observed at the site where ventral axons are sorted from dorsal axons 
(K. Y. Chung et al. 2000). Removal of GAG chains from embryonic brains by 
intraventricular injection of ChABC caused enlargement of the anterior optic tract, suggesting 
that CSPGs define the optic tract’s anterior boundary (Ichijo & Kawabata 2001). Studies 
using ChABC indicate that CSPGs may also be essential for establishing age-related axon 
order in the mouse optic tract (Leung et al. 2003). Whereas slices from E14 mouse embryo 
brains typically show an increase in CSPG immunoreactivity in the optic tract that 
corresponds with an accumulation of phalloidin-stained axonal growth cones in the 
superficial optic fiber layer, slices treated with ChABC abolished this pattern, suggesting that 
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the organization of the developing axons had been disrupted in the absence of CS GAGs 
(Leung et al. 2003). 
RGC axons project to visual targets in the brain to form synapses, and CSPGs prevent 
these axons from aberrant innervation of non-target regions. Early work suggested that 
CSPGs in the mouse neocortex can differentially promote or inhibit axonal extension, and 
proposed a role for CSPGs in segregating afferent and efferent axon tracts (Bicknese et al. 
1994). Addition of CSPG to cultured rat thalamic neurons reduced cell adhesion and 
promoted axonal growth, an outcome that was not replicated in rat hippocampal neurons, 
implying a cell-type-specific effect (Fernaud-Espinosa et al. 1994). Experiments in which 
embryonic thalamic neurons were plated on ex vivo mouse forebrain slices showed that the 
cortical plate repels neurites, whereas the intermediate zone and subplate facilitate neurite 
growth, and that these opposing effects were both blunted by ChABC treatment (Emerling & 
Lander 1996). This suggested that different CSPGs, or perhaps different CS-binding 
molecules, direct cortical development in a regional manner. While comprehensive 
characterization of the cortex ECM has yet to be undertaken, many cortical CSPGs have been 
characterized. Neurocan and phosphacan in the cortical subplate were identified as 
permissive substrates for thalamocortical axons (Fukuda et al. 1997). Conversely, in a study 
of rat embryo explants, enriched levels of neurocan in the hypothalamus and epithalamus 
appeared to repel axons, enabling axons to extend toward their proper targets in the thalamus 
(Tuttle et al. 1998). Understanding the precise nature of CSPG-directed axon guidance will 
require a more thorough understanding of which core proteins, GAG chains, sulfation 
patterns, and CS-affiliated molecules are expressed both temporally and regionally in the 
thalamus and cortex. 
 
CSPGs are upregulated following injuries to the visual system 
 
While CSPG deposition following acute damage to the brain and spinal cord has been 
thoroughly characterized, few studies have examined the distribution and temporal 
progression of CSPG expression in the visual system. It has been observed that cultured 
RGCs exhibit reduced neurite outgrowth on ex vivo substrates derived from gliotic tissue. 
Treating these substrates with ChABC enhanced axonal extension, implicating the CSPGs as 
critical components of inhibition of neurite growth by the glial scar (Mckeon 1995). CSPG 
accumulation has been observed 24 hours (Sellés-Navarro et al. 2001) and 3 days 
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(Sengottuvel et al. 2011) after optic nerve injury in rats, and after 24 hours in mice (Brown et 
al. 2012). The presence of axon growth-inhibiting CSPGs in the injured optic nerve can be 
inferred by the findings of studies that do not directly measure their expression. For instance, 
when RhoA, a downstream effector of CSPGs, was inactivated by viral-mediated expression 
of C3 ribosyltransferase in RGCs, axon regeneration in the optic nerve was enhanced (Fischer 
et al. 2004). Intravitreal injection of a Rho antagonist (C3-07) promoted RGC axon 
regeneration after microcrush lesion in rats (Bertrand et al. 2005), and inhibition of Rho 
kinase (ROCK) likewise enhanced RGC axon regeneration after optic nerve crush (ONC) 
(Lingor et al. 2007). Similar results were found in cats after inhibiting ROCK with Y-39983 
(Sagawa et al. 2007). The ROCK inhibitor Y-27632 also enhanced RGC survival and axon 
regeneration after rat ONC (Tan et al. 2012). Mice lacking the CSPG receptor RPTPσ 
exhibited enhanced RGC axon regeneration after ONC, an effect that was mediated by 
MAPK and Akt kinase activity (Sapieha et al. 2005). 
While the glial scar inhibits axonal extension, it is possible to partially overcome this 
obstacle with the application of robust pro-regenerative stimuli, as has been demonstrated 
repeatedly (Park et al. 2008; de Lima et al. 2012; Lim et al. 2016). There is evidence that 
stimulating RGC regeneration, for instance with the implantation of a peripheral nerve graft, 
may reduce scar formation via the upregulation of matrix metalloproteases (MMPs), which 
degrade CSPGs (Ahmed et al. 2005). Similarly, peripheral nerve graft implantation following 
ONC attenuated the expression of RPTPα and LAR, two putative CSPG receptors, in 
comparison to ONC-only controls, indicating that regenerating axons may be less sensitive to 
CSPGs (Lorber et al. 2004). However, the scar remains a substantial barrier even in the 
presence of pro-regenerative stimuli. Three-dimensional reconstructions of individual RGC 
axons have illustrated that stimulated axons exhibit aberrant, circuitous growth on the 
proximal side of the glial scar, indicating an inability to effectively penetrate this region 
(Bray et al. 2017). 
Unlike mammals, invertebrates successfully regenerate their CNS tracts following injury. 
The mechanisms underlying this difference have been extensively studied, and continue to be 
a topic of interest in neural regeneration research. In goldfish, whose optic nerve regenerates 
after an ONC injury, CSPG immunoreactivity is observed within the first three weeks 
following injury, corresponding with the period during which RGC axons extend and 
reestablish their connections with central targets (Battisti et al. 1992). By six weeks, CSPG 
levels return to baseline. Interestingly, the upregulated CSPG in the optic nerve is spatially 
organized, associating with regenerating axons in columns (Battisti et al. 1992). This seems 
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to suggest a growth-promoting role for CSPGs, an observation supported by evidence that 
RGCs in goldfish retinal explants exhibit enhanced axonal outgrowth following the addition 
of exogenous 4S GAGs (Challacombe & Elam 1997). More research is required to determine 
the potential differences in gene expression within goldfish RGCs that enable them to 
associate with CSPGs and successfully regenerate after optic nerve injury. 
CSPGs are also upregulated following retinal damage. While neurocan expression is low 
in the mature retina, transient ischemia significantly enhances neurocan mRNA levels in rat 
retinas, suggesting that neurocan plays a role in the retina’s response to injury (Inatani et al. 
2000). In a related study, decorin was found to be upregulated in the inner retinal layers 
following ischemia (Inatani, Tanihara, Honjo, et al. 1999). Enhanced CSPG deposition in the 
retina has also been observed in several murine models of inherited photoreceptor 
degeneration, in conjunction with astrogliosis (Barber et al. 2013). 
 
CSPGs are implicated in degenerative and demyelinating disease 
 
Traumatic injury to the visual system is less common than neurodegenerative diseases 
such as glaucoma and multiple sclerosis, which can cause permanent visual impairment and 
blindness. The accumulation of CSPGs has been observed in the optic nerve head of rats 
subjected to elevated IOP for prolonged periods (Johnson et al. 1996). In 8-month-old 
DBA/2J mice, which naturally develop a glaucoma-like phenotype within their first year of 
life, a significant upregulation of both GFAP-expressing astrocytes and CSPGs was observed 
in the endfeet of Muller glia in the inner nuclear layer of the retina (Inman et al. 2011). These 
findings potentially link CSPG accumulation with the loss of axon density in glaucoma. 
Conversely, administering the disaccharide (DS) product of ChABC digestion (CSPG-DS) 
appears to have neuroprotective effects: intravenous injection of CSPG-DS in rats with 
chronic and acute elevations of IOP protected RGCs from cell death (Bakalash et al. 2007). 
The same group also observed neuroprotective effects of CSPG-DS in rodent models of 
inflammation-associated degeneration (Rolls et al. 2006) and spinal cord injury (Rolls et al. 
2008). As noted previously, unlike humans, rodents do not have a lamina cribrosa; therefore, 
certain aspects of glaucomatous optic nerve damage are difficult to model in mice and rats. 
However, the accumulation of CSPGs has been confirmed in studies of monkeys with laser-
induced glaucoma, where CSPGs were found in the lamina cribrosa (Fukuchi et al. 1994). In 
the eyes of human glaucoma patients, CSPGs have been detected in the optic nerve head 
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(Tezel et al. 1999), juxtacanalicular tissue (Knepper et al. 1996), and in the stroma beneath 
the corneal epithelium and endothelium (Uusitalo 1994). Curiously, mRNA for two CSPGs 
(CSPG4 and aggrecan) was found to be downregulated in a microarray of optic nerve head 
astrocytes from human glaucoma patients (Rosario Hernandez et al. 2002). However, this 
may be a side effect of elevated protein levels stimulating a self-regulating negative feedback 
mechanism (Inman et al. 2011). 
 CSPGs also appear at the site of demyelinated lesions in rodent models of multiple 
sclerosis. Much of this evidence arises from studies of the spinal cord, where axon 
regeneration and remyelination are enhanced by therapies that block the synthesis of CSPGs 
(Keough et al. 2016), pharmacologically reduce CSPG levels (Feliu et al. 2017), digest GAG 
chains with ChABC (Bartus et al. 2014), or disrupt the interactions between CSPGs and their 
receptors (Lang et al. 2014). In studies of optic nerve regeneration, one key concern is that 
regenerating axons are not myelinated, and therefore may fail to efficiently convey action 
potentials to the brain (Bei et al. 2016). CSPGs inhibit OPC growth and differentiation in 
vitro, and this inhibition is reversed by treatment with ChABC (Siebert & Osterhout 2011; 
Pendleton et al. 2013; Lau et al. 2012). Treating OPCs with the Rho inhibitor Y-27632 
produced the same effect (Siebert & Osterhout 2011). Therefore, elevated CSPG expression 
in demyelinated areas of the optic nerve are likely to impede the remyelination process, 
limiting the potential for recovery of visual function. It is worth noting that myelin itself, and 
the myelin debris released into the optic nerve after injury, also inhibits axonal growth. One 
study identified the CSPGs brevican and versican V2 on differentiated oligodendrocytes, and 
showed that inhibiting CSPG synthesis with xylosides prevented oligodendrocytes from 
stimulating the collapse of axonal growth cones, providing a possible mechanism by which 
myelin inhibits axonal growth (Niederöst et al. 1999). 
 
1.7  |  TARGETING CSPGS IN VIVO 
 
Given the growth-inhibitory properties of CSPGs, targeted removal or modification of 
GAG chains has the potential to improve axon regeneration, remyelination, and functional 
recovery after injury or degeneration of visual pathways. Several in vivo approaches have 
been developed to reduce CSPG-mediated inhibition of axons, including treatment with 
CSPG-targeting enzymes, disruption of CSPG synthesis with xylosides, and interference with 
CSPG receptor binding and downstream signaling. 
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1.7.1  |  Enzymatic modification 
 
 ChABC has been extensively studied as a potential therapy for reducing CSPG 
inhibition of axonal regeneration. Enzymatic digestion of GAG chains using ChABC renders 
CSPGs permissive to neurite extension in culture and enhances axon regeneration after spinal 
cord injury in rodents (Bradbury et al. 2002). Typically, ChABC is delivered by direct 
application, either by injection (Bradbury & Carter 2011) or implantation of an enzyme-
carrying scaffold (Lemons et al. 1999; Hyatt et al. 2010). It is also possible to engineer 
astrocytes to express ChABC under an astrocyte-specific promoter (Cafferty et al. 2007). 
Despite many promising findings that ChABC promotes axonal regeneration and, in the case 
of spinal cord injury, some recovery of motor function, there are several drawbacks to using 
this enzyme therapeutically. Robust long-distance regeneration remains rare, and the 
maintenance of regenerated connections over extended periods remains to be reliably 
demonstrated. Further, the thermal stability of ChABC is questionable, as the enzyme loses 
its activity fairly quickly under physiological conditions (Tester et al. 2007). The enzyme’s 
bacterial origins also make it more difficult to envision clinical trials in human beings. 
Many recent efforts have substantially improved the stability and delivery of ChABC. 
For instance, production of a humanized enzyme from mammalian cells has been engineered 
(Muir et al. 2010). A thermostabilized ChABC was shown to maintain its activity for up to 4 
weeks in vitro at 37°C, which led to long-term suppression of GAG levels (Lee et al. 2010). 
Incorporating the ChABC gene into a viral vector enabled active secretion of ChABC from 
infected cells (Zhao et al. 2011). More recently, a dual vector system was used to create a 
doxycycline inducible “switch” whereby the ChABC gene activation could be temporally 
controlled (Burnside et al. 2018). Collectively, these and other efforts have led to greater 
stability and improved delivery of ChABC. 
Another enzyme that modifies GAG chains is arylsulfatase B (ARSB). ARSB isolated 
from human cartilage was shown to have a molecular weight of 51 kDa and Km of 2.6 mM 
for the substrate 4-nitrocatechol sulfate (Gold et al. 1976). The primary function of ARSB is 
to cleave sulfate groups from GalNAc at the C4 position at the non-reducing ends of CS and 
DS GAG chains, thereby enabling breakdown of complex polysaccharides (Litjens & 
Hopwood 2001). This process occurs intracellularly, in the lysosome, rather than in the 
extracellular matrix, although ARSB has also been localized to the ECM in some mammalian 
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cells (Mitsunaga-Nakatsubo et al. 2009). The optimal pH of the ARSB reaction is at about 5, 
although the enzyme remains effective at neutral pH (Roy 1987). While the active site of 
ARSB has been identified (Figure 1.18), the subsequent steps in GAG degradation and 
signaling cascade(s) activated by removal of 4S from the non-reducing end of CS or DS are 
not fully understood (Cammisa et al. 2013). 
 
 
Figure 1.18. Structure and active site of ARSB. ARSB structure depicted as a ribbon. (A) 
The active site residue K145 (yellow) has a conserved binding pocket (brown). (B) Adjoining 
pockets (green) are shown in order of decreasing conservation, with (C) further pockets 
(orange) and (D) the least conserved pockets (pink). Figure adapted from (Cammisa et al. 
2013). 
 
Mutations of the ARSB enzyme in humans cause failure of polysaccharide 
degradation in the lysosome and lead to the accumulation of polysaccharides in the cartilage 
and other tissue (Litjens & Hopwood 2001). This condition is known as 
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mucopolysaccharidosis type VI (MPS VI, also known as Maroteaux-Lamy syndrome). The 
link between ARSB and MPS VI was shown by culturing fibroblasts from the skin of MPS 
VI patients and characterizing the dermatan sulfate that accumulated in these cultures, which 
was primarily N-galactosamine-4-sulfate (O’Brien et al. 1974). The observation that cells 
from MPS VI patients exhibited markedly reduced (15%) enzymatic activity of ARSB 
confirmed that severe dysfunction of this enzyme was linked to the accumulation of 
polysaccharides that underlies the primary symptoms of the disease (Shapira et al. 1975). 
MPS VI is now treated clinically by enzyme therapy with recombinant human ARSB. While 
ARSB has been used experimentally in mice with spinal cord injury (Yoo et al. 2013), it 
remains relatively understudied in comparison with ChABC. 
 
1.7.2  |  Xylosides 
 
 CSPGs can also be targeted in vivo by blocking their synthesis with xylosides, which 
inhibit the assembly of GAG chains by interfering with the addition of disaccharide units to 
the core protein. CSPGs produced in the presence of xylosides therefore lack GAG chains, 
and are thus far less inhibitory to neurons. Xyloside administration in the subacute phase 
following spinal cord injury enhanced axon regeneration and motor recovery in mice (Rolls 
et al. 2008). In a model of demyelination, application of xylosides reduced the total 
demyelinated area in comparison with controls, and also enhanced the number of mature 
oligodendrocytes found in the plaque (Lau et al. 2012). Application of xylosides in the visual 
system has been limited, but one study in micropigs observed that intravitreal injection of p-
nitrophenyl-0-D-xylopyranoside disrupted the IPM and caused degeneration of photoreceptor 
outer segments, eventually leading to retinal detachment (Lazarus & Hageman 1992). The 
injections were administered to adult (4-6 months) animals, indicating that continued CSPG 
production may be required to maintain retinal integrity. Because xylosides are often 
delivered systemically, targeting specific areas of CNS lesions is generally not possible, 
making xylosides unlikely to translate to human clinical therapies. 
 
1.7.3  |  Interfering with receptors and signaling pathways 
 
Another strategy for overcoming CSPG-mediated axon inhibition is interfering with 
signaling pathways downstream of CSPGs. The neuronal receptors for CSPGs have not been 
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comprehensively characterized, but it has been proposed that CSPG inhibition is mediated by 
receptors in the leucocyte common antigen-related phosphatase (LAR) family, the receptor 
RPTPσ, or the nogo-receptors NgR1 and NgR3 (Shen et al. 2009; Dickendesher et al. 2012; 
Fisher et al. 2011). Despite the debate surrounding the identities of putative CSPG receptors, 
many aspects of the downstream signaling pathways activated in the presence of CSPGs are 
known (Yu et al. 2017). Interfering with signaling pathways could prevent CSPG-induced 
signals from effecting gene expression or silencing, thereby avoiding the dystrophic response 
within the neuron, or even reconfigure the cytoskeletal rearrangements associated with 
impaired axon growth (Yu et al. 2012). In the visual system, interventions that inactivate the 
Rho/ROCK pathway have been shown to enhance RGC axon regeneration after ONC 
(Fischer et al. 2004; Lingor et al. 2007). Similarly, pharmacological inhibition of EGFR, 
another downstream effector of CSPGs, promotes regeneration of RGC axons (Koprivica et 
al. 2005). The degree of redundancy among these pathways is unclear, and it remains to be 






Restoration of vision by regenerating RGC axons is likely to require clinical therapies 
that address both intrinsic and extrinsic mechanisms of regeneration failure. Because the cell 
bodies of RGCs are easily accessible by injections into the eye, efforts to regenerate RGC 
axons have primarily focused on developing therapies that modify the intrinsic state of RGCs. 
While some studies have examined the formation and composition of the glial scar that forms 
in the optic nerve after acute injury, a comprehensive investigation of CSPGs has not been 
attempted, and the sulfation dependence of these proteins has not been addressed. The 
objectives of this PhD thesis were to devise a simple, reliable technique for administering 
therapeutic substances to the lesioned optic nerve, to elucidate the dynamics of sulfated 
CSPG accumulation in the glial scar, and to selectively target inhibitory CSPGs to facilitate 
regeneration of injured RGC axons. 
Chapter 3 describes the development of a protocol for targeting the extracellular 
matrix in the lesioned optic nerve, with the following specific experimental aims: 
1. To detail a step-by-step protocol for generating a controlled optic nerve lesion in 
mice, implanting a sterile gelfoam sponge at the lesion site, and analyzing the 
tissue to determine the effects of the intervention on RGC survival and axon 
regeneration. 
2. To use two enzymes, ChABC and ARSB, to modify CSPGs in the lesioned optic 
nerve. The activity and stability of both enzymes will be assessed, first in vitro 
and then in vivo, with implanted scaffolds recovered over several days and 
assayed for the persistence of active enzyme. The penetration of active enzymes 
into the axon fibers of the optic nerve will be evaluated by detecting the 
byproducts of ChABC digestion, so-called “stubs,” by immunohistochemistry and 
Western blot. 
In Chapter 4, the expression of CSPGs by glial cells at the site of an optic nerve lesion 
is analyzed in two different models of CNS injury, and the ability of ARSB to selectively 
target 4S GAGs and enhance RGC axon regeneration is evaluated, with the following specific 
experimental aims: 
1. To demonstrate the effects of CSPGs on neurite growth in vitro, and the ability of 
ARSB to reverse their inhibitory properties. 
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2. To analyze the time course, spatial distribution, and composition of CSPGs 
deposited in the glial scar following acute injuries to the optic nerve and spinal 
cord in mice and rats. Immunohistochemistry and Western blot analysis will be 
used to characterize changes in astrocyte reactivity and microglial activation, and 
to observe the production of CSPGs, particularly the 4S motif. 
3. To determine whether using ARSB to modify CSPG sulfation at the non-reducing 
ends of GAG chains enhances the ability of RGCs to regenerate their axons 
following an acute injury. Mice will be treated with implanted ARSB or ChABC 
scaffolds following ONC, and RGC regeneration will be stimulated by ocular 
inflammation from an intravitreal injection of Zymosan. The regeneration of RGC 
axons will be assessed at multiple time points to determine the extent and duration 
of the effect. Treated optic nerve tissue will be further analyzed to determine 
whether ARSB and ChABC modify the glial component of the glial scar, and 
differences between ARSB and ChABC, which have different mechanisms, will 
be assessed. 
Chapter 5 describes the effects of several therapies that stimulate RGC axon 
regeneration by modifying intrinsic growth pathways, and then combines these interventions 
with ARSB treatment to stimulate robust long-distance regeneration, with the following 
experimental aims: 
1. To demonstrate the effects on RGC survival and axon regeneration of (i) 
inflammatory stimulation, (ii) enhancing endogenous electrical activity, and (iii) 
stimulating the mTOR pathway. 
2. To combine these therapies with ARSB treatment of the lesioned optic nerve and 
examine long-distance axonal regeneration through the optic chiasm, including an 
assessment of RGC navigation and pathfinding in distal regions of the optic 
pathway, and to comment on the viability of combinatorial therapies for 





LIST OF ABBREVIATIONS 
 
4S  4-sulfation 
6S  6-sulfation 
AAV  adeno-associated virus 
ARSB  arylsulfatase B 
cAMP  cyclic adenosine monophosphate 
CGN  cerebellar granule neuron 
ChABC chondroitinase ABC 
CM  conditioned medium 
CNO  clozapine-N-oxide 
CNS  central nervous system 
CS  chondroitin sulfate 
CS-GAG chondroitin sulfate glycosaminoglycan 
CSPG  chondroitin sulfate proteoglycan 
CTβ  choleratoxin β 
dpc  days post crush 
DRG  dorsal root ganglion 
DS   disaccharide 
E  embryonic day 
ECM  extracellular matrix 
GAG  glycosaminoglycan 
GalNAc N-Acetylgalactosamine 
GAP-43 growth-associated protein 43 
GCL  ganglion cell layer 
GFAP  glial fibrillary acidic protein 
HS  heparan sulfate 
Iba1  ionized calcium-binding adapter molecule 1 
INL  inner nuclear layer 
IOP  intraocular pressure 
IPL  inner plexiform layer 
KS  keratan sulfate 
LGN  lateral geniculate nucleus 
MMP  matrix metalloproteinase 
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MPS VI Mucopolysaccharidosis type VI 
NG2  neural/glial antigen 2 
Ocm  oncomodulin 
ONC  optic nerve crush 
ONL  outer nuclear layer 
OPC  oligodendrocyte precursor cell 
OPL  outer plexiform layer 
PBS  phosphate buffered saline 
PI3K  phosphoinositide 3-kinase 
PNN  perineuronal net 
PNS  peripheral nervous system 
PTEN  phosphatase and tensin homolog 
RGC  retinal ganglion cell 
RPE  retinal pigment epithelium 
RPTP  receptor-type protein tyrosine phosphatase 
TGFβ  transforming growth factor β 
TM  trabecular meshwork 




CHAPTER 2: METHODS 
 
2.1  |  ANIMALS 
 
All experiments and procedures were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) at the National 
Institutes of Health and the United Kingdom Animal (Scientific Procedure) Act of 1986. 
Female C57Bl/6 mice aged 6-8 weeks (Charles River) and female Sprague-Dawley rats 
weighing 250-275 g were housed in a pathogen free facility with free access to food and a 
standard 12 h light/dark cycle. Sample sizes were determined by statistical power calculations 
from pilot experiments and the results of previous studies, as described below. Animals were 
randomly allocated into experimental groups. Animals were removed from the study if 
bleeding occurred during the optic nerve crush or scaffold implantation surgery. 
 
2.2  |  CELL CULTURE 
 
Cell culture experiments were performed by Dr. Caitlin Mencio. Primary 
hippocampal neuron cultures were prepared from embryonic (e17-18) C57Bl/6 mouse brains. 
Hippocampi were dissected and dissociated into single cell suspensions. Dissociated cells 
were seeded onto coverslips coated with poly-L-lysine and cultured in 500 μL Neurobasal 
medium containing B27 supplement and 24 mM KCl. After allowing 2 h for neuronal 
attachment, 500 μL of Neurobasal medium containing B27 supplement and 24 mM KCl that 
had been incubated for 4 h with no treatment, 10 µg/ml CSPG (for final concentration of 5 
µg/ml), or CSPG (10 µg/ml) + ARSB (2 µg/ml) (final concentrations 5 µg/ml and 1 µg/ml, 
respectively) was added. Cells were incubated for 48 h at 37°C and 5% CO2 atmosphere and 
then fixed and stained for DAPI and βIII-tubulin. 
Primary cortical astrocyte cultures were prepared from neonatal (1-3 days) C57Bl/6 
mouse brains as described previously (Wang et al. 2008). Cerebral cortices were dissected 
and dissociated into single cell suspension. Dissociated cells were seeded into T-75 flasks and 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) at 37°C and 5% CO2 atmosphere until cells grew to confluence (10-
14 days). Flasks were shaken for 20 hours (120 rpm, 37°C) to detach microglia, 
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oligodendrocytes, and neurons from the more adherent astrocytes. After shaking, the medium 
was replaced. Media replacement was repeated 24 hours after the shaking period. 
To harvest conditioned media from reactive astrocytes, purified astrocytes were plated 
into T-75 flasks in serum-containing medium. After reaching confluence, astrocytes were 
incubated with serum-free media overnight and treated with TGF-β (10 ng/mL), ARSB (1 
ng/mL), TGF-β and ARSB, or neither (untreated controls), for 7 days. After harvesting, 
conditioned media was centrifuged at 800 rpm for 5 min to remove debris before being split 
into three aliquots of 2 mL each. Aliquots were treated with no enzyme, ARSB (1 μg/mL), or 
ChABC (1 μL/mL) for 4 h prior to addition to neuronal cultures. 
Cerebellar granule neurons (CGNs) were isolated as previously described (Wang et al. 
2008). Dissociated CGNs were cultured in 500 μL Neurobasal medium containing B27 
supplement and 24 mM KCl and plated on poly-L-lysine-coated coverslips in 24-well plates. 
After allowing 2 h for neuronal attachment, 500 μL of treated conditioned medium was 
applied to each well in triplicate. Cells were incubated for 24 h and then fixed and stained for 
DAPI and βIII-tubulin. In co-culture experiments, dissociated CGNs were plated at a density 
of 5×104 cells/well onto a confluent monolayer of astrocytes in 24-well plates that had been 
treated for 7 d with ARSB (1 ng/mL), TGF-β (10 ng/mL) or TGF-β and ARSB. 
 
2.3  |  NEURITE OUTGROWTH ANALYSIS 
  
Neurite outgrowth analysis was performed by Dr. Caitlin Mencio. After fixation and 
staining, at least 60 images were taken across two coverslips per condition. Files were 
analyzed by an experimenter blinded to the experimental conditions. Neurons were measured 
if they were isolated from other neurons and had distinct nuclei and at least one neurite longer 
than the diameter of the cell body. The longest neurite was measured for each neuron and at 
least 60 neurons were measured for each condition. Each experiment was performed in 
triplicate. 
2.4  |  GENOTYPING 
 
2.4.1  |  DNA extraction 
 
Ear clips were obtained from transgenic and wildtype mice and flash frozen in liquid 
nitrogen. 50 µL alkaline lysis buffer (200 mg NaOH, 14.88 mg EDTA, 200 mL H2O) was 
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added to the tubes, which were then heated at 95 °C for 1 h. 50 µL of neutralization buffer 
(1.3 g Tris-HCl, 200 mL H2O) was then added, and samples were frozen at -20 °C. 
 
2.4.2  |  PCR 
 
Primers were designed to bracket a sequence from the mutant p110α gene. PCR was 
then performed according to previously established methods. Briefly, a reaction mixture was 
prepared (12.5 µL GoTaq Hot Start Green Master Mix 2X, 0.5 µL upstream primer, 0.5 µL 
downstream primer, 6.5 µL nuclease-free water, and 5.0 µL DNA template). PCR was 
performed according to the protocol detailed in Table 2.1. 
 
Table 2.1. PCR protocol. 
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PCR products (10 µL per sample) were separated in a 1% agarose gel immersed in 1X 
TBE buffer and 0.01% ethidium bromide. Electrophoresis was performed at 100 V for 35 
min. Bands were imaged under UV light and images were analyzed using ImageJ. 
2.5  |  ENZYME ACTIVITY ASSAYS 
 
Activity of ChABC and ARSB was assessed immediately before surgery. ChABC 
(Amsbio 100332-1A) was reconstituted at 50 U/mL in a solution containing 100 mM 
Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) and 0.1% BSA. ChABC 
activity was measured by spectrophotometrically detecting the production of disaccharides 
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cleaved from the glycosaminoglycan chains of CSPGs, as has been previously described 
(Suzuki et al. 1968). The active production of these cleaved disaccharides can be measured 
by monitoring an increase in absorbance at 232 nm. Approximately 1 μL ChABC was added 
to 99 μL of CS-A (Sigma, 500 μg/mL in 1X PBS). Using an Ultrospec 3100pro 
spectrophotometer in kinetics mode, absorbance was measured at 232 nm every 15 s for 5 
min. The enzyme was deemed active if an absorbance of at least 1.0 AU was reached within 
5 min. 
 ARSB (Naglazyme®) was obtained in acidic PBS (pH 5.5) from Biomarin (San 
Rafael, CA). ARSB activity was measured by detecting the cleavage of a sulfate group from 
p-nitrocatechol sulfate (PNCS), which yields a product with an absorbance peak at 510 nm 
(Porter et al. 1969; Knaust et al. 1998). 1 μL of 1 μg/μL ARSB was added to 1 mL of assay 
buffer containing 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) at pH 6.5. A stock 
solution of 100 mM 4-PNCS was diluted to 2 mM in 50 mM MES buffer. In a 96-well 
microplate, 75 μL of diluted ARSB was combined with 75 μL of 2 mM 4-PNCS substrate. As 
a negative control, 75 μL of MES buffer without ARSB was combined with 75 μL of 2 mM 
4-PNCS. The plate was incubated at 37°C for 1 h. The reaction was then quenched by adding 
150 μL of 0.2 N NaOH to each well. Absorbance was measured at 510 nm. 
 To measure enzyme activity at time points after in vivo implantation, scaffolds were 
recovered from freshly dissected optic nerves and placed in 1.5 mL Eppendorf tubes and 
stored on ice. For scaffolds loaded with ChABC, 2 μL of fresh enzyme buffer solution (100 
mM Tris-HCl, 0.1% BSA) was added to the bottom of the tube, and the scaffold was 
immersed in this solution. After approximately 1 h on ice, 1 μL of the enzyme buffer was 
removed and added to the CS-A substrate in the spectrophotometer, and A232 was measured 
over 5 min as described above. For scaffolds loaded with ARSB, 250 μL of MES buffer was 
added to the tube containing the recovered scaffold. After approximately 1 h, three aliquots of 
75 μL were removed from this solution and each combined with 75 μL 4-PNCS in a 96-well 
microplate. Samples were incubated at 37°C for 24 h, after which the reaction was quenched 
by adding 150 μL of 0.2 N NaOH. Absorbance was measured at 510 nm. In both cases, 
recovered scaffolds loaded with enzyme buffer served as controls. 
2.6  |  PREPARATION OF ZYMOSAN/CPT-CAMP AND ENZYME SCAFFOLDS 
 
In accordance with established protocols (Yin et al. 2003; de Lima et al. 2012), 
Zymosan A (Sigma Z4250) was suspended in sterile PBS at a concentration of 12.5 μg/μL, 
74 
 
incubated at 37°C for 10 min, and vortexed. Lyophilized CPT-cAMP (Sigma C3912) was 
dissolved to achieve a final concentration of 50 mM CPT-cAMP. Aliquots were stored at 4°C 
for up to two weeks. Sterile gelfoam sponges were cut to roughly 2 mm3 and placed to soak 
in a sterile tube containing 5 μL of either ChABC, ARSB, or the control buffer. Tubes were 
stored on ice for up to 4 h before surgical implantation. 
 
2.7  |  OPTIC NERVE CRUSH AND IMPLANTATION OF ENZYME SCAFFOLDS 
 
Optic nerve crush was performed as described previously (Park et al. 2008). The optic 
nerve was exposed intraorbitally, and curved forceps were inserted beneath the external 
ocular muscle, avoiding the ophthalmic artery and retrobulbar sinus. The nerve was crushed 
approximately 1 mm behind the eye for 10 s. Immediately after the crush, eyes were 
monitored fundoscopically for signs of ischemia, and mice were observed for bleeding in the 
hours following surgery. Mice received a subcutaneous injection of 1 mg/kg buprenorphrine 
as an analgesic and topical application of ophthalmic ointment to prevent corneal drying. 
For implantation of enzyme scaffolds, the optic nerve was exposed by gently 
reopening the conjunctiva and inserting curved forceps behind the eye. Carefully avoiding the 
ophthalmic artery and retrobulbar sinus, the enzyme- or buffer-soaked gelfoam scaffold was 
placed in direct contact with the optic nerve at the site of the crush lesion, approximately 1 
mm behind the eye. Retinal blood flow was assessed fundoscopically, and mice received a 
subcutaneous injection of 1 mg/kg buprenorphrine and topical application of ophthalmic 
ointment. 
 
2.8  |  INTRAVITREAL INJECTION 
 
2.8.1  |  Zymosan, CPT-cAMP, and PBS 
 
Intravitreal injections of Zymosan or a PBS control were administered immediately 
following implantation of the gelfoam scaffold. 2 μL of the injecting solution was drawn into 
a sterile 5 μL Hamilton syringe with a 33-gauge removable needle. In the case of Zymosan 
injections, the syringe was inspected to ensure that the needle was not blocked by Zymosan 
particles. The solution was then slowly injected through the superior nasal sclera at a 45° 
angle, avoiding the lens, external ocular muscle, and blood vessels. A sterile 33-gauge needle 
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was used to puncture the cornea and drain the anterior chamber before removing the injecting 
needle, to reduce intraocular pressure and prevent reflux of the injected solution. Different 
needles were used for Zymosan and PBS injections to prevent contamination, and the syringe 
was rinsed thoroughly with ethanol followed by sterile PBS between injections. 
 
2.8.2  |  Viruses 
 
The viruses used for in vivo studies are listed in Table 2.2, including the titer and 
source. The commercially developed AAV2-hM3Dq virus map can be found in Figure 2.1. 
 
Table 2.2. Viruses used for in vivo studies. 
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Figure 2.1. Vector map of AAV2-hM3Dq. Image shows map of AAV2-hSyn-hM3Dq-
mCherry virus used for in vivo studies. Image from Addgene. 
 
Intravitreal injections of viruses were administered 14 d prior to ONC. 1.5 μL of the 
injecting solution was injected, as described above. Different needles were used for different 
viruses to prevent contamination, and syringes were rinsed with ethanol followed by sterile 
PBS between injections. 
 
2.8.3  |  CTβ 
 
 Intravitreal injections of 1.0 μg/μL CTβ (Sigma) were administered 2 d prior to 
perfusion harvest. 2 μL of the solution was injected, as described above. The syringe was 




2.9  |  DORSAL COLUMN CRUSH 
 
 Dorsal column crush was performed as described previously (Cheah et al. 2016). 
Animals were shaved, and an incision was made above the dorsal spinal column. Vertebrae 
were exposed by pulling away skin and muscle and holding the tissue apart with sterile 
retractors. The T10 vertebral bone was removed by laminectomy. The spinal cord was 
exposed and the meninges carefully removed. The dorsal column was then crushed with 
jeweller’s forceps for 10 s. The muscle and skin were sutured, and animals received a 
subcutaneous injection of 1 mg/kg buprenorphrine. Animals were carefully monitored for 
signs of infection in the days following surgery, and their mobility and bladder function were 
assessed daily. 
 
2.10  |  WESTERN BLOT 
 
2.10.1  |  Sample preparation 
 
 Mice were anesthetized using 1-2% isoflurane and exsanguinated, followed by 
cervical dislocation. Optic nerves were severed between the globe and the optic and cut into 
four equally sized segments of approximately 1.0-1.5 mm each. Nerve segments were 
immediately placed in sterile 1.5 mL Eppendorf tubes containing cold 40 µL lysis buffer 
(cOmplete Lysis-M, EDTA-free, Roche). Tissue was mechanically homogenized using a 
sterile pestle and centrifuged to separate dissolved protein from insoluble components. 
Protein concentration in the supernatant was determined using the BCA assay 
(ThermoFisher). Samples were frozen and stored at -80°C. 
 
2.10.2  |  Immunoblotting 
 
 Proteins were separated by SDS-PAGE under reducing conditions and transferred to a 
0.45 µm PVDF membrane. Membranes were blocked with PBS containing 0.2% Tween-20 
and 5% skim milk for 1 h at room temperature. To detect ChABC-digested CSPGs, 
membranes were incubated with the primary mouse monoclonal antibody BE-123 (Millipore 
MAB2030) diluted in an immunoenhancing reagent (Can Get Signal, Toyobo) and 5% skim 
milk for 2 h at 4°C, then washed and incubated with an HRP-conjugated anti-mouse IgG 
78 
 
secondary antibody for 30 min at room temperature. Signals were visualized with myECLTH 
Imager (ThermoFisher). 
 
2.11  |  ENZYME TREATMENT OF BRAIN SECTIONS 
 
Free-floating 30 µm sections of mouse brain were incubated with either ChABC 
(Sigma C3667, ≥ 20 µg/mL), ARSB (pH 5.5, Biomarin, 1 mg/mL), or a control buffer (50 
mM Tris, 60 mM sodium acetate, and 0.02% BSA, pH 8.0) in individual wells of a 24-well 
plate. ChABC and ARSB were assayed to confirm activity before being added to the wells. 
Brain sections were incubated with enzyme and control solutions at 37°C for 8 h. To confirm 
that ARSB was active during the 8 h incubation period, three additional control groups were 
used: brain sections incubated with ARSB and 4-PNCS (1 mM), sections incubated with 
control buffer and 4-PNCS, and empty wells incubated with control buffer and 4-PNCS only. 
After the incubation, three aliquots of 70 μL were removed from each well and combined 
with 70 μL of 0.2 N NaOH. Absorbance was measured at 510 nm. 
 
2.12  |  IMMUNOHISTOCHEMISTRY 
 
2.12.1  |  Tissue preparation 
 
Optic pathway tissue  
 
Mice were anesthetized using 1-2% isoflurane and transcardially perfused with PBS 
followed by 4% paraformaldehyde (PFA). Optic nerves or whole optic pathway tissue were 
dissected, laid flat on 13 mm filter paper (Millipore AABG01300), and immersed in 4% PFA. 
The tissue was post-fixed overnight, then immersed in 30% sucrose for at least 24 h for 
cryoprotection. Tissue was embedded in Tissue-Tek OCT and snap-frozen for cryosectioning. 
14 µm longitudinal sections were obtained on charged Superfrost microscope slides using a 
Leica CM3050 cryostat. Slides were dried and stored at -80°C. 
Retinas 
 
Whole eyes were dissected from perfused mice and placed in 4% PFA for 2 h. The 
solution was then replaced with 1X PBS. Whole mount retinas were prepared by removing 
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the cornea and lens, making four exterior cuts at half the radius of the retina, and gently 
peeling away the sclera to isolate the intact retina. Any vitreous body still attached to the 




 For analysis of perineuronal nets, fresh brain tissue was dissected from a C57Bl/6 
mouse and immediately immersed in 4% PFA. Tissue was post-fixed for 24 h, cryoprotected 




 Following perfusion with 4% PFA, the spinal column was isolated and the vertebral 
bones removed. Intact spinal cord tissue was dissected and post-fixed in 4% PFA overnight. 
Tissue was cryoprotected in 30% sucrose for 24 h, embedded in Tissue-Tek OCT, and snap-
frozen for sectioning. 
 
2.12.2  |  Immunostaining 
 
Optic pathway and spinal cord 
  
For antibodies detecting CSPGs and glial cell activation (Table 2.3), slides with optic 
nerve or spinal cord sections were incubated for 1 h in blocking solution (PBS containing 3% 
goat serum and 0.2% Triton X-100), then incubated overnight at 4°C in primary antibodies 
diluted in the blocking solution. Slides were washed three times for 5 min with PBS, 
incubated for 2 h with secondary antibodies, washed, and mounted onto glass coverslips with 
Fluoromount medium (Sigma). 
 The GAP-43 antibody was incubated as previously described (Leon et al. 2000). 
Briefly, slides were rinsed in TBS (50 mM Tris buffer containing 8.766 g/L NaCl) and then 
washed with methanol for 10 min. Slides were blocked in TBS containing 10% donkey serum 
for 1 h. The GAP-43 antibody was diluted 1:50,000 in a solution of TBS2T (50 mM Tris 
buffer, 17.532 g/L NaCl, and 0.1 % Tween) containing 5% donkey serum and 2% BSA. 
Slides were incubated with primary antibody overnight on a rocking platform. Slides were 
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then washed with TBS2T for 1 h, with TBS2T plus 5% donkey serum and 2% BSA for 1 h, 
and with TBS2T for 1 h, all on a rocking platform. The secondary antibody was diluted 
1:1,000 in TBS2T plus 5% donkey serum and 2% BSA. Slides were incubated with the 
secondary antibody solution for 2 h, followed by 30 min washes with TBS2T, TBS2T, and 





 Free-floating whole mount retinas were washed twice in 1X PBS with 0.5% TritonX-
100 for 5 min. All washing steps were performed on a rocking plate at slow speed. Retinas 
stained with Brn3a were frozen at -80 °C for 8 min to permeabilize the plasma membrane, 
then thawed and washed three times with PBS/0.5% Triton for 5 min, followed by blocking 
with PBS, 2% BSA, 2% Trion, and 10% donkey serum for 1 h at room temperature. Retinas 
stained with RBPMS moved directly from the initial washing step to blocking with PBS, 2% 
BSA, 2% Triton, and 10% goat serum. Retinas were incubated with primary antibodies 
overnight at 4 °C, washed with PBS/2% Triton for 5 min, then washed three times with 
PBS/0.5% Triton for 30 min each. Retinas were incubated with secondary antibodies for 2 h 
at room temperature, washed five times with PBS for 30 min each, then mounted with the 
ganglion cell layer facing up on a glass superfrost slide using Fluoromount mounting 




 For detection of perineuronal nets, free-floating brain sections were washed with 1 
mL of PBS containing 0.02% Triton-X100 three times for 30 min. Sections were incubated 
with 250 µL biotinylated Wisteria floribunda agglutinin (WFA) overnight at 4°C on a rocking 
platform. Sections were then washed with 1 mL PBS/0.02% Triton three times for 5 min, 
incubated with 250 µL TRITC-conjugated streptavidin for 1 h at room temperature, washed 
with 1 mL PBS three times for 5 min, stained with DAPI, and mounted using Fluormount and 




2.12.3  |  Antibodies 
 













6x His tag (rabbit) 
Secondary antibodies 
donkey anti-sheep, Alexa Fluor 488 
donkey anti-sheep, Alexa Fluor 568 
donkey anti-goat, Alexa Fluor 568 
goat anti-rabbit, Oregon Green 488 
goat anti-rabbit, Alexa Fluor 633 
goat anti-chicken, Alexa Fluor 488 
goat anti-mouse, Alexa Fluor 568 
goat anti-mouse IgM mu chain, Dylight 650 
 
Perineuronal net detection 













































Thermo Fisher (A-11057) 
Thermo Fisher (O-6381) 
Thermo Fisher (A-21070) 
Thermo Fisher (A-11039) 











2.12.4  |  Microscopy and Image Processing 
 
 Tissue was imaged using a Zeiss 780 confocal microscope with 20X, 40X, and 63X 
objectives. Z-stacks were maximally projected onto a single plane using Zeiss image 
processing software. For images used in fluorescence quantification, image capture settings 
were held constant, and samples from within each group were imaged at the same time. 
Fluorescence intensity was measured using ImageJ, with identical settings for all samples 
within each analysis. 
 
2.13  |  QUANTIFICATION OF RGC SURVIVAL AND AXON REGENERATION 
 
2.13.1  |  RGC survival 
 
 At least eight 20X images of each whole mount retina were taken, one from the 
central retina of each quadrant and one from the peripheral retina of each quadrant. The 
number of Brn3a+ or RBPMS+ cells was counted manually for each image and averaged, then 
compared against the contralateral control retina. All imaging and cell counting was 
performed by an observer blinded to the experimental conditions. 
 
2.13.2  |  Axon regeneration 
 
Axons were counted from deconvoluted confocal images (maximum intensity 
projections of at least 10 z-stack slices of 0.87 µm each). In ImageJ, vertical lines were drawn 
through each nerve section at 0.25 mm intervals starting from the lesion site, and the number 
of GAP-43+ axons crossing each line was manually counted. Four sections were counted for 
each nerve. The number of regenerating axons per nerve was then calculated at each distance 
using a previously developed formula (Lim et al. 2016; Bei et al. 2016), with the total number 
of axons equal to πr2 (r being the maximum recorded radius of the optic nerve section) times 









Axon counting was verified by a separate observer blind to the experimental 
conditions. For quantification of longest axon, the same images were used. GAP-43+ axons 
were identified, and the length of the longest detectable axon was measured from the lesion 
site using ImageJ. 
 
2.14  |  STATISTICS 
 
Sample size for axon regeneration experiments was determined based on preliminary 
data from a pilot experiment. The number of regenerating axons counted at 0.50 mm distal 
from the lesion site was obtained from groups of mice treated with either Zymosan + ARSB 
(n = 4) or Zymosan + Buffer (n = 5). The control group had a mean of 104±53 axons at 0.50 
mm, while the ARSB-treated group had a mean of 260±84 axons. Based on these numbers, 
we assumed a standard deviation of 75, to be equal for each group, and estimated using a 
two-sided two sample t-test that n = 9 mice per group would be required to achieve 80% 
power (at the 0.025 level) to compare ARSB treatment to a buffer control. 
All statistical tests were performed using GraphPad Prism 7.0 (GraphPad Software, 
La Jolla, CA). Axon regeneration was assessed using two-way ANOVA and Bonferroni post-





CHAPTER 3: TARGETING THE EXTRACELLULAR MATRIX IN THE 
LESIONED OPTIC NERVE 
 
3.1  |  INTRODUCTION 
 
The visual system is a valuable model for studying mechanisms of CNS regeneration 
due to its accessibility: neurons in the retina are easily targeted by intravitreal injection of 
therapeutic agents. However, in order to modify the extracellular environment through which 
regenerating axons are growing, the optic nerve must be accessed directly. The optic nerve 
lies beneath the ophthalmic artery and external ocular muscles, and can only be accessed by 
delicate microsurgery. Methods of direct injection of therapeutic compounds into the optic 
nerve have been reported in rats (Raykova et al. 2015; D’Onofrio et al. 2011), but there 
appear to be no published protocols for injection into the mouse optic nerve. This represents a 
significant difference between the optic nerve and the spinal cord or brain, which, with 
stereotaxic surgery, are commonly exposed for direct injection of therapeutic agents. It is 
possible, however, that the environment of the mouse optic nerve can be modified by 
diffusion of substances through the meninges, an imperfect yet, as I show below, effective 
route for delivering enzymes or small molecules into the axon fibers. In this chapter, I present 
a detailed protocol for targeting the extracellular matrix of the mouse optic nerve by soaking 
sterile gelfoam scaffolds in a solution containing an active therapeutic enzyme, such as 
ChABC or ARSB. Following the protocol, I show data from my optimization of this 
technique, demonstrating that implanted enzymes retain their activity in vivo and successfully 
modify optic nerve CSPGs. Further, I share useful data regarding the protein yield of small 
segments of dissected optic nerve for Western blot or other quantitative analyses not 
specifically outlined in my protocol. 
 
3.1.1  |  Advantages of studying CNS regeneration in the visual system 
 
Studying CNS injury and repair in the visual system has numerous advantages. The 
retina and optic nerve are considered part of the CNS and share many important properties 
with the brain and spinal cord, notably the failure of their axons to regenerate after injury. 
The eye itself is far more surgically accessible than the brain or spinal cord, shortening 
procedure times and reducing the risk of pain and complications in animal subjects. The 
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positioning of the ganglion cells within the vitreous-facing layer of the retina makes them 
receptive to substances injected into the posterior chamber of the eye, such as viruses 
carrying modified genes, neurotrophic factors, stem cells, and small molecules. The neuronal 
component of the optic nerve consists of only one cell type, the RGC, and axons extend 
unidirectionally over a well-defined path. RGC subtypes are well characterized, with 
emerging research adding to the growing library of subtype-specific genetic and 
morphological markers. The retina can be visualized through the transparent cornea, and 
repair can be assessed by dissecting retinal and optic nerve tissue and labeling surviving 
RGCs or regenerating axons. Because RGC soma are all located within a single retinal layer, 
the entire population can be examined in individual preparations, such as the retinal whole 
mount. The optic nerve itself can be studied histologically. Dyes are easily injected into the 
vitreous humor, where they have direct access to RGCs. Dyed RGCs enable the visualization 
of axon tracts, traveling either anterograde (injected in the vitreous humor) or retrograde 
(injected at the sites of synapses with visual targets in the brain). Synapse formation and 
stability at brain targets can be observed histologically with immunohistochemistry and 
electron microscopy. Additionally, a multitude of tests—ranging from electroretinography, in 
which a flash of light triggers responses from the entire population of retinal neurons, which 
can be measured with specific signals associated with unique cell populations, to behavioral 
measurements, such as the optokinetic reflex, direct and consensual pupil response, visual 
cliff, and looming response—can collectively assess incremental changes in visual function. 
By utilizing the eye’s physical accessibility and the diverse array of techniques for 
imaging and functional assessment, it is possible to evaluate changes in several domains 
relating to CNS regeneration. These include cell survival in the retina, the degeneration and 
regeneration of RGC axons in the optic nerve, and synaptogenesis and reinnervation of visual 
targets in the brain. While caution should be exercised in applying findings from the optic 
nerve to other CNS tissues, such as the brain and spinal cord, studying regeneration of RGCs 
in the visual system remains integral to studies of CNS regeneration as a whole. 
 
3.1.2  |  Models of optic nerve injury 
 
 Regeneration studies in the optic nerve are conducted in many species. CNS axons of 
non-mammals, such as fish or amphibians, regenerate spontaneously, and substantial 
foundational work has been performed in these systems. However, translation to human 
86 
 
conditions relies on studies in mammals, whose axons do not spontaneously regenerate. Rat 
and mouse models share several key similarities with human systems, and experiments can be 
performed over a relatively long time course. However, even between rodent species there 
exist appreciable differences in genetics and physiology. Mice are more commonly used for 
genetic manipulations, as myriad transgenic lines exist, with more becoming available at a 
steady pace, and genome maps are more detailed. Rats, on the other hand, are physically 
larger and therefore more amenable to the delicate surgeries required to induce optic nerve 
injury and subsequently to study extracted tissue. It is important to acknowledge differences 
between published literature examining regeneration in mice and rats, as treatments 
successful in one model will not necessarily translate to another, let alone to human patients. 
As in human patients, experimental injuries used in studies of animal subjects can be 
roughly divided into acute insult and progressive degenerations. The former encompasses 
natural injuries such as head trauma or stroke as well as experimentally induced optic nerve 
crush or microcrush lesions, and the latter is best illustrated in the optic nerve by 
experimentally induced glaucoma. The nature of the injury profoundly affects the cellular and 
molecular responses, and must be selected carefully based on the objectives of the study 
being performed. 
For glaucoma studies in particular, anatomical differences between rodents and 
humans must be acknowledged, including the absence of the lamina cribrosa in mice and rats 
and the difficulty of assessing the progression of the disease over time. While elevating IOP 
in animals has proven challenging, several rodent models of glaucoma have been developed, 
with varying degrees of success. Many rely on laser-induced occlusion of drainage pathways 
in the eye (Levkovitch-Verbin et al. 2002), causing aqueous build-up and elevated IOP. An 
advantage of laser occlusion is its thoroughness, producing reliable and well-controlled 
increases in IOP when performed correctly. However, it also causes inflammation around the 
sites of laser damage. Other techniques for blocking aqueous drainage include injecting beads 
or gels into the anterior chamber and directing them toward the angle. While less controlled 
than the laser occlusion model, these methods do not cause as much inflammation and are 
likely more similar to the physiological conditions in glaucoma. IOP can also be elevated by 
cauterizing the episcleral vein (Garcia-Valenzuela et al. 1995) or directly injecting saline into 
the aqueous humor pathway (Morrison et al. 1997). Additionally, a genetically inbred strain 
of DBA/2J mice was discovered to develop abnormally elevated IOP as the mice age, 
eventually mimicking the glaucomatous RGC loss seen in other models. It is crucial to 
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acknowledge that this wide array of injury and degeneration models will lead to differing 
results from therapeutic interventions to induce axon regeneration, with advantages and 
disadvantages inherent to each. 
Other models of optic nerve injury include the induction of transient ischemia in the 
retina by temporarily elevating IOP (Sellés-Navarro et al. 1996) or by ligating the ophthalmic 
vessels to restrict the retinal blood supply (Lafuente et al. 2002). However, by far the most 
common method used in regeneration studies is optic nerve crush (ONC). 
 
3.1.3  |  Optic nerve crush 
 
ONC directly injures RGC axons in the optic nerve and has been widely adopted for 
regeneration studies. ONC leads to the degeneration of disconnected axons and dieback to the 
site of the lesion, as well as the progressive death of RGCs in the retina over a relatively short 
timescale. While the direct clinical relevance of this type of injury is limited, its reliability 
and the ease of visualizing regenerating axons make ONC an attractive model for studying 
the effects of interventions both intrinsic (targeting RGCs in the retina) and extrinsic 
(modifying the extracellular environment of the optic nerve). Despite its ubiquity, the ONC 
model remains a topic of debate, in large part due the difficulty of distinguishing spared from 
regenerating axons (Fischer et al. 2017). Small differences in experimental technique—such 
as the type of forceps used, duration of crush, the distance of the lesion behind the eye, and so 
on—can yield important differences in effect. This has contributed to controversy around 
studies in which significant regeneration is observed (Pernet & Schwab 2014). 
In this chapter, I describe the intravitreal injection of an adeno-associated virus 
(AAV) targeting RGCs in the mouse retina. AAV serotype 2 (AAV2) reliably infects RGCs 
(Buch et al. 2008), and its efficiency is easily measured by extracting treated, uninjured 
retinas and comparing fluorescently tagged proteins synthesized by the genes carried in the 
virus with immunostaining for RGC markers such as RBPMS (Kwong et al. 2010). Typically, 
genes delivered by AAV2 are fully expressed within 2 weeks after injection (Buch et al. 
2008). At this time, RGC axons are injured with optic nerve crush, which requires a 
straightforward surgery wherein curved forceps are inserted behind the eye and the optic 
nerve is compressed or “crushed” at a distance of 1 mm. The extracellular environment at the 
lesion is then targeted by implanting a sterile gelfoam scaffold carrying a therapeutic enzyme 
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in direct contact with the optic nerve. Two days before tissue collection, the retrograde axon 
tracer choleratoxin β (CTβ) is injected intravitreally to visualize regenerating axons. At the 2-
week post crush time point, the retinas and optic nerves are dissected. I describe a technique 
whereby the optic pathway, including the optic nerve head, optic chiasm, and proximal 
portion of the optic tract, can be dissected whole and intact for analysis of axons regenerating 
over long distances. Given the recent improvements in stimulating high levels of RGC axon 
growth, this strategy is critical for assessing the navigation of regenerating axons, particularly 
their ability to cross properly at the optic chiasm, a site where many axons make aberrant 
projections and fail to follow the paths defined during visual system development (Pernet & 
Schwab 2014; Pernet et al. 2013; Luo et al. 2013). I describe in detail methods for visualizing 
and quantifying the number of surviving RGCs in the retina and the number of regenerating 
axons in the optic nerve. My methods synthesize commonly used strategies that have been 
adapted by multiple established laboratories but, to my knowledge, not yet collected into a 
comprehensive step-by-step guide. This protocol details the basic components of 
experimental injury and basic treatments, but it can be flexibly adapted for myriad 
interventions and experiment designs. The total time required for one cohort of mice is less 
than 5 weeks, and the techniques can be easily learned and integrated into any laboratory 
setup or surgical facility. 
 
 




I have listed the reagents and equipment used in our laboratory, but similar 
commercially available alternatives can be easily substituted as appropriate. 
 
ANIMALS 
• Adult female C57Bl/6J mice (6-8 weeks old). Animal use should abide by the relevant 
authorities’ guidelines, and appropriate approval from the institutional animal use 
committee must be obtained. Controls for sex and age are essential. Use animals of 




• Tetracaine hydrochloride eye drops (0.5% (wt/vol); Bausch & Lomb, cat. no. 24208-
920-64) 
• Tropicamide eye drops (1.0%, Sandoz, cat. no. 61314-355-02) 
• Ketamine hydrochloride (10 ml of 100 mg/mL solution for injection; Pfizer) 
• Xylazine (Rompun) (2% (wt/vol) injectable solution; Bayer, cat. no. 816474) 
• Buprenorphine SR (Zoopharm) 
• Lacri-Lube eye ointment (2.5 g; Allergan, cat. no. 5089GB) 
• Euthatal injectable solution (200 mg/mL; Rhone-Merieux, cat. no. 838093) 
• Phosphate buffered saline (10%; 1 L; Crystalgen, cat. no. 221-133-10) 
• Viruses 
• Cholera Toxin Subunit B (Recombinant), Alexa Fluor 555 conjugate (Thermo Fischer 
Scientific, cat. no. C34776) 
• Paraformaldehyde (20%, Electron Microscopy Sciences, cat. no. 15713-S) 
• Ethanol (Sigma-Aldrich, cat. no. 459836) 
• Tissue-Tek O.C.T. compound (Thermo Fisher Scientific, cat. no. 23-730-571) 
• Sodium azide (Sigma-Aldrich, cat. no. S2002) 
• Anti-RBPMS (rabbit IgG, Phosphosolutions, cat. no. 1830-RBPMS) 
• Anti-rabbit IgG, Oregon Green conjugate (goat, Molecular Probes cat. no. O-6381) 
• Normal goat serum (Thermo Fischer Scientific, cat. no. 16210072) 
• Triton X-100 (Sigma-Aldrich, cat. no. X100) 
• Sucrose (MP Biomedicals, cat. no. 152584) 
• Distilled water 
• Ice 
EQUIPMENT 
• Sterile operating bench 
• Operating microscope (Zeiss OPMI CS-1 Varioskop) 
• Dumont #5 straight forceps, Titanium straight tip (FST, cat. no. 11252-40) 
• Dumont #5/45 curved forceps, Dumoxel standard tip (FST, cat. no. 11251-35) 
• Vannas spring scissors, 2.5 mm blade, straight tip (FST, cat. no. 15000-08) 
• PVA foam surgical spears, sterile (Network Medical Products, cat. no. 40-415-USA) 
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• Cover glasses, circular, 12 mm (Carolina, cat. no. 633029) 
• 5 µL syringe, Model 65 (Hamilton, cat. no. 7633-01) 
• 33-gauge removable needles, 0.375 in, point style = 2 (Hamilton, cat. no. 7803-05) 
• 30-gauge Monoject needle, sterile (Thermo Fisher Scientific, cat. no. 22-557-172) 
• Gelfoam (Pfizer, cat. no. 031508) 
• Dissecting microscope (Nikon, cat. no. SMZ645) 
• High intensity halogen illuminator (Chiu Technical Corporation, cat. no. F0-150) 
• Operating scissors (Roboz, cat. no. RS-6751) 
• Moloney curved forceps (Roboz, cat. no. RS-8254) 
• Adson dressing forceps, 4.75 in. (V. Mueller, cat. no. NL1410) 
• Extra narrow scissors, 23 mm edge, straight tip (FST, cat. no. 14088-10) 
• Dumont #5 straight forceps, Titanium straight tip (FST, cat. no. 11252-40) 
• Vannas spring scissors, 2.5 mm blade, straight tip (FST 15000-08) 
• Small weigh boats (Heathrow Scientific, cat. no. 1420A) 
• 20 µL pipette (Rainin, cat. no. 17014392) 
• 20 µL pipette tips (Denville Scientific, cat. no. P1121) 
• 24 well flat bottom polystyrene plate, sterile (Corning Incorporated, cat. no. 3524) 
• 48 well flat bottom polystyrene plate, sterile (Corning Incorporated, cat. no. 3548) 
• Mixed cellulose esters membrane, 0.80 µm pore size (EMD Millipore, cat. no. 
AABG01300) 
• Liquid transfer pipettes (Samco, cat. no. #204) 
• Cryostat (Leica Biosystems, cat. no. CM3050) 
• Charged microscope slides (Globe Scientific, cat. no. 1354W) 
• Cover glass (24 x 60 mm2; Thermo Fisher Scientific, cat. no. 12-553-465) 
• Fluoromount aqueous mounting medium (Sigma-Aldrich, cat. no. F4680) 
• Confocal microscope (Zeiss, model no. LSM 780, inverted) 
• Image analysis software (ImageJ, developed by Wayne Rasband, National Institutes 
of Health; http://rsb.info.nih.gov/ij/index.html) 
REAGENT SETUP 
 
PBS (1×) To make 0.1 M PBS, dilute 100 mL of 10× stock solution with 900 mL of distilled 




PFA (4%)-PBS solution (0.1 M) (wt/vol, 1 L) To make 4% PFA, dilute 20 mL 20% PFA 
stock solution with 80 mL 1× PBS. Make sufficient volume for roughly 10 mL PFA per 




Preparation of operating microscope Turn on the operating microscope and arrange all 
surgical instruments on a sterile drape. All surgical procedures should be performed under 
sterile conditions using instruments treated by heat or gas sterilization and immersed in a 
bead sterilizer between animal subjects. 
 
Microscope settings for image acquisition Our images are acquired using a Zeiss confocal 
microscope, but any similar microscope can be used with optimized settings. To acquire 
images of CTβ+ regenerating axons in optic nerve sections, we used laser power of 5.0 and 
gain of 800. To acquire images of RBPMS+ RGCs in retinal flatmounts, we used laser power 
of 8.0 and gain of 800. 
 
3.3  |  PROCEDURE 
 
Intravitreal injection of virus (2 h) 
1| Anesthetize 2-3 mice at a time by administering an intraperitoneal (i.p.) injection of 
ketamine (10 mg/kg) and xylazine (100 mg/kg) mixture. Confirm the depth of anesthetic 
with a paw pinch. Mice should be unresponsive with no withdrawal reflex, but maintain 
regular, unlabored breathing. All procedures involving animals should follow the 
relevant institutional regulatory board guidelines and regulations. 
2| Place the mouse on a heating pad under the operating microscope and fix the head using 
a stereotaxic bite bar. Apply one drop of 0.5% tetracaine to the left eye for numbing, 
followed by 1 drop of 1.0% tropicamide to dilate the pupil. Wait ~60 seconds for the 
drops to take effect. 
3| Draw 1 uL of AAV2 virus (stored on ice) into the Hamilton syringe. Grasp the 
conjunctiva at the limbus with forceps to steady the globe. Inject the solution through the 
superior nasal sclera at a 45° angle, avoiding the lens, external ocular muscle, and blood 
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vessels. The needle should be visible through the dilated pupil and its position can be 
monitored visually. 
4| To relieve intraocular pressure and prevent backflow of the injected solution, puncture 
the anterior chamber with a sterile 30-gauge needle to drain the aqueous humor. After a 
few seconds, withdraw the syringe and rinse the injected eye with a few drops of sterile 
saline solution. Apply lubricating ointment (e.g., LacriLube) to both eyes. 
5| Inject 1.0 mg/kg buprenorphine SR (e.g. 0.02 mL for a 20 g mouse) subcutaneously and 
place the mouse in a heated chamber with supplemental oxygen flow until it recovers 
from anesthesia and becomes mobile. Upon full recovery and resumption of normal 
exploratory behavior, typically 60-90 min., return the mouse to its cage. Rinse the 
syringe with ethanol followed by sterile PBS between injections. If different viruses are 
being used, it is advisable to switch needles as well. 
6| Repeat steps #2-5 for each subsequent mouse. When surgeries are completed, clean and 
sterilize all instruments and return the mice to their housing facility. Monitor mice for 
signs of ocular inflammation over the following days, treating the cornea with 
lubricating ointment if it appears dry or irritated. 
Optic nerve crush and implantation of gelfoam scaffold (4 h) 
7| AAV2 takes ~2 weeks to achieve robust expression of the delivered gene in retinal 
neurons. On day 14 after the virus injection, anesthetize 2-3 mice at a time, as above. 
8| Use a hemostat to clamp the skin above the upper eyelid, drawing it back to expose the 
globe. Prolapse the globe so it protrudes slightly. Ensure the sclera remains moist 
throughout the procedure. Apply sterile saline with a sterile cotton swab as needed. 
Drying of the eye can lead to cornea damage. 
9| Make small incision in conjunctiva, moving from inferior-temporal to superior-temporal 
in an arc of about 45°. With micro-forceps, grasp the conjunctiva near the limbus and 
rotate the globe nasally to expose its posterior aspect. With the forceps tips closed to 
avoid puncturing the sclera, slide the curved forceps through the open incision in the 
conjunctiva and underneath the external ocular muscle. Carefully open the forceps to 
reveal the optic nerve, grasp the nerve 1 mm from the globe, and clamp down firmly for 
10 seconds. It is essential to avoid puncturing the ophthalmic artery or damaging the 
external ocular muscle. If the artery bursts and severe bleeding occurs, surgery should be 
abandoned and the mouse should be euthanized and removed from the study. Mice 
should be monitored in the days following surgery to ensure no bleeding has occurred. 
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Mydriasis should be observed upon crush. Rinse a small circular cover glass with sterile 
PBS and hold it against the globe to flatten the cornea and visualize the fundus. Ensure 
that the retinal blood flow is undisturbed; retinal arteries should be visibly perfused. 
Ischemia caused by bleeding of retinal or ophthalmic blood vessels can compromise 
retinal neurons. 
10| With curved forceps, remove the gelfoam scaffold from its sterile tube (stored on ice). 
Carefully insert the scaffold through the open incision in the conjunctiva until it is in 
contact with the lesioned optic nerve, approximately 1 mm behind the globe. Carefully 
remove the forceps and rotate the globe back into place. Apply lubricating ointment 
(e.g., LacriLube) to both eyes. 
11| Inject 0.02 mL buprenorphine SR subcutaneously and place the mouse in a heated 
chamber with supplemental oxygen flow until it recovers from anesthesia and becomes 
mobile. Upon full recovery and resumption of normal exploratory behavior, typically 60-
90 min., return the mouse to its cage. Rinse the syringe with ethanol followed by sterile 
PBS between injections. If different viruses are being used, it is advisable to switch 
needles as well. 
12| Repeat steps #8-10 for each subsequent mouse. When surgeries are completed, clean and 
sterilize all instruments and return the mice to their housing facility. Monitor mice for 
signs of ocular inflammation or bleeding over the following days, treating the cornea 
with lubricating ointment if it appears dry or irritated. 
Intravitreal injection of axon tracer (2 h) 
13| On day 12 after optic nerve crush (2 days prior to tissue collection), anesthetize 2-3 mice 
at a time, as above. 
14| Draw 1 µL of CTβ (stored on ice) into the Hamilton syringe. Grasp the limbus with 
forceps to steady the globe. Inject the solution through the superior nasal sclera at a 45° 
angle, avoiding the lens, external ocular muscle, and blood vessels. Puncture the anterior 
chamber with a sterile 30-gauge needle. Withdraw the syringe and rinse the eye with a 
few drops of saline. Apply ophthalmic ointment and recover animals as above. 
Tissue collection (8 h) 
15| Transcardial perfusion. On day 14 after optic nerve crush, administer a fatal dose of 
euthatal (sodium pentobarbitone; 1.5 mL per mouse, i.p.) and ensure the mouse is fully 
anesthetized by confirming lack of withdrawal reflex. Using operating scissors, open the 
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chest cavity, make two cuts on either side of the cavity to retract the ribs, and open the 
diaphragm to expose the heart. Pierce the left ventricle with a needle attached to an 
elevated PBS drip, and clamp the cardiac tissue around the needle with a hemostat to 
keep the needle in place. Make a small cut in the right atrium to open the circulation. 
16| Perfuse the mouse with PBS (0.1 M, pH 7.4) for ~5 min or until the circulation is 
completely flushed and the fluid flowing from the right ventricle is clear. 
17| Perfuse the mouse with 4% PFA in 0.1 M PBS for ~5 min. PFA is toxic. Perform 
perfusions in a fume hood and wear personal protective equipment, including gloves, 
goggles, and a face mask. 
18| Optic nerve dissection. Isolate the head with large operating scissors. With small narrow 
scissors, make an incision in the skin, moving caudal-to-rostral from the base of the skull 
to the nose. Make a similar cut in the skull bone, followed by two lateral cuts from the 
base of the skull to just above the orbit on each side. With forceps, peel the bone forward 
to remove it, exposing the brain. 
19| Cut the olfactory bulbs and lift the brain to expose the optic nerves and chiasm. With 
Vannas spring scissors, carefully cut the optic tract, leaving the optic chiasm intact. 
Remove and discard the brain. 
20| Remove the orbital bone behind the globe, taking care not to disturb the optic nerve. 
With Vannas spring scissors, carefully remove the meninges from the optic nerve, 
cutting from the optic chiasm entry point to the optic nerve head. Separate the optic 
nerve from the globe. Repeat for both optic nerves, then carefully remove the intact optic 
pathway and lay it flat on a piece of filter paper. Transfer the filter paper to a labeled 24 
well plate containing 1 mL of 4% PFA. Post-fix the nerves overnight at 4 °C. The optic 
nerve is extremely delicate, particularly at the lesion site. Any strain on the nerve may 
deform or disconnect the tissue. It is also essential to lay the nerve flat on the filter 
paper, as bending or twisting of the nerve may disrupt the ultrastructure of the axons. 
21| Globe dissection. Isolate the globe away from the orbital cavity with a curved 
ophthalmic scissor. The globe can be more easily exposed by removing the eyelids. 
Transfer the intact globe to a labeled 48 well plate containing 1 mL of 4% PFA. Post-fix 
the globe for 60 min at room temperature. 
22| Retinal flatmount preparation. Place the post-fixed globe in a small weigh boat filled 
with PBS. Use microscissors to make an incision at the limbus, then cut along the limbus 
to remove the cornea. Remove the lens and iris, taking care to prevent retinal 
detachment, as the lens may be connected to the retina via the vitreous body. While 
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grasping the sclera to stabilize it, insert closed forceps between the sclera and retina and 
gently nudge the retina free of the sclera. When the retina is fully detached from the 
limbus, pinch the optic disc with forceps to sever connecting axons. Carefully remove 
any strands of vitreous body still attached to the retina. Make four exterior cuts, roughly 
half the radius of the retina, dividing the retina into equal quadrants to create a “clover 
leaf” shape. Using a liquid transfer pipette, transfer the retina to a 48 well plate. Store in 
0.05% sodium azide for up to 4 weeks prior to immunostaining. 
Optic nerve processing (3 d) 
23| After optic nerves have been post-fixed for 24 h in 4% PFA, replace the solution with 
30% sucrose for cryoprotection. 
24| Immediately before sectioning, immerse optic nerves in OCT compound for at least 5 
min. Taking care not to touch the lesion site or damage the nerve, transfer the nerve to 
the surface of a glass SuperFrost slide, and place the slide on dry ice to snap-freeze the 
tissue, ensuring the nerve lies perfectly flat and straight. As the OCT begins to freeze, 
carefully add a small dollop of OCT on top of the nerve, avoiding the creation of any air 
bubbles. 
25| Freeze OCT in a cubic embedding mold to create a uniform block with no air bubbles. 
Mount the block of OCT in the cryostat and arrange the cryostat blade such that the OCT 
block sectioned easily. Cut the block down to create a flat surface, then remove the 
detachable mounting stub with the block affixed. Mark the orientation of the block to 
ensure the cutting angle of the blade remains unchanged upon re-mounting. Cryostat 
blades are sharp and should be handled with care. 
26| Using a razor blade, carefully detach the embedded optic nerve embedded from the glass 
slide, checking that the tissue is visible in the flat surface of the frozen OCT with no 
bubbles, chips or breaks. Place a dollop of OCT on the flat surface of the mounted block 
and quickly adhere the flat surface containing the embedded nerve directly to the block, 
ensuring that the nerve is flush and positioned along the vertical axis. After this 
“sandwich” has solidified, re-mount the stub in the cryostat. 
Section the optic nerve at 14 um thickness onto glass superfrost slides. A flat nerve of 
roughly 300 um thickness should produce around 20 sections, which can be distributed 
across multiple slides. Dry the slides, wash at least three times with PBS, add 2-3 drops 
of mounting medium, and carefully lay cover glass over the slides, avoiding bubbles. 
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Store slides at 4 °C until they are ready for imaging. Slides can also be stored below -20 
°C and immunostained prior to mounting and imaging. 
Retinal flatmount processing (3 d) 
27| Remove sodium azide solution and wash three times with 1 mL 0.5% Triton X-100 in 
PBS (PBST) at room temperature. The 48-well plate containing the floating retinas 
should be placed on a rocker at a slow speed for all washing and incubation steps. When 
removing solutions, take care to pipette from the corner of the well so as not to suck up 
or damage the delicate retinal tissue. 
28| Add 500 µL blocking buffer (PBS, 2% BSA, 2% Triton, 10% NGS). Incubate for 1 h. 
29| Add 350 µL primary antibody (rabbit anti-RBPMS, diluted 1:500 in blocking buffer). 
Incubate overnight at 4 °C. 
30| Wash three times with PBST for 30 min each at room temperature. 
31| Add 350 µL secondary antibody (Oregon green-conjugated goat anti-rabbit IgG, diluted 
1:1,000 in PBST). Incubate for 2 h at room temperature. Wrap the 48 well plate with 
aluminum foil to prevent photobleaching of fluorophores. 
32| Wash three times with PBS for 30 min each at room temperature. If desired, DAPI may 
be added (diluted 1:10,000 in PBS) in the second wash. 
33| Using a fine paint brush, transfer the retina to a glass SuperFrost slide. Ensure the 
ganglion cell layer is facing up, and use the paint brush to remove any wrinkles. Use a 
dry wipe to remove excess PBS before adding mounting medium to the slide and 
carefully applying a glass cover slip. Handling retinal tissue with the paint brush may 
damage cells. Take care not to disrupt the ganglion cell layer. 
34| Keep mounted slides in a dark container at 4 °C to preserve fluorescent signal until they 
are ready for imaging. 
Image capture (12 h) 
35| Optic nerve imaging. Use a Zeiss 780 confocal microscope with Zeiss imaging software. 
Using the 40× objective with immersion oil and the red channel, identify the optic nerve 
crush lesion site by locating the area of high density CTΒ-labeled axons. Perform a 
bounded grid tile scan by positioning the imaging field at the top and bottom of the 
lesion, store these positions, and then move to the distal end of the optic nerve and store 
the positions where the optic tracts exit the optic chiasm. Capture a tiled, z-stacked 
image (using a step size of < 1 μm) that contains the entire optic nerve and chiasm. 
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Repeat this step for each section to be imaged, at least four sections per mouse. It is 
straightforward to substitute alternative models of confocal microscopes and 
corresponding software without altering the protocol. All image capture and analysis 
should be performed by an experimenter blinded to the experimental groups and 
conditions. 
36| Retinal flatmount imaging. Use the Zeiss 780 confocal microscope with Zeiss imaging 
software (a standard epifluorescence microscope is also acceptable). Focus on the 
ganglion cell layer, which will contain green RBPMS+ and red CTΒ+ RGCs. Using the 
20× objective, capture three 500 μm × 500 μm regions of the retina from each quadrant: 
one from the central retina, one from the middle retina, and one from the peripheral 
retina. Each retina should yield 12 images. 
Image analysis (4 h) 
37| Optic nerve image analysis. Use ImageJ software to open each of the tiled, z-stacked 
images. In the Image menu, select Stacks, followed by Z Project to create a maximum 
intensity projection of the z-stack. Using the line tool, draw a horizontal line of 0.25 mm 
length extending distally from the lesion site. The lesion site can be identified by the 
bright line of severed axons. In samples with robust regeneration, it is useful to examine 
the DAPI channel to identify the lesion site, which contains substantially higher 
cellularity. Using the line tool, measure the radius of the optic nerve at the 0.25 mm 
point and record this number. Draw a vertical line at the 0.25 mm point, and use the 
microscope tool to zoom in so that CTΒ+ axons are easily visible. Count the total number 
of CTΒ+ axons transecting the vertical line and record this number. Repeat this step for 
successive distances in increments of 0.25 mm, proceeding from the lesion site to the 
optic chiasm (typically about 4-5 mm total, assuming a lesion located 1.0 mm from the 
eye). Count at least four sections from each optic nerve. When measuring distances in 
μm from saved images, it is essential to confirm that the metadata accurately converts 
pixels to μm. This can be done by opening the ‘Image’ menu and selecting ‘Properties.’ 
38| Retinal flatmount image analysis. Use ImageJ software to open each of the 500 μm × 
500 μm captured images. In the Image menu, select ‘Channels tool’ and convert to 
grayscale, then select ‘Split channels’ to isolate the green RBPMS channel. In the Image 
menu, select Adjust, then Threshold to apply a threshold to eliminate background noise. 
The threshold will be dependent on the brightness settings used during image 
acquisition, but as a general rule, the round, brightly stained RBPMS+/CTΒ+ RGCs 
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should be preserved while any faded RBPMS+/CTΒ- cells should be excluded. Select the 
multi-point tool and mark each cell in the image. Record the total number of cells per 
image. 
Calculations (1 h) 
39| RGC axon regeneration. The total number of regenerating CTΒ+ axons per nerve at each 
distance increment is calculated using a formula defined previously (Lim et al. 2016; Bei 






Where r = the maximum measured radius of the optic nerve at the defined distance 
increment, in µm, n = the number of transecting axons, t = the thickness of the section, in 
µm, which in this protocol equals 14 µm. 
40| RGC survival. Eight 20× images of each whole mount retina are acquired, one from the 
central retina of each quadrant and one from the peripheral retina of each quadrant. The 
total number of surviving RBPMS+ RGCs is calculated by using the average total 
number of counted RGCs per image to define the mean RGC density (cells/mm2) in each 
sample. The total area of the retinal sample is obtained by acquiring a tiled image of the 
whole retina, defining the boundary in ImageJ, and measuring the area of the bounded 
region. Multiplying the mean RGC density by the total area of the retina yields the total 
number of surviving RBPMS+ cells. To determine percent survival, this value is 
compared with the number of RBPMS+ cells calculated in the non-lesioned contralateral 




The timing information below corresponds to an experiment in which 18 animals are used: 
Steps 1-6, intravitreal injection of virus: 2 h 
Steps 7-12, optic nerve crush and implantation of gelfoam scaffold: 4 h 
Steps 13-14, intravitreal injection of axon tracer: 2 h 
Steps 15-22, tissue collection: 8 h 
Steps 23-26, optic nerve processing: 3 d 
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Steps 27-34, retinal flatmount processing: 3 d 
Steps 35-36, image capture: 12 h 
Steps 37-38, image analysis: 4 h 
Steps 39-40, calculations: 1 h 
 
3.4  |  TROUBLESHOOTING 
Troubleshooting advice can be found in Table 3.1. 
 
Table 3.1 | Troubleshooting table. 
Step Problem Possible reason Solution 
1, 7, 13 Animals continue 
to exhibit 
withdrawal reflex. 
Anesthetic dose is 
insufficient. 
Wait at least 15 min, then 
administer an additional injection 
of ketamine (10 mg/kg). If the 
mouse still does not display proper 
depth of anesthesia, remove the 
subject from the study. 
 
9 Bleeding occurs 
due to damage of 
the ophthalmic 
artery. 
Surgical error. Immediately euthanize the mouse 
and note the removal of the subject 
from the study. 
 




Tissue was deformed 
during the fixation or 
embedding step, or 
mounted at an angle. 
Adjust the angle of the cryostat. If 
the optic pathway is not in a flat 
plane, section as much of the 
tissue as possible and evaluate 
sections during image acquisition. 
Images where the lesion site is not 
detectable should be discarded. 
40 Survival of RGCs 
in lesioned, 
untreated control 





Perform a pilot experiment with 
lesioned, untreated controls and 
assess RGC survival at several 
time points. Ensure that the RGC 
death profile matches previously 
published time course to confirm 
that surgical technique is adequate. 
 
3.5  |  RESULTS 
 
3.5.1  |  Anticipated results from a generalized experiment 
 
RGC axons undergo Wallerian degeneration immediately following ONC, and the 
cell bodies in the retina start dying within 5 to 6 days in the absence of treatment (Fischer & 
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Leibinger 2012). By 14 days, roughly 90% of RGCs have become unviable, and are therefore 
unable to contribute to the regeneration of axonal tracts (Fischer & Leibinger 2012). 
Intravitreal injection of AAV2 typically infects 80-90% of RGCs, with some off-target 
infection of Muller glia and other retinal neurons (Buch et al. 2008). In our laboratory, we 
have found that the enhancement of cell survival correlates with the quality of the injection, 
as reflux of injected virus can lead to lower infection efficiency. The RBPMS antibody 
reliably labels 94-97% of RGCs and does not label other retinal neurons (Kwong et al. 2010). 
This means that efficiency of injected AAV2 with a gene for a fluorescently tagged protein 
such as GFP can be easily quantified by co-labeling with RBPMS and calculating the number 
of GFP+/RBPMS+ cells in retinal flatmounts. Furthermore, cells that survive after injury can 
be identified as GFP+ or GFP-. Regenerating axons are easily visualized with CTβ, although 
care should be taken when analyzing tissue sections, as axons spared by an incomplete ONC 
will also be CTβ+. Another advantage of CTβ is that it enables 3D visualization of 
regenerating axons via whole mounting and tissue clearing of nerve tissue, followed by 
confocal or light sheet fluorescence microscopy (Luo et al. 2013). Optic nerve sections 
should be examined for signs of spared axons, including uncharacteristically straight paths 
and groups of axons near the periphery of the nerve traveling long distances (Figure 3.1) 





Figure 3.1. Identifying spared vs. regenerating axons. (a) Micrograph showing incomplete 
crush of a mouse optic nerve results in the presence of spared axons that are visualized by 
CTβ injected 3 weeks following the surgery. (a’) Inset showing spared axons that appear 
uncharacteristically linear, often grouped near the periphery of the optic nerve. (a’’) Inset 
showing spared axons traversing the optic chiasm into the contralateral optic tract, again with 
uncharacteristically linear morphology and close grouping. Asterisk indicates lesion site. 
Scale bar = 200 μm. Figure adapted from (Fischer et al. 2017). 
 
Many pro-regenerative therapies are additive, meaning that their enhancement of axon 
regeneration is greater when delivered together than separately. This creates a necessity for 
rigorous control groups where individual components of a therapy are tested in isolation, to 
determine whether they are additive or redundant, and to what degree. Different treatments 
can also stimulate regeneration from different RGC subtypes, as was recently demonstrated 
(Norsworthy et al. 2017). It may be useful for future experiments to utilize transgenic mouse 
lines with labeled RGC subtypes to determine whether treatments preferentially enhance 
regeneration from specific subtypes. Optic nerve sections may also be probed with antibodies 
against specific cell markers and proteins, enabling studies of the interactions between 
regenerating axons and non-neuronal cells or extracellular matrix in the optic nerve. My 
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protocol describes the basic steps of an ONC experiment, but adaptations and additions such 
as these permit a wide range of flexibility for analysis of different mechanisms and outcomes. 
I have detailed an experiment using adult C57/Bl6 mice. It is known that the regenerative 
capacity of RGCs declines with age (Goldberg, Klassen, et al. 2002), and so the numbers 
given here do not reflect those likely to be found in much younger or older animals. Given 
the fact that many degenerative CNS conditions occur more frequently in older populations 
of patients, future studies may wish to examine more carefully the effects of age on RGC 
survival and axon regeneration, and the receptiveness to treatments such as those described 
here. 
 
3.5.2  |  Enzymatic modification of the extracellular matrix in the mouse optic nerve 
 
To demonstrate the efficacy of applying CSPG-targeting enzymes directly to the optic 
nerve, I first assayed their activity over time in vitro and in vivo, and then measured the 
functional digestion of GAG chains by ChABC in optic nerve tissue. ChABC cleaves GAG 
chains at the linkage sites between disaccharides, releasing them from the proteoglycan core 
protein (Figure 3.2a). These disaccharide products possess an absorbance peak at 232 nm. 
Therefore, the activity of ChABC can be reliably measured by introducing a small volume of 
ChABC into a solution containing purified CSPG substrate, and then quantifying the change 
in absorbance at 232 nm. ARSB activity can be measured by introducing the enzyme to a 
solution containing 4-nitrocatechol sulfate, a 4-sulfated substrate whose absorbance peak 
shifts from yellow to red (510 nm) when the 4S group is removed (Roy 1987) (Figure 3.3b). 
I incubated ARSB and ChABC at physiological temperature (37 °C) for 4 d and found that 







Figure 3.2. Maintenance of ChABC and ARSB activity in vitro. (a) Schematic diagram 
showing chondroitinase ABC digestion of the glycosaminoglycan chain and the reaction 
products. (b) Schematic diagram showing arylsulfatase B digestion of 4-nitrocatechol sulfate 
and the reaction products. (c) Graph showing changes in assayed activity of ChABC and 





 I then evaluated the activity of ARSB and ChABC in vivo. Gelfoam scaffolds soaked 
with ARSB, ChABC, or a control buffer were implanted in direct contact with non-lesioned 
mouse optic nerves (Figure 3.3a). Mice were sacrificed at 1, 2, and 4 d post implantation 
(dpi), gelfoam scaffolds were recovered, and their contents were assayed for ARSB or 
ChABC activity. Activity detected from recovered scaffolds was then normalized against 
fresh stock solutions of the two enzymes. At 1 dpi, solutions from ARSB-loaded scaffolds 
showed significantly (p < 0.05) higher ARSB activity than buffer-loaded scaffolds (Figure 
3.3b). The ChABC-loaded scaffolds showed no measurable difference in recovered ChABC 
activity at any time point when compared with buffer-loaded scaffolds (Figure 3.3b). Next, 
the ability of implanted enzymes to modify CSPGs within the optic nerve was tested. 
Because changes in terminal sulfation of GAG chains can only be detected by highly 
sensitive methods such as mass spectrometry, I relied on ChABC, whose digestion products 
are easily detected by immunohistochemistry, as representative of both enzymes. ChABC-
loaded scaffolds were implanted in lesioned mouse optic nerves at 3 dpc, then recovered at 5 
dpc (Figure 3.3c). Immunoreactivity of CS-56, which detects intact CSPGs, was significantly 
(p < 0.05) decreased in ChABC-treated samples when compared with buffer-treated samples 
(Figure 3.3d-e). Correspondingly, immunoreactivity of BE-123, which detects “stub” 






Figure 3.3. Maintenance of ChABC and ARSB activity in vivo. (a) Schematic diagram 
showing treatment of non-lesioned optic nerves with ARSB, ChABC, or buffer. (b) Graph 
showing activity of enzymes recovered from implanted gelfoam scaffolds, normalized to 
activity measurements from enzyme solutions prior to implantation. Statistical significance 
was determined by Student’s t-test. * p < 0.05. (c) Schematic diagram and experiment 
timeline showing treatment of lesioned optic nerves with ChABC or buffer. (d) Micrographs 
showing CS-56 staining of ChABC-treated and control optic nerves. Scale bar = 100 µm. (e) 
Graph showing quantification of CS-56 fluorescence intensity of insets centered at the lesion 
site. Statistical significance was determined by Student’s t-test. * p < 0.05. (f) Micrographs 
showing BE-123 staining of ChABC-treated and control optic nerves. Scale bar = 100 µm. 
(g) Graph showing quantification of BE-123 fluorescence intensity of insets centered at the 




 Quantitative analysis of protein or RNA from mouse optic nerve tissue is challenging 
due to the nerve’s small size (~5 mm from eye to optic chiasm, with a diameter of ~250 μm). 
Isolating the site of a lesion, where astrogliosis takes place over the days and weeks following 
ONC, is even more difficult, as collecting too much tissue reduces the signal-to-noise ratio 
around the lesion site, whereas collecting too little yields insufficient amounts of protein or 
RNA. I developed a dissection protocol that enables successful Western blot analysis of 
tissue from the region directly behind the eye, containing the ONC lesion site, and measured 
the average protein yield. Optic nerves from non-lesioned mice were cut into four equal-sized 
segments of ~1 mm length and each placed in 30 μL of lysis buffer (cOmplete™ Lysis-M 
EDTA-free buffer, Sigma) (Figure 3.4a). Tissue was mechanically homogenized with a 
sterile pestle and centrifuged. The protein concentration of the supernatant was measured 
using a bicinchoninic acid (BCA) assay. The average protein amount of 1 mm optic nerve 
segments was 11.3±0.48 µg (mean±SE). To assess whether the BCA was precise and confirm 
that extracted proteins could be detected by immunoblotting, I loaded 2 μg protein from 
individual segments isolated from two optic nerves (left and right) of the same mouse, then 
performed gel electrophoresis and Western blot analysis using an anti-β actin antibody. Actin 
bands of comparable intensity were observed in the membrane (Figure 3.4b), confirming that 
protein extracted from 1 mm segments of mouse optic nerve can be semi-quantitatively 






Figure 3.4. Extraction of protein from optic nerve segments. (a) Schematic diagram 
showing dissection of optic nerve tissue into ~1 mm segments and preparation of protein 
lysates. (b) Western blot image showing optic nerve protein extracts from two optic nerves 




3.6  |  DISCUSSION 
 
Few experimental therapies that seek to stimulate optic nerve regeneration target the 
extracellular matrix, due to the relative difficulty of accessing the optic nerve directly as 
opposed to introducing therapeutic substances into the eye. In rats, direct injection of 
enzymes or tracers into the optic nerve has been demonstrated, although such studies remain 
rare (Raykova et al. 2015; D’Onofrio et al. 2011). In mice, some studies have used gelfoam to 
deliver therapeutic substances, but the kinetics and efficiency of delivery were not reported 
(Brown et al. 2012). Here, I have outlined a complete protocol for a prototypical experiment 
involving intravitreal injection, optic nerve crush, application of gelfoam scaffolds to the 
optic nerve, collection of tissue, and analysis of RGC survival and axon regeneration. I 
present evidence that confirms the maintenance of activity and effectiveness of CSPG-
targeting enzymes delivered to the optic nerve via an implanted scaffold, and I show that 
protein extracted from small segments of optic nerve tissue can be semi-quantitatively 
analyzed using Western blot. This detailed and rigorous protocol will facilitate the use of 
ECM-targeting therapies in future studies of optic nerve regeneration, a crucial consideration 
for combinatorial treatments that endeavor to stimulate long-distance regeneration of RGC 
axons. 
An important finding was that ARSB maintains its activity over an appreciable 
timescale both in vitro and in vivo, whereas ChABC activity declines quickly under 
physiological conditions. It is important to note that most of the loaded enzyme in our 
gelfoam scaffold will have diffused away by the time the scaffold is recovered days after the 
implantation; therefore, the observance of significant trace amounts of ARSB activity in the 
scaffold is indicative of more robust activity, not adequately reflected by the low amplitude 
of the assay’s absorbance change. Similarly, while my protein yield of 11.3 μg per 1 mm 
nerve segment is relatively small, I showed that this amount is sufficient for repeated Western 
blot analyses, making this strategy amenable to the detection of changes in protein expression 
at the site of an ONC lesion. In Chapter 4, I utilize the methods described here to evaluate 
changes in CSPG expression following injury and design a therapy that uses ARSB and 




CHAPTER 4: IDENTIFICATION OF A CRITICAL SULFATION IN 
CHONDROITIN THAT INHIBITS AXONAL REGENERATION 
 
4.1  |  INTRODUCTION 
 
The deposition of inhibitory CSPGs at the site of CNS lesions is a major obstacle to 
regeneration of neurons in the brain, spinal cord, and optic nerve. While experimental 
therapies such as injections of ChABC to digest the GAG chains of CSPGs have been 
attempted in the spinal cord (Bradbury & Carter 2011), most treatments in the visual system 
prioritize intrinsic modifications to RGCs. These interventions have demonstrated substantial 
success in stimulating moderate levels of axonal regeneration, and in some cases, axons have 
been reported at central targets in the brain (de Lima et al. 2012; Kurimoto et al. 2010; Lim et 
al. 2016). Given these advances, addressing the extrinsic barriers to regeneration has emerged 
as a critical next step in promoting robust, long distance regeneration of visual neurons. As I 
noted in Section 1.6.6, evidence exists that CSPGs may be upregulated in the optic nerve 
(Brown et al. 2012; Sellés-Navarro et al. 2001; Sengottuvel et al. 2011; Qu & Jakobs 2013), 
but a comprehensive examination of this phenomenon has not been performed, and no studies 
have specifically analyzed changes in 4S GAGs following injury. Among the key challenges 
of modifying the extracellular matrix in the optic nerve are refining the methods of surgical 
intervention (addressed in Chapter 3) and selectively targeting inhibitory molecules without 
altering damage-restricting and/or growth-promoting features of the lesion 
microenvironment. In this chapter, I describe the importance of 4-sulfated CSPGs as 
inhibitors of neuronal growth and axonal regeneration, characterize the extracellular features 
of astrogliosis following acute injury to the optic nerve, and provide evidence that ARSB 
specifically cleaves 4S from the non-reducing ends of GAG chains and promotes 
regeneration after optic nerve crush. 
 
4.1.1  |  Reactive gliosis as a barrier to axon regeneration 
 
In recent years, studies of astrogliosis have overturned the long-held notion that the 
astrocytic scar is unilaterally opposed to axon regeneration. A recent study discovered that 
reactive astrocytes can be divided into two genetically distinct subtypes, of which only one, 
A1 astrocytes, actively suppresses axon growth (Liddelow et al. 2017). The RNA expression 
profiles of A1 and A2 astrocytes were described, and it was discovered that A1 astrocytes are 
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activated by microglia-secreted cytokines. Upon activation, A1 astrocytes induce death of 
neurons and oligodendrocytes and contribute to the failure of CNS axons to regenerate 
following injury. The study showed evidence that specifically blocking A1 astrocyte 
formation enhances RGC survival after ONC. Whether A1 and A2 astrocytes produce CSPGs 
equally, or whether the CSPGs they produce might differ in their sulfation pattern or core 
proteins, was not explored and thus deserves further study. In a similar approach, another 
group characterized astrocyte responses to spinal cord injury over time (Hara et al. 2017). 
They described three phases of astrocyte reactivity based on morphological and genetic 
criteria: naïve astrocytes (NAs) populate the uninjured spinal cord; reactive astrocytes (RAs) 
were found at 7 days post injury (dpi) and expressed nestin and β-catenin; and scar-forming 
astrocytes (SAs) were found at 14 dpi and expressed N-cadherin and Sox9. Notably, RNA 
analysis revealed that SAs expressed elevated levels of several CSPG-related transcripts. 
Blocking the transformation of RAs to SAs reduced glial scar formation and GFAP 
expression, and increased the number of GAP-43+ axons in spinal cord lesions. These 
findings imply that the emergence of SAs between 7 and 14 dpi is instrumental to the glial 
scar’s inhibition of axon regeneration. The link between SAs and CSPG production is likely a 
primary driver of this effect, although the published study did not investigate this connection. 
Additional evidence suggests that CSPGs, rather than astrocytes themselves, are 
responsible for the hostile effects of the glial scar on regenerating axons. It has been shown 
that preventing astrogliosis in the spinal cord by using transgenic mice engineered to kill 
proliferating scar-forming astrocytes successfully attenuates astrocytic scar formation but 
fails to promote axon regeneration (Anderson et al. 2016). Notably, even ablating chronic 
astrocytic scars 5 weeks after injury did not lead to spontaneous regeneration (Anderson et al. 
2016). These transgenic mice did not show decreased CSPG levels within or around the 
lesion after astrocytic scar ablation, perhaps due to the fact that many non-astrocytic cells 
were found associated with CSPGs, implying that these non-astrocytic cells may produce 
CSPG after injury (Anderson et al. 2016). It is therefore likely that the persistence of CSPGs 
within the astrocytic scar, rather than the astrocytes themselves, is a primary source of 
extrinsic axon inhibition in CNS lesions, and that attenuating astrogliosis without reducing 
the deposition of axon-inhibitory CSPGs is insufficient to promote regeneration and 
functional recovery. The observation that regenerating axons associate with astrocyte 
processes (Davies et al. 1997) further supports the theory that astrocytes in the glial scar are 
not intrinsically inhibitory to axonal growth. 
111 
 
The mechanisms by which CSPGs inhibit axonal growth are not entirely understood. 
During neuronal development, as described previously, CSPGs play the role of repulsive 
guidance cues, inducing growth cone turning away from areas of high CSPG concentration to 
prevent growing axons from deviating from their proper paths (Erskine & Herrera 2007). 
This process appears to be largely mediated by the binding of surface receptors in neurons to 
domains in the GAG chains of CSPGs, initiating signaling cascades that lead to growth cone 
collapse. However, evidence also exists that argues for an attractive interaction between 
axons and CSPGs. Some have argued that growth cones become entrapped by CSPGs by 
showing cultured neurons with axons stalled in areas coated with CSPGs (Filous et al. 2014). 
Treating cultures with ChABC appears to “release” these trapped axons (Filous et al. 2014). 
The contact points between axons and CSPG occasionally express proteins associated with 
synapse formation (Filous et al. 2014). This aggressive “stabilization” of growth cones leads 
to the formation of dystrophic endbulbs at the axon terminal (Lang et al. 2014). Therefore, it 
could be argued that, in some contexts, CSPG-mediated inhibition of axon growth is a 
product of excessive adhesion as opposed to repulsion. Importantly, this specific observation 
appears to be predominantly related to the NG2 proteoglycan, which is expressed on the 
surface of OPCs (Filous et al. 2014). Whether this phenomenon also holds true for CSPGs 
produced by reactive astrocytes or activated microglia was not explored. Understanding the 
differences between the mechanisms of CSPG interactions with axons in development and 
following injury, as well as of different CSPG core proteins and GAG chains, is therefore 
essential for developing treatments that aim to stimulate axonal regeneration. 
Despite their central role, CSPGs are by no means the only component of the glial scar 
that inhibits axonal regeneration. For instance, extensive research has demonstrated that 
activated macrophages can cause the retraction of axons through physical contact, 
ligand/receptor interactions, and secretion of proteases (Silver 2016; Horn et al. 2008; Busch 
et al. 2009; Busch et al. 2010; Hollis & Zou 2012; Gensel et al. 2015). Additionally, 
neurotoxic A1 astrocytes appear to play a key role in the spread of tissue damage and 
regeneration failure after injuries (Liddelow et al. 2017). While I have focused my 
experiments on modifying CSPGs, addressing the roles of these other cells, including how 
they interact with CSPGs and other ECM proteins, is vital for developing a comprehensive 
understanding of the glial scar and designing therapies that most effectively enable axons to 




4.1.2  |  Importance of GAG sulfation after CNS injury 
 
Studies that link CSPGs to the failure of axon regeneration overwhelmingly fail to 
distinguish between differentially sulfated GAG chains, often showing instead that digestion 
of GAG chains with ChABC enhances neurite growth in vitro and axon regeneration in vivo 
(Bradbury & Carter 2011). The importance of sulfation in governing CSPG function has been 
demonstrated using sodium chlorate, which broadly eliminates GAG sulfation (Smith-
Thomas et al. 1995). Recent studies have characterized the behaviors of specific sulfation 
motifs. For instance, axons grow readily over surfaces coated with 6S CSPGs (Wang et al. 
2008), and deleting the enzyme that adds 6S to GAGs impairs axonal regeneration in mice 
(Lin et al. 2011). In contrast, axons avoid 4S GAGs, an effect abolished by treatment with 4-
sulfatase (Wang et al. 2008). Elevation of 4S has been observed after traumatic brain injury 
(Yi et al. 2012). Notably, the area of CSPG immunoreactivity surrounding the lesion core 
overlapped with 4S, but not 6S, suggesting a differential expression of these sulfation motifs 
following injury (Yi et al. 2012). Production of 4S was not limited to a single cell type, but 
was associated with astrocytes, microglia, macrophages, OPCs, and fibroblasts, implying 
multicellular sources of 4S GAG, although direct evidence of production was not 
demonstrated in each case (Yi et al. 2012). In addition to the brain, another study showed 
elevation of 4S deposition after spinal cord injury, and found that treating the lesioned area 
with ARSB improved motor function (Yoo et al. 2013). Blocking 4,6S with a custom 
antibody enhanced regeneration of RGC axons after ONC (Brown et al. 2012). The case of 
4,6S is particularly interesting, as it may be possible that GAG chains with terminal 4,6S 
could be converted to growth-permissive 6S motifs in the presence of ARSB. An age-related 
increase in the ratio of 4S to 6S was linked to declines in plasticity and memory (Foscarin et 
al. 2017; Miyata et al. 2012), indicating that sulfation-specific changes may be programmed 
to convert an environment that promotes growth and plasticity during development into a 
more inhibitory, stabilized environment in adulthood. Collectively, these observations 
suggest that reducing 4S while preserving 6S on intact GAG chains may be a viable strategy 
to enable growing axons to overcome CSPG-mediated inhibition, and that this may ultimately 
be more effective than indiscriminate reductions in sulfation or destruction of GAGs. I 
therefore sought to use ARSB to selectively remove 4S from the non-reducing ends of 




4.1.3  |  Arylsulfatase B 
 
ARSB is an enzyme that cleaves 4S groups from GalNAc at the non-reducing ends of 
GAG chains (Litjens & Hopwood 2001). ARSB is generally localized in the lysosome, where 
it initiates a stepwise degradation of GAGs. In humans, several mutations of the gene 
encoding ARSB have been reported (Litjens & Hopwood 2001). The absence or dysfunction 
of lysosomal ARSB interferes with GAG degradation, leading to an accumulation of partially 
degraded GAGs in the lysosome. Because this pathology affects multiple cell types, many 
tissues and organs are affected, leading to an extensive pathological phenotype. In humans, 
this condition is known as mucopolysaccharidosis type VI (MPS VI) or Maroteaux-Lamy 
syndrome. Its symptoms include skeletal abnormalities such as short stature and facial 
dysmorphism, stiff joints, clouding of the cornea, cardiac abnormalities, and 
hepatosplenomegaly. Interestingly, the nervous system is generally not affected, and patients 
have normal intelligence and do not suffer cognitive deficits. The myriad effects elsewhere in 
the body mean that patients with MPS VI suffer enormous reductions in quality of life. They 
also have a dramatically reduced life expectancy, often dying within two decades of birth. 
MPS VI affects anywhere from 1 in 100,000 to 1 in 1,300,000 patients depending on the 
population studied (Harmatz et al. 2004). The severity of this illness has led to aggressive 
research aimed at replacing absent or defective ARSB. In recent years, an enzyme 
replacement therapy was developed using recombinant human ARSB and has shown 
remarkable success (Naglazyme, Biomarin) (Muñoz-Rojas et al. 2010; Harmatz et al. 2004; 
Harmatz 2005). According to Biomarin, patients who undergo enzyme replacement therapy 
with Naglazyme experience a 23% improvement in a walking distance test and a 38% 
improvement in a stair-climbing test, indicative of reduced breathing difficulties and 
increased endurance. These beneficial effects were maintained over a period of ten years of 
regular treatments. 
The application of ARSB in the nervous system is relatively new. As a lysosomal 
enzyme, ARSB exhibits peak activity at acidic pH. However, evidence from in vitro and in 
vivo studies (Yoo et al. 2013), as well as my own work, demonstrates that ARSB maintains 
moderate activity even at neutral pH, making therapeutic use in the extracellular matrix of the 
CNS a viable possibility. One study has shown that ARSB can be inhibited by ethanol, and 
that when exogenous ARSB was added to astrocyte cultures, the presence of ethanol led to 
increases in CSPGs, including 4S, and inhibited the growth of neurites from neurons 
cocultured with these astrocytes (Zhang et al. 2014). The study concluded that the presence of 
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ARSB supports neurite growth and may reduce total 4S levels, and that silencing ARSB 
reverses these effects. ARSB was also delivered to the site of a spinal cord injury in mice, 
leading to improvements in motor function (Yoo et al. 2013). The objective of my studies 
was to characterize the increase in 4S expression within the glial scar following an optic 
nerve crush lesion, and then to selectively target elevated 4S by directly administering ARSB 
to the injured area. I combined ARSB with an intrinsic stimulus known to stimulate the 
regeneration of RGC axons, and evaluated the effects of ARSB both on axonal regeneration 
and on the morphology and composition of the glial scar. 
 
4.2  |  RESULTS 
 
4.2.1  |  ARSB reverses the inhibition of neurite growth caused by 4-sulfated CSPGs 
 
ARSB selectively cleaves sulfate groups from the C4 position of GalNAc at the non-
reducing ends of GAG chains (Figure 4.1a). In work performed by Dr. Caitlin Mencio, we 
studied whether this reaction can alter the inhibitory properties of CSPGs. We used a 
previously established cell culture model of the glial scar (Wang et al. 2008), where 
monolayers of confluent mouse astrocytes were treated with TGF-β to stimulate elevated 
CSPG production (Figure 4.1b). To assess whether neurite inhibition by CSPGs could be 
reduced through ARSB treatment, cultures of dissociated mouse hippocampal neurons were 
exposed to 5 µg/ml CSPG with and without ARSB treatment for 48 h. Cultures were stained 
for βIII-tubulin, and the lengths of neurites were measured. Neurons grown in the presence of 
CSPGs were significantly shorter (p < 0.0001) than untreated neurons (neurite length 
[mean±SE]: 77.7±6.2 µm and 122.2±9.3 µm, respectively) (Figure 4.1c-d). Growth was 
unaffected by CSPGs that had been treated with ARSB, suggesting that ARSB treatment was 
sufficient to remove neurite outgrowth inhibiting characteristics of CSPGs (Figure 4.1c-d). 
To test the actions of ARSB in a cellular model, monolayers of confluent mouse 
astrocytes were treated with TGF-β to stimulate elevated CSPG production (Figure 4.1b). 
Mouse cerebellar granule neurons (CGNs) were then seeded onto these astrocytes and 
allowed to grow for 24 h. Cultures were stained for GFAP and βIII-tubulin, and the lengths of 
CGN neurites were measured. Neurons growing on TGF-β-treated astrocytes exhibited 
significantly (p = 0.0024) lower neurite outgrowth than those plated on untreated control 
astrocytes (neurite length [mean±SE]: 67.4±4.4 µm and 89±7.6 µm, respectively) (Figure 
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4.1e-f). However, incubating TGF-β-treated co-cultures with ARSB restored average neurite 
length to the levels observed in untreated controls (Figure 4.1e-f), suggesting that cleaving 
4S from the non-reducing ends of GAG chains is sufficient to neutralize the inhibitory effects 
of CSPGs on neurons. 
To demonstrate that ARSB acts on extracellular CSPGs, rather than being internalized 
into astrocytes and interfering with CSPG production or secretion, conditioned medium (CM) 
was collected from TGF-β-treated astrocytes and left untreated, treated with ARSB or treated 
with ChABC. The isolated and treated CM was added to separately cultured CGNs. 
Application of CM from TGF-β-treated astrocytes significantly reduced neurite outgrowth 
while ARSB treatment reversed this effect to a degree equivalent to ChABC (Figure 4.2). 
Together, these findings demonstrate that the presence of CSPGs can inhibit neurite 
outgrowth, and that this inhibition is overcome by exposing the CSPGs to either ARSB or 
ChABC 
To further validate that ARSB does not interfere with CSPG secretion, the level of 
CSPGs in CM was measured by immunoblotting with the antibody CS-56, which reacts with 
4S and 6S groups on GAG chains (Avnur & Geiger 1984). The increase in CSPGs caused by 
TGF-β treatment (Wang et al. 2008) was not altered by treatment with ARSB, even after 
repeated additions (Figure 4.1b), indicating that its enhancement of neurite growth was 
derived from modifying the sulfation pattern rather than attenuating CSPG production or 
secretion. These data also demonstrate that CS-56 immunoreactivity is not altered by removal 





Figure 4.1. ARSB reverses neurite outgrowth inhibition caused by 4-sulfated CSPGs. (a) 
Schematic diagram showing actions of ARSB and ChABC on GAG chains. (b) Western blot 
showing CS-56 signal in conditioned medium. (c) Micrographs showing hippocampal 
neurons treated with no treatment, CSPG (5 µg/ml), or CSPG+ARSB. Scale bar = 25 µm. (d) 
Plot showing lengths of longest neurite measured from β-III-tubulin stained neurons. 
Statistical significance was determined by one-way ANOVA. (e) Micrographs showing co-
cultures of CGNs grown on astrocytes and treated with TGF-β, TGF-β and ARSB, or no 
treatment. Scale bar = 25 µm. (f) Plot showing lengths of longest neurite measured from β-
III-tubulin stained neurons. Statistical significance was determined by one-way ANOVA. * p 





Figure 4.2. ARSB reverses neurite outgrowth inhibition caused by 4-sulfated CSPGs. (a) 
Micrographs showing CGNs treated with astrocyte conditioned medium containing TGF-β 
and either ARSB, ChABC, or no enzyme. Scale bar = 25 µm. (b) Plot showing length of 
longest neurite measured from β-III-tubulin stained neurons, displayed as median. Statistical 
significance was determined by two-way ANOVA with Tukey post-hoc test for multiple 
comparisons. * p < 0.05. Figure produced by Dr. Caitlin Mencio. 
 
4.2.2  |  4-sulfated CSPGs are elevated following injuries to the optic nerve and spinal 
cord 
 
To assess the time course and spatial distribution of CSPG and 4S GAG deposition after 
injury, optic nerve crush or dorsal column crush surgery was performed on cohorts of adult 
mice and rats, and tissue was collected 1, 3, 5, 7, 14, and 21 dpc (Figure 4.3, examples of 
mouse optic nerve crush and rat dorsal column crush). CSPG content in the lesion area was 
detected using CS-56 and 2H6, an antibody that reacts predominantly with 4S (Yamamoto et 
al. 1995), and to a lesser degree, with 6S (Sugiura et al. 2012) and 2,6S (Matsushita et al. 
2018). CS-56 immunohistochemistry revealed an increase in CSPG deposition at the lesion 
during the scar-forming phase at 7 dpc in all conditions (Figure 4.4a-c). 4S was also visibly 
enhanced in both species and injury models (Figure 4.4a-c). In non-lesioned sham control 
tissue, CSPGs were evenly distributed within the tissue and meninges. In mouse ONC tissue, 
where CSPG was assessed over an extended time course and immunoreactivity was 
quantified from multiple replicate samples, levels of CSPG and 4S peaked at 7 dpc and 
remained high as late as 21 dpc (Figure 4.5). A specific increase in 4S expression was noted, 
with levels reaching 2.5-fold those in non-lesioned sham controls (fold change [mean±SE]: 
2.53±0.15). The elevation of CSPGs was further confirmed by Western blot analysis of tissue 
segments collected from the optic nerve or spinal cord lesion in rats. Bands detected by CS-
56 at 50 kB showed a reliable increase in lesioned vs. non-lesioned tissue (Figure 4.4d-e). 




rats lead to astrogliosis and elevated expression of CSPGs, especially those with 4S GAGs, 




Figure 4.3. 4-sulfated CSPGs accumulate in the glial scar after injury. Schematic 
diagram depicting optic nerve crush and dorsal column crush surgeries. Micrographs showing 
injured tissue 7 days after injury analyzed by immunohistochemistry with CS-56 in (i, ii) 
mouse optic nerve and (iii, iv) rat spinal cord. Scale bar = (i) 100 µm, (ii) 50 µm, (iii) 400 





Figure 4.4. 4-sulfated CSPGs accumulate in the glial scar after injury. Micrographs 
showing (a) mouse optic nerve crush, (b) rat optic nerve crush, and (c) mouse and rat dorsal 
column crush tissue. Sections were analyzed by immunohistochemistry with antibodies 
detecting CSPGs (CS-56) and 4S (2H6). Scale bars = (a) 50 µm, (b) 100 µm, and (c) 200 µm. 
(d) Western blot analysis showing elevation of CS-56 signal within lesioned rat optic nerve 






Figure 4.5. Optic nerve crush stimulates sustained elevation of chondroitin sulfate 
proteoglycans and inhibitory 4S epitopes. Fluorescence intensity of CS-56 and 2H6 
immunostaining expressed as fold change vs. non-lesioned sham controls. Insets from n = 3 
animals per condition were used. Statistical significance versus sham was determined by 
Student’s t-test. * p < 0.05, ** p < 0.005. Colored asterisks indicate significance for different 
groups (CS-56 = green, 2H6 = magenta). 
 
The axons of injured mouse RGCs were visualized with fluorescently-tagged CTβ. CTβ 
was injected intravitreally 1 d prior to tissue harvest. CTβ+ axons failed to traverse the injury 
site and instead formed dystrophic endbulbs that appeared to be associated with areas of high 
CSPG deposition (Figure 4.6a-ii, arrows), which included areas of high 4S immunostaining 
as detected by the 2H6 antibody (Figure 4.6b-ii, arrows). When CTβ+ axons did penetrate 
the lesion site, they appeared to do so through areas where CSPG signals were comparatively 







Figure 4.6. Retinal ganglion cell axon growth is blocked by 4-sulfated CSPGs in the glial 
scar. (a) Micrographs showing lesioned mouse optic nerve tissue at 7 dpc. Axons are 
visualized with CTβ and form dystrophic endbulbs in areas of high CSPG immunoreactivity. 
(i) Co-labeling of CTβ and CS-56 shows axons terminating in areas of high CSPG 
expression. (ii) Inset shows dystrophic endbulbs in CTβ+ axons. (iii) CS-56 channel shows 
pattern of CSPG expression. (iv) CTβ channel alone shows paths of axons. Scale bar = 100 





4.2.3  |  CSPGs associate with reactive astrocytes and activated microglia 
 
The sources of CSPG deposition have been well characterized in other CNS tissues, 
where CSPGs have been observed to associate with astrocytes, OPCs, microglia, 
macrophages, and meningeal fibroblasts, implying that they may be produced by multiple cell 
types (Yi et al. 2012). Reactive gliosis is a multicellular process, and to understand how glial 
cells contribute to CSPG deposition in the optic nerve, I validated the time course of astrocyte 
reactivity and microglia activation by immunohistochemistry with GFAP (to detect 
astrocytes) and Iba1 (to detect microglia and macrophages) (Figure 4.7, 4.8). My results 
aligned with the observations of others who have assessed the responses of astrocytes and 
microglia to ONC injury (Qu & Jakobs 2013). At 7 dpc, GFAP immunoreactivity was 
enhanced, with reactive astrocytes withdrawing from the lesioned area to form a cavity that 
was filled with Iba1+ activated microglia and macrophages (Figure 4.7b-i). Astrocyte 
morphology was visibly changed, with many GFAP+ cells becoming hypertrophic and 
extending elongated processes that defined the lesion boundary (Figure 4.7b-iii). Some 
GFAP+ cells were also found within the lesion core (Figure 4.7b-vii, arrow). Likewise, 
Iba1+ cells displayed more intense immunoreactivity and were larger and rounder, with 
retracted processes (Figure 4.7b-viii, arrow), distinct from cells in the distal optic nerve or 
in the non-lesioned sham condition, which exhibited a striated morphology (Figure 4.7a-






Figure 4.7. Elevation of CSPGs corresponds to peak of astrogliosis. Micrographs showing 
(a) sham or (b) 7 dpc mouse optic nerve tissue analyzed by immunohistochemistry with 
antibodies detecting reactive astrocytes (GFAP), activated microglia and macrophages (Iba1), 





Figure 4.8. Reactive astrocytes and activated microglia form glial scar after optic nerve 
crush. Micrographs showing mouse optic nerve tissue analyzed by immunohistochemistry 




High magnification images revealed that CSPGs were closely associated with both 
reactive astrocytes and microglia, both around the boundary of the lesion and within the 
lesion core (Figure 4.7, 4.9). This association was observed with both CS-56 and 2H6 
immunostaining (Figure 4.9). Glial cells that were associated with elevated levels of CSPG 
typically displayed reactive or activated morphologies (Figure 4.9-iii, iv, vi, viii). 
 
 
Figure 4.9. CSPGs associate with astrocytes and microglia at the lesion site. Micrographs 
showing mouse optic nerve tissue analyzed by immunohistochemistry with antibodies 
detecting reactive astrocytes (GFAP) and activated microglia and macrophages (Iba1), as 
well as CSPGs (CS-56) and 4S GAGs (2H6). (i-iv) CSPGs are elevated at 7 dpc and associate 





4.2.4  |  Optic nerve crush elevates CSPG expression in the retina 
 
ONC severs RGC axons in the optic nerve, which leads the distal axon segments to 
undergo Wallerian degeneration, leaving behind cellular debris including myelin, which can 
itself be highly inhibitory to the subsequent regeneration of the injured axons. This axonal 
damage, when left untreated, also contributes to the progressive death of most RGCs, with 
their cell bodies in the retina undergoing apoptosis in the days and weeks following the 
lesion. I sought to assess whether there are changes to CSPGs or reactive gliosis in the retina 
following ONC. Retinas were collected from mice at the time points described above, 
sectioned, and stained with antibodies against CSPGs, astrocytes, and microglia. I observed a 
robust gliotic response at 21 dpc in comparison with non-lesioned sham control retinas 
(Figures 4.10, 4.11). In control retinas, GFAP+ astrocytes were largely restricted to the GCL, 
with no processes extending into the IPL, CS-56 immunoreactivity was essentially 
undetectable (Figure 4.10-i, iii). At 21 dpc, GFAP+ astrocytes were visibly reactive, and 
several extended processes into the IPL and INL (Figure 4.10-ii, iv). Reactive astrocytes in 
the GCL were associated with regions of elevated CS-56 immunoreactivity, suggesting that 
they were producing CSPGs. Elevation of 4S GAGs was also observed (Figure 4.11). In non-
lesioned sham control retinas, 2H6 immunoreactivity was low in the GCL (Figure 4.11-iii), 
and Iba1+ microglia were distributed throughout the retina (Figure 4.11-i). Microglia had 
striated morphologies, suggesting they were not activated (Figure 4.11-v). At 21 dpc, Iba1+ 
cells were rounder and many had withdrawn their processes, suggesting an activated state 
(Figure 4.11-ii, iv, vi). 4S GAGs were visibly elevated in the GCL (Figure 4.11-iv). 
Together, these observations suggest that the reactive gliosis and deposition of CSPGs 
observed in the optic nerve also occurs, at least to some extent, within the retina, including 






Figure 4.10. Optic nerve crush stimulates astrocyte reactivity and upregulates CSPGs in 
the retina. Micrographs showing mouse retina sections from (i) non-lesioned sham controls 
and (ii) 21 days post ONC, analyzed by immunohistochemistry with antibodies detecting 
CSPG (CS-56) and reactive astrocytes (GFAP). Insets (iii, iv) show elevation of CSPG in 





Figure 4.11. Optic nerve crush activates microglia and upregulates 4S GAG in the 
retina. Micrographs showing mouse retina sections from (i) non-lesioned sham controls and 
(ii) 21 days post ONC, analyzed by immunohistochemistry with antibodies detecting 4S 
GAG (2H6) and microglia (Iba1). Insets (iii, iv) show elevation of 4S GAG in conjunction 
with activated microglia in the GCL. Insets (v, vi) show activated microglia in the IPL. Scale 
bar = 50 µm, inset = 10 µm. Abbreviations: GCL = ganglion cell layer; INL = inner nuclear 





4.2.5  |  Modifying CSPG sulfation enhances retinal ganglion cell axon regeneration 
 
Given the in vitro evidence presented above showing that 4S is critical to CSPG-
mediated inhibition of neurite growth, and the observation that 4S is highly expressed within 
optic nerve lesions, I investigated whether cleaving 4S from the non-reducing ends of GAG 
chains at the ONC lesion site would enhance RGC axon regeneration in the mouse optic 
nerve. To accomplish this, an intrinsic pro-regenerative stimulus, Zymosan A and CPT-
cAMP (Leon et al. 2000; Yin et al. 2003), was combined with direct application of ARSB to 
the lesioned nerve. ChABC was used as a control to evaluate the effects of digesting GAG 
chains entirely rather than selectively removing 4S groups. 
Mice received ONC, followed 3 days later by an intravitreal injection of Zymosan A 
(12.5 µg/µL) supplemented with CPT-cAMP (50 mM), followed immediately by 
implantation of a gelfoam scaffold loaded with 5 μL of ARSB (1 mg/mL), ChABC (455 
µg/mL), or control buffer. At 14 dpc, optic nerves were dissected, sectioned, and stained for 
GAP-43 to detect regenerating axons. In accordance with previous reports (Leaver et al. 
2006), we found that GAP-43 selectively labels regenerating axons, as GAP-43 signal is 
absent from intact, non-lesioned optic nerves (data not shown). On its own, injection of 
Zymosan/CPT-cAMP induced significantly (p = 0.0226) higher RGC axon regeneration than 
PBS controls at 14 dpc (axons at 0.25 mm distal to the lesion [mean±SE]: 282±83.4 and 
42.3±11.1, respectively) (Figure 4.12a-c). Zymosan did not alter CSPG expression at the 
lesion site (Figure 4.12d-e). When Zymosan was combined with enzyme delivery, both 
ARSB and ChABC significantly (p = 0.0006 and p < 0.0001, respectively) enhanced RGC 
axon regeneration compared with the buffer control (axons at 0.25 mm distal to the lesion 
[mean±SE]: 472±62, 535±123, and 217±53, respectively) (Figure 4.13). Interestingly, 
delivering ARSB or ChABC in the absence of Zymosan injection did not enhance RGC axon 





Figure 4.12. Zymosan and CPT-cAMP stimulate axon regeneration. (a) Experiment 
timeline and schematic diagram showing intravitreal injection of Zymosan/CPT-cAMP or 
PBS. (b) Micrographs showing GAP-43-labeled optic nerves from mice treated with 
Zymosan or PBS. Arrows indicate lesion site. Scale bar = 200 µm. (c) Graph showing the 
number of regenerating axons at distances distal to the lesion site, displayed as mean +/- 
SEM. Statistical significance was determined by two-way ANOVA with Bonferroni post-hoc 
test for multiple comparisons. * p < 0.05. (d) Micrographs showing CS-56 immunostaining at 
the lesion site of optic nerves from animals treated with Zymosan or PBS. Arrows indicate 
lesion site. Scale bar = 100 µm. (e) Graph showing quantification of CS-56 fluorescence 
intensity (arbitrary units) measured from 150 × 150 µm insets centered at ONC lesion site. 





Figure 4.13. Selectively targeting inhibitory CSPGs enhances retinal ganglion cell axon 
regeneration. (a) Experiment timeline and schematic diagram showing intravitreal injection 
of Zymosan/CPT-cAMP and implantation of gelfoam scaffolds containing ARSB, ChABC, 
or control buffer. (b) Micrographs showing GAP-43-labeled optic nerves from mice treated 
with Zymosan/CPT-cAMP and gelfoam scaffolds loaded with ARSB, ChABC, or control 
buffer. Arrows indicate lesion site. Scale bar = 200 µm. (c) Graph showing the number of 
regenerating axons at distances distal to the lesion site, displayed as mean +/- SEM. 
Statistical significance was determined by two-way ANOVA with Bonferroni post-hoc test 
for multiple comparisons. * p < 0.05, ** p < 0.005, *** p < 0.001, **** p < 0.0001. Colored 
asterisks indicate statistical significance for different groups (ARSB = magenta, ChABC = 
green). (d) Graph showing average length of longest GAP-43+ regenerating axon. Statistical 





Figure 4.14. CSPG-targeting enzymes alone do not induce axon regeneration. (a) 
Experiment timeline and schematic diagram showing delivery of ARSB, ChABC, and control 
buffer to the lesioned optic nerve via implanted gelfoam scaffold. (b) Micrographs showing 
GAP-43-labeled optic nerves from mice treated with ARSB, ChABC, and control buffer. 
Arrows indicate lesion site. Scale bar = 100 µm. (c) Graph showing the number of 




The products of the reaction catalyzed by ARSB are not readily detectable by 
immunohistochemistry or Western blot; therefore, to specifically validate the penetration of 
ARSB into the optic nerve fibers, mice received ONC surgery, and gelfoam scaffolds soaked 
in 200 µg/mL His-Tagged ARSB or control buffer were implanted behind the eyes at the 
ONC lesion site (Figure 4.15a). Tissue collected at 1 dpc was analyzed by 
immunohistochemistry using anti-His antibody, and recovered scaffolds were tested for the 
presence of active ARSB. His-Tagged ARSB was detected in lesioned tissue using 
immunohistochemistry (Figure 4.15b), and active enzyme was detected from recovered 
scaffolds (Figure 4.15c). To further validate that the enzymes had successfully penetrated the 
optic nerve and modified CSPGs, I stained ChABC-treated samples with the antibody BE-
123, which recognizes the “stubs” produced on proteoglycans by ChABC digestion of the 
GAG chains (Figure 4.16a). Immunohistochemistry analysis revealed significantly more BE-
123 immunoreactivity in ChABC-treated nerves (Figure 4.16a-b), while Western blot 
analysis of non-lesioned sham control tissue treated with ChABC revealed BE-123 signal 
exclusively in nerve segments exposed to ChABC-loaded scaffolds (Figure 4.16c). Together, 
these observations establish that the enzymes released from the scaffold penetrate the tissue 





Figure 4.15. Tagged ARSB penetrates the optic nerve. (a) Schematic diagram showing 
delivery of ARSB or control buffer to lesioned optics nerve via implanted gelfoam scaffold. 
Optic nerves were dissected at 1 dpi and divided into four segments (#1-4). Micrographs 
showing thresholded images of lesioned optic nerves treated with ARSB-His or buffer and 
stained with anti-His antibody. Arrows indicate lesion site. Scale bar = 200 µm. (b) Graph 
showing quantification of anti-His fluorescence intensity measured from insets centered at 
the lesion site. Statistical significance was determined by Student’s t-test. * p < 0.05. (c) 
Graph showing ARSB activity of recovered gelfoam scaffolds compared with 100 ng/mL 





Figure 4.16. ChABC penetrates the optic nerve and modifies GAG chains. Zymosan was 
delivered to the retina via intravitreal injection and ARSB, ChABC, and control buffer were 
delivered to the lesioned optic nerve via implanted gelfoam scaffolds. (a) Schematic diagram 
showing delivery of ChABC or buffer to lesioned optic nerves via implanted gelfoam 
scaffold. Micrographs showing thresholded images of lesioned optic nerves treated with 
ChABC or buffer and stained with BE-123. Arrows indicate lesion site. Scale bar = 200 µm. 
(b) Graph showing quantification of BE-123 fluorescence intensity measured from insets 
centered at the lesion site. Statistical significance was determined by Student’s t-test. * p < 
0.05. (c) Schematic diagram showing delivery of ChABC to non-lesioned optics nerve via 
implanted gelfoam scaffold. Optic nerves were dissected at 1, 2, and 4 dpi and divided into 
four segments (#1-4). Western blot analysis showing enzyme-treated optic nerve segments 




4.2.6  |  ARSB promotes axon regeneration with an extended therapeutic window 
  
 The duration of the regeneration enhancing effects of ARSB was assessed by 
measuring axon regeneration at early and late time points. At 7 dpc, only 4 days after 
implantation of the gelfoam scaffolds, a small but significant (p = 0.0149) increase in the 
number of axons navigating through the lesion site was already detectable in the ARSB-
treated group compared with the buffer control (axons at 0.50 mm distal to the lesion 
[mean±SE]: 69.2±12.3 and 16.0±8.9, respectively) (Figure 4.17a-d). By 28 dpc, regenerating 
axons were found extending as far as 4.0 mm beyond the lesion site, to the optic chiasm entry 
point (Figure 4.17e-g). There was a significant (p = 0.0002) increase in the number of axons 
in ARSB-treated animals versus buffer-treated controls (axons at 0.25 mm distal to the lesion 
[mean±SE]: 568±96.3 and 273±63.0, respectively). The enhancing effect of ARSB treatment 
appeared to be concentrated at distances proximal to the lesion site (0.25-1.50 mm). At 
distances beyond 1.50 mm, there was relatively little difference between the ARSB-treated 
and buffer-treated groups (Figure 4.18a-b). I isolated this effect by subtracting the number of 
regenerating axons in the Zymosan/buffer groups from those in the Zymosan/ARSB groups 
(Figure 4.18c). ARSB strongly increased the number of axons regenerating through the 









Figure 4.17. ARSB enhances axon regeneration over an extended therapeutic window. 
(a) Experiment timeline and schematic diagram showing intravitreal injection of Zymosan 
and CPT-cAMP and delivery of ARSB and control buffer to the lesioned optic nerve via 
implanted gelfoam scaffold. (b) Micrographs showing GAP-43-labeled optic nerves from 
mice treated with Zymosan/CPT-cAMP and gelfoam scaffolds loaded with ARSB or a 
control buffer. Arrows indicate lesion site. Scale bar = 200 µm. (c) Graph showing the 
number of regenerating axons at distances distal to the lesion site, displayed as mean +/- 
SEM. Statistical significance was determined by two-way ANOVA with Bonferroni post-hoc 
test for multiple comparisons. * p < 0.05. (d) Graph showing length of the longest 
regenerating axon, displayed as mean +/- SEM. Statistical significance was determined by 
Student’s t-test. (e) Micrographs showing GAP-43-labeled optic nerves from mice treated 
with intravitreal injections of Zymosan and gelfoam scaffold loaded with ARSB or a control 
buffer. Arrows indicate lesion site. Scale bar = 200 µm. (f) Graph showing the number of 
regenerating axons at distances distal to the lesion site, displayed as mean +/- SEM. 
Statistical significance was determined by two-way ANOVA with Bonferroni post-hoc test 
for multiple comparisons. ** p < 0.005, *** p < 0.001, **** p < 0.0001. (g) Graph showing 
length of the longest regenerating axon, displayed as mean +/- SEM. Statistical significance 





Figure 4.18. ARSB strongly enhances axon regeneration proximal to the lesion site. (a-b) 
Graphs showing the number of regenerating axons at distances distal to the lesion site, 
displayed as mean +/- SEM. Data were collected from separate cohorts of mice where 
regeneration was quantified at 7, 14, and 28 days following ONC. (c) Graph showing the 
average increase in regenerating axons for each measured distance and time point, calculated 
by subtracting the number of axons in the buffer-treated group from the number of axons in 




4.2.7  |  ARSB does not alter the astrocytic scar or perineuronal nets 
 
 To determine whether treatment with ARSB alters glial cells at the lesion site, tissue 
from enzyme-treated nerves was stained with GFAP and Iba1. Neither ARSB nor ChABC 
treatment disrupted formation of the astrocytic scar. The area delineated by GFAP+ astrocytes 
decreased over time but was not significantly different between treatment groups at any time 
point (Figure 4.19c-d). Correspondingly, the total GFAP immunoreactivity increased from 7 
to 28 dpc as astrocytes repopulated the glial scar region, but no differences were observed 
between treatment groups (Figure 4.19e). Both ChABC and ARSB increased Iba1 
immunoreactivity relative to the buffer control (fluorescence intensity [mean±SE]: 21.7±2.95, 
12.9±1.71, and 6.96±1.79, respectively), but ChABC elicited significantly (p < 0.05) higher 
Iba1 immunoreactivity than ARSB (Figure 4.19a-b). 
In addition to their deposition in the glial scar, CSPGs are a major component of PNNs, 
structures that limit synaptic plasticity in the brain and spinal cord but are not present in the 
optic nerve. ChABC is known to disturb PNNs and alter plasticity in the visual cortex 
(Pizzorusso et al. 2002). To evaluate whether ARSB alters CSPG structure beyond the 
selective cleavage of 4S groups, we incubated post-fixed mouse brain tissue sections with 
ARSB (1 mg/mL), ChABC (≥ 20 µg/mL), or buffer control, and detected PNNs with Wisteria 
floribunda agglutinin (WFA). ChABC completely eliminated WFA-stained PNNs (Figure 
4.20). However, incubation with ARSB left PNNs intact, with no observable differences from 








Figure 4.19. ARSB provokes muted immune response but does not alter astrocyte 
reactivity, glial scar size, or association of regenerating axons with astrocyte processes. 
(a) Micrographs showing Iba1 immunostaining at the optic nerve crush site for samples 
treated with Zymosan/CPT-cAMP and ChABC, Zymosan/CPT-cAMP and ARSB, 
Zymosan/CPT-cAMP and a control buffer, no treatment, and non-lesioned controls. Scale bar 
= 50 µm. (b) Graph showing quantification of Iba1 fluorescence intensity measured as % area 
of thresholded insets centered at the lesion site. Statistical significance was determined by 
Student’s t-test. * p < 0.05, *** p < 0.001. (c) Micrographs showing GFAP and GAP-43 
immunostaining at the optic nerve crush site for samples treated with Zymosan/CPT-cAMP 
and either ARSB, ChABC, or a control buffer and analyzed at 7, 14, and 28 dpc. Arrows 
indicate lesion site. Scale bar = 100 µm. (d) Graph showing quantification of glial scar size 
measured as the area delineated by GFAP+ astrocytes at the optic nerve crush site. Statistical 
significance was determined by Student’s t-test. (e) Graph showing quantification of GFAP 






Figure 4.20. ARSB preserves CSPG-rich perineuronal net structure. Micrographs 
showing mouse cortex from tissue incubated with control buffer, ChABC, or ARSB for 8 h at 
37°C and stained with WFA to detect perineuronal nets. Images (iv), (v), and (vi) are insets 




4.3  |  DISCUSSION 
 
The glial scar is considered a major impediment to axonal regeneration in the optic nerve 
and elsewhere in the CNS. Here, I have shown that the injured optic nerve develops a glial 
scar rich in CSPGs, including the 4S motif, and that these CSPGs inhibit the extension of 
regenerating RGC axons. I show evidence that the human enzyme ARSB promotes neurite 
growth in culture without altering production or secretion of GAG chains. I then demonstrate 
that ARSB enhances the regeneration of RGC axons following optic nerve injury. The 
treatment is robustly effective even when administered 3 days after injury, an important 
consideration for translational therapies. Enhanced regeneration was evident as early as 7 
days post ONC and remained significant at 28 days, illustrating an extended therapeutic 
window from a single treatment. ARSB is active in vivo, provokes less Iba1 
immunoreactivity than ChABC, and preserves perineuronal structures that depend on intact 
GAG chains. Taken together, these findings demonstrate that the 4S motif at the non-
reducing end of CS GAG chains plays a critical role in mediating the inhibitory actions of 
CSPGs. Given the clinical approval for ARSB as an enzyme replacement therapy in human 
patients, my evidence that ARSB enhances axon regeneration in the optic nerve means that 
future treatments could readily combine ARSB with intrinsic approaches to achieve robust 
regeneration of damaged or degenerated axons in the CNS. 
 
4.3.1  |  CSPG deposition is a key source of axon growth inhibition in the glial scar 
 
The formation of a glial scar, including deposition of sulfated proteoglycans, is well 
documented in the brain and spinal cord (Bradbury et al. 2002; Bradbury & Carter 2011; Yi 
et al. 2012; Burnside & Bradbury 2014; Galtrey & Fawcett 2007). Studies that have 
suggested that CSPGs are upregulated after ONC have not quantified this phenomenon or 
explored its time course (Brown et al. 2012; Sengottuvel et al. 2011; Sellés-Navarro et al. 
2001). Others have sought to circumvent CSPG-mediated inhibition by inactivating key 
signaling pathways that are initiated when CSPG ligands interact with their RPTP receptors 
on neurons. For instance, evidence shows that suppressing the Rho/ROCK pathway, which is 
activated by exposure to CSPGs, enhances regeneration of RGC axons after ONC (Fischer et 
al. 2004; Lingor et al. 2007). Likewise, inhibiting EGFR, another downstream effector of 
CSPGs, promotes RGC axonal regeneration (Koprivica et al. 2005). However, there is a 
dearth of comprehensive, quantitative evidence of CSPG deposition within the lesion area 
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following ONC. Similarly, the evidence that exists fails to discriminate between different 
sulfation patterns. Therefore, I sought to identify whether and to what extent 4S is expressed 
among the CSPGs in the glial scar. I analyzed not only the mouse optic nerve, but also rat 
optic nerve and mouse and rat spinal cord, to ensure that my findings were generally 
translatable between rodent species and across different types of CNS injury. 
I found that CSPGs, and 4S GAGs in particular, were significantly elevated after mouse 
ONC, reaching peak levels at 7 dpc. This was similarly true of samples from injured rat optic 
nerve, mouse spinal cord, and rat spinal cord. The precise timing of CSPG deposition appears 
to differ slightly between species: elevated levels of CS-56 and 2H6 immunoreactivity were 
first evident at earlier time points in the rat optic nerve than in the mouse. The association of 
CSPGs with astrocytes and microglia was similar across conditions, suggesting that the 
multicellular sources of these inhibitory proteins are mostly conserved. The sustained 
elevation of CSPGs at 21 dpc suggests that the optic nerve environment remains hostile to 
axon growth for extended periods after injury. I observed that RGC axons appeared to 
terminate in areas of high CSPG expression in optic nerve lesions. Axonal growth cones 
exhibited dystrophic morphology, forming the characteristic endbulbs indicative of stalled 
growth. Notably, sites at which axons terminated in association with CSPG deposition 
contained visibly high levels of 4S immunoreactivity. 
Cleaving 4S from the non-reducing ends of GAG chains with ARSB, or completely 
digesting GAG chains with ChABC, both enhanced axon regeneration without disrupting 
formation of the astrocytic scar. This supports a critical role for CSPG deposition, rather than 
scar formation per se, as a primary cause of axon growth inhibition. This is consistent with 
findings that ablating astrocytic scar formation without reducing CSPG levels does not lead 
to spontaneous regeneration of axons (Anderson et al. 2016; Silver 2016). Conversely, 
blocking the formation of neurotoxic A1 astrocytes (Liddelow et al. 2017), or the 
transformation of reactive astrocytes into scar-forming astrocytes, which express elevated 
levels of CSPG-related transcripts (Hara et al. 2017), were found to significantly enhance cell 
survival and axon regeneration, respectively. My findings support the notion that many 
aspects of astrogliosis are in fact essential to preserving tissue integrity and promoting 
survival of injured neurons, and that it is a specific component of this response—namely, the 
deposition and sustained expression of inhibitory 4S GAGs—that opposes axonal 
regeneration. 
Accumulating evidence that sulfation is a primary determinant of CSPG behavior raises 
questions of which of the putative CSPG receptors bind to different sulfated motifs, and 
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whether these interactions trigger different or overlapping signaling cascades. Of the 
vertebrate type-IIa RPTP receptors—LAR, RPTPσ and RPTPδ—RPTPσ and LAR are known 
to bind CSPGs with high affinity. This binding appears to be dependent on interactions with 
GAG chains, as it can be disrupted by treatment with ChABC (Shen et al. 2009; Fisher et al. 
2011). In mice where RPTPσ or LAR receptors were knocked out, isolated dorsal root 
ganglion neurons were less sensitive to a mixture of CSPGs in vitro, and axon regeneration 
after a spinal cord injury was improved in vivo (Fisher et al. 2011; Lang et al. 2014). 
Sulfation appears to be an integral component of these ligand-receptor interactions. Neurons 
from RPTPσ-/- mice fail to bind to 4S or 6S CSPGs, but will still bind DS, 4,6S, and 2,6S 
(Dickendesher et al. 2012). The dynamic flexibility in the interaction between receptors and 
their proteoglycan ligands has already been demonstrated in one context: it is known that the 
receptor RPTPσ interacts with both CSPGs and HSPGs, possibly via different binding sites, 
and that binding of RPTPσ to CSPGs impedes axonal growth, whereas binding to HSPGs is 
growth-permissive. This flexibility may extend to sulfation patterns as well, although 
substantial future work will be required to investigate this possibility. 
 
4.3.2  |  Delayed application of ARSB promotes regeneration 
 
 
Most experimental therapies that stimulate RGC axon regeneration involve interventions 
at the time of injury or, in the case of many gene therapies, several weeks prior to injury 
(Buch et al. 2008). While such studies are immensely valuable for identifying therapeutic 
targets and elucidating mechanisms of RGC axon regeneration, they are not readily 
translatable to human patients. In humans, CNS tracts are often damaged by acute trauma, 
such as spinal cord injury, traumatic brain injury, and stroke, or by progressive 
neurodegenerations, as in the case of glaucoma and multiple sclerosis. In such cases, 
intervening before or even immediately following the injury is often not possible. Therefore, 
identifying therapies that effectively promote regeneration even after a delay is a top priority 
for clinically translatable research. I found that delivery of ARSB in conjunction with 
Zymosan/CPT-cAMP significantly enhanced RGC axon regeneration when administered 3 
days after ONC, making a strong case for its future clinical viability. 
Delaying ARSB treatment may confer additional advantages beyond clinical 
considerations such as time of treatment. The mechanisms of CSPG expression and inhibition 
of neurons have been shown, in some contexts, to be time-sensitive, with intervention more 
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effective after a delay than immediately following an insult. One study has argued that CSPG 
synthesis in the acute phase (0-2 dpi) may actually promote, rather than inhibit, recovery. 
Rolls et al. (2008) blocked CSPG synthesis immediately after spinal cord injury in mice and 
found that axon regeneration and functional recovery were impaired, whereas blocking 
synthesis in the subacute phase (2-7 dpi) enhanced regeneration and recovery. This argues for 
a potential role of CSPGs in the lesion area for reducing damage and/or promoting growth. 
Some possible explanations for such a role are described below. 
 
4.3.3  |  ARSB preserves perineuronal structures 
 
Some studies have proposed a role for CSPGs as regulators of microglia and macrophage 
localization and phenotype. After injuries to the mature CNS, CSPGs have been shown to 
recruit blood-borne monocytes and bias macrophages toward a resolving phenotype (Shechter 
et al. 2011), and to regulate the spatial organization of microglia and macrophages and 
promote neurotrophic factor production by resident microglia after spinal cord injury (Rolls 
et al. 2008; Shechter et al. 2009). Stripping CSPGs of their GAG chains, e.g. by treatment 
with ChABC, may impede these repair functions. The presence of CSPGs during the acute 
phase of injury also alters monocyte phenotype and is linked to the production of the matrix 
metalloprotease MMP-13, which degrades CSPGs, suggesting a potential feedback loop 
wherein CSPGs regulate immune cells before indirectly catalyzing their own destruction 
(Rolls et al. 2008). Taken together, this evidence argues for the usefulness of an intervention 
that renders CSPGs more permissive to axon extension without degrading GAG chains. 
Selectively modifying sulfation with ARSB could reduce GAG-mediated inhibition of 
neurons without disrupting their interactions with other cells. 
To demonstrate that ARSB preserves perineuronal structures composed of CSPGs, I 
analyzed the effects of ARSB treatment on PNNs in the mouse cortex. It has been known 
since the work of Hubel and Wiesel that the visual cortex requires input from retinal neurons 
in order to achieve functional organization (Wiesel & Hubel 1963). The discovery of critical 
periods, during which cortical networks reorganize according to the intensity and selective 
patterns of neural activity, arose from Hubel and Wiesel’s observations in the visual system 
and has since been expanded to many other domains of nervous system development. The 
visual cortex remains an essential system for studying the role of the ECM in regulating 
neural plasticity. In the early postnatal period, networks in the visual cortex respond to and 
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organize themselves around the inputs of retinal neurons (Berardi et al. 2003). As 
development continues, the expression of CSPGs in the retina and optic pathways 
progressively declines, and in the thalamus, CSPGs drop to barely detectable levels within 
the third postnatal week in rats (Vitellaro-Zuccarello et al. 2001). The subsequent emergence 
of CSPGs in the cortex signals the end of the critical period (Hockfield et al. 1990). At this 
stage, CSPGs become restricted to PNNs, which cluster around the soma and dendrites of 
GABAergic interneurons (Wang & Fawcett 2012). The formation of PNNs coincides with a 
sustained suppression of cortical plasticity. Repeated injections of ChABC into the visual 
cortex of adult rats caused reductions in PNNs and led to a pronounced increase in ocular 
dominance plasticity (Pizzorusso et al. 2002). ChABC injection alleviated other impairments 
associated with monocular deprivation in rats, including reduced receptive field size, low 
visual acuity, and loss of dendritic spine density (Pizzorusso et al. 2006). A similar 
phenomenon was observed in the superior colliculus, where ChABC injection degraded GAG 
chains and increased the sprouting of intact retinal axons (Tropea et al. 2003). Intriguingly, 
the sulfation pattern of brain CSPGs appears to play an important role in visual cortex 
plasticity. Transgenic mice engineered to overexpress human C6ST-1, the enzyme that 
catalyzes addition of 6S to CS GAG chains, exhibited a decreased ratio of 4S to 6S GAGs 
(Miyata et al. 2012). These mice underwent normal visual development, but showed a 
reduced number of PNNs during and after the critical period, despite no observed reductions 
in the total amount of CSPG core proteins, as well as lower levels of Otx2 (Miyata et al. 
2012). C6ST-1 overexpressing neurons failed to undergo spike shortening at levels 
comparable to those in neurons in wildtype mice, indicating that elevated 6S in the visual 
cortex may prolong mechanisms linked to synaptic plasticity (Miyata et al. 2012). These 
observations provide a strong incentive for studying the differential effects of ARSB and 
ChABC on PNNs. 
When I treated mouse cortical tissue with ARSB and ChABC, I found that ChABC 
eliminated PNNs, whereas ARSB left PNNs intact. The fact that ARSB preserved PNN 
structures supports the argument that ARSB might be used to modify CSPGs in the glial scar 
while leaving their GAG chains intact, potentially freeing them to continue to regulate 
microglia and macrophage recruitment, although additional studies will be required to prove 
this definitively. My evidence also supports the idea that ARSB might be useful beyond 
studies of axon regeneration and in areas other than the optic nerve, with potential 
applications to investigations of neural plasticity, memory formation, and other processes 
dependent on PNNs or other CSPG microstructures. The ubiquity of CSPGs in the CNS 
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provides myriad opportunities for using ARSB, with its selective action on axon-growth-
inhibiting C4S motifs, to alter the extracellular matrix and influence axonal growth and 
connectivity. I am currently collaborating with Dr. Panpan Yu, at Jinan University in China, 
to design in vivo experiments that will test the effects of ARSB injections in the mouse brain 
following controlled cortical injury. Our preliminary results show that injections of ChABC 
into the mouse cortex eliminate WFA+ PNNs within the injection radius, whereas ARSB 
injections appear to preserve PNNs. Future studies will assess whether and how these 
enzymes alter plasticity and memory in mice by comparing the animals’ performance on a set 
of behavioral assays. 
 
4.3.4  |  ARSB activity and mechanism 
 
The precise mechanism of how ARSB modifies the inhibitory actions of GAG chains is 
unknown. ARSB did not reduce the total amount of sulfated GAG in the culture medium as 
detected by the anti-CS antibodies, suggesting that its effects are mediated by altering GAG 
chain sulfation. ARSB, a lysosomal enzyme, maintains its highest activity at acidic pH, 
raising the question of whether it can cleave sulfate groups from secreted CSPGs, or whether 
lysosomal uptake is required. Others in my laboratory have observed that ARSB cleaves 4S 
from extracellular GAG chains in culture medium, suggesting that its activity at neutral pH is 
sufficient to perform its sulfatase function. This was validated by my discovery that ARSB 
promotes regeneration of optic nerve axons when administered exogenously. 
The advantages of ARSB over ChABC, while they exert equivalent pro-regenerative 
effects when administered at the site of an optic nerve lesion, are compelling. ARSB has 
relatively lower immunogenicity than ChABC in vitro (Yoo et al. 2013). ARSB has also been 
shown to maintain its activity longer in vitro than ChABC, implying a more extended 
therapeutic window (Yoo et al. 2013). While the durability of ARSB in vivo has not been 
characterized, studies have shown that ChABC injected directly into rat brains maintains 
detectable activity levels for at least 10 days (Lin et al. 2007), and that even low levels of 
ChABC activity can suppress CSPG levels in vivo for periods of weeks (Chau et al. 2004; 
Hyatt et al. 2010), suggesting that ARSB may potentially last even longer. Unlike ChABC, 
ARSB is highly stable at physiological temperature and pH (Yoo et al. 2013). Crucially, 
ARSB is a human enzyme with approval for clinical use, meaning its transition from animal 
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models to human therapies will face fewer obstacles (Muñoz-Rojas et al. 2010; Harmatz et al. 
2004; Harmatz 2005). 
Another important distinction between ChABC and ARSB is that their enzymatic activity 
produces different byproducts. It has been observed that cleavage of inhibitory GAG chains 
by ChABC generates disaccharide byproducts that, intriguingly, seem to promote axon 
regeneration independently: administering CSPG disaccharide after spinal cord injury led to 
significant improvements in motor recovery (Rolls et al. 2008). This calls into question the 
assumption that ChABC promotes regeneration exclusively by reducing GAG-mediated axon 
growth inhibition. Instead, some of its effect may derive from the presence of these growth-
promoting disaccharide products. 
One challenge of studying ARSB in vivo is the lack of a straightforward readout for its 
enzymatic activity. I used the production of CSPG “stubs” stripped of their GAG chains by 
ChABC, which are detectable by antibodies such as BE-123, as an indicator for the delivery 
of active enzyme from implanted gelfoam scaffolds and penetration into the optic nerve 
fibers. The fact that ARSB and ChABC enhanced RGC axon regeneration equally implies 
that ARSB was present and active within the optic nerve, but future studies will be required 
to characterize the efficiency and thoroughness of its actions in vivo. 
 
4.3.5  |  Combining extrinsic and intrinsic stimuli enhances axon regeneration 
 
Treating lesioned optic nerves with ARSB or ChABC alone failed to enhance 
regeneration, but combining them with Zymosan/CPT-cAMP promoted significantly greater 
regeneration than the intrinsic treatment alone. Most studies demonstrating long distance 
regeneration of RGC axons achieve their effects by modifying the intrinsic state of RGCs: 
knocking out the tumor suppressor PTEN (Park et al. 2008), delivering growth factors 
(Sieving et al. 2006), stimulating inflammatory pathways (Yin et al. 2003), enhancing the 
endogenous activity of RGCs (Lim et al. 2016), chelating neurotoxic ions in the retina (Li et 
al. 2017), and various combinations thereof. In Chapter 5, I describe my efforts to combine 
multiple intrinsic therapies with delivery of ARSB to the optic nerve crush lesion site to 
stimulate long-distance regeneration of RGC axons. 
Despite these advances, however, knowledge of how regenerating axons traverse the 
glial scar and navigate the growth-inhibitory microenvironment is incomplete. Studies that 
have examined the three-dimensional growth patterns of regenerating RGC axons 
consistently find that axons induced to regenerate via intrinsic manipulations display highly 
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irregular and aberrant growth patterns (Luo et al. 2013; Bray et al. 2017; Fischer et al. 2017). 
Understanding how axons respond to their extrinsic microenvironment, particularly the 
sulfated GAG chains within the glial scar, will be vital to future efforts to stimulate robust 
long-distance regeneration of retinal neurons and successful innervation of visual targets in 
the brain. 
 
4.3.6  |  Summary 
 
I analyzed optic nerve and spinal cord lesions in mice and rats and observed a common 
response to injury, where reactive astrocytes, activated microglia, and macrophages begin to 
form a glial scar at the lesion site, depositing elevated levels of CSPGs, including the highly 
inhibitory 4S motif. The presence of 4S in the lesioned tissue blocked RGC axons from 
regenerating beyond the crush site and led to growth cone collapse and the formation of 
dystrophic endbulbs. Directly targeting 4S at the non-reducing ends of GAG chains with 
ARSB, and digesting GAG chains entirely with ChABC, significantly enhanced the extension 
of RGCs induced to regenerate by intravitreal injection of Zymosan and CPT-cAMP. This 
enhancement was notable for several reasons:  
1) The therapy was administered at a delay, 3 days post injury. The effects of the 
intervention were visible across a wide therapeutic window, from 7 d to as late as 28 d of 
continued growth.  
2) ARSB, a human enzyme, produced less immunoreactivity for Iba1, a marker of 
activated microglia and macrophages, implying that it may be less immunogenic than 
ChABC, a bacterial enzyme.  
3) ARSB did not directly modify astrocytes or alter the formation of the astrocytic scar in 
the optic nerve, and preserved the structure of PNNs in the cortex, indicating its specificity to 
the inhibitory 4S epitope rather than global changes to CSPGs more broadly.  
 
Together, these findings point to a potential therapeutic strategy that selectively targets 
4S GAGs in CNS lesions, reversing the inhibitory actions of CSPGs without preventing them 
from engaging in other regulatory or potentially growth-promoting functions. Future studies 
will need to address the need for ARSB to be paired with an intrinsic stimulus, as Zymosan 
and many other experimental pro-regenerative stimuli are unsuitable for clinical use. Despite 
these challenges, this work lays a foundation for translational research on the ability of a 
152 
 





CHAPTER 5: COMBINING INTRINSIC AND EXTRINSIC STIMULATION 
TO ACHIEVE LONG-DISTANCE RGC AXON REGENERATION  
 
5.1  |  INTRODUCTION 
 
Early evidence that adult mammalian CNS neurons are capable of regenerating their 
axons was obtained when researchers found that axons extended into peripheral nerve grafts 
implanted at sites of injured CNS tissue, including the brain (Benfey & Aguayo 1982), spinal 
cord (Richardson et al. 1980; David & Aguayo 1981), and optic nerve (So & Aguayo 1985). 
Over the following decades, it was discovered that intrinsic manipulations of neurons, such as 
inactivation of Rho, a GTPase that participates in the signaling cascade activated by axon-
inhibiting CSPGs, also stimulate low levels of axon regeneration (Lehmann et al. 1999). In 
recent years, a multitude of experimental therapies have been developed that either modify 
the intrinsic state of CNS neurons or remove growth-inhibiting obstacles from their 
environment. Many of these interventions activate or suppress discrete molecular pathways, 
contributing to a body of evidence that suggests axon growth depends on many overlapping 
signaling systems (He & Jin 2016). Achieving robust regeneration of CNS tracts is therefore 
likely to require combinatorial treatments that address a host of both intrinsic and extrinsic 
factors. Of the treatments that have purported to achieve successful long-distance axon 
regeneration in the optic nerve, essentially all have utilized multiple intrinsic stimuli (de Lima 
et al. 2012; Lim et al. 2016; Kurimoto et al. 2010). None, however, have combined intrinsic 
manipulations with direct modification of the extrinsic microenvironment, such as targeting 
the growth-inhibiting glial scar. In this chapter, I sought to develop a therapy that activates 
multiple intrinsic growth pathways in combination with using ARSB to reduce CSPG-
mediated inhibition of axon extension through the glial scar, with the goal of stimulating 
regeneration of retinal neurons through the optic chiasm to reach central visual targets in the 
brain. 
 
5.1.1  |  Zymosan and CPT-cAMP promote regeneration by activating inflammatory 
pathways 
 
 One of the early intrinsic mechanisms that successfully stimulated regeneration of 
RGC axons was the use of lens injury to provoke an inflammatory response in the retinas of 
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rats (Leon et al. 2000; Fischer et al. 2001). Creating a small puncture wound in the lens with 
an injecting needle enhanced RGC survival in the retina and promoted mild levels of axon 
regeneration in the optic nerve. These early studies confirmed that inflammatory pathways 
were responsible for this effect by injecting Zymosan, a bacterial cell wall protein known to 
stimulate inflammation, into the vitreous. Zymosan injection was sufficient to promote RGC 
survival and axon regeneration even in the absence of lens injury (Leon et al. 2000). 
Successive studies further clarified the role of inflammation in promoting RGC axon 
regeneration. Zymosan activates macrophages in the rat retina, and it was discovered that 
macrophage-secreted factors are at least partially responsible for Zymosan’s enhancement of 
axon regeneration (Yin et al. 2003). The protein oncomodulin (Ocm) was identified as a 
macrophage-derived factor that promotes RGC survival and axon regeneration in rats, even in 
the absence of other treatments (Yin et al. 2006). The binding of Ocm to rat RGCs requires 
cyclic adenosine monophosphate (cAMP), and Ocm activates a signaling cascade that 
includes Ca2+/calmodulin kinase, suggesting that cAMP and calcium are required for its pro-
regenerative effect (Yin et al. 2006). Injecting both Ocm and cAMP led to higher sustained 
levels of Ocm in the mouse retina and doubled the number of regenerating RGC axons in the 
optic nerve (Kurimoto et al. 2010). A subsequent study confirmed that intraocular 
inflammation stimulates release of Ocm from activated macrophages in both mice and rats, 
and that blocking the binding of Ocm to its receptor abolishes its positive effects on RGCs 
(Yin et al. 2009). It was later shown that specific downstream signaling pathways are 
required for inflammation-induced regeneration. Injection of lipopolysaccharide (LPS), an 
inflammatory agent, failed to stimulate regeneration of RGC axons (Baldwin et al. 2015). 
Intravitreal injection of curdlan, a form of β(1, 3)-glucan that is considered the active 
ingredient of Zymosan, stimulated regeneration via dectin-1 signaling, and knockout mice 
lacking dectin-1 failed to exhibit axon regeneration following Zymosan injection (Baldwin et 
al. 2015). Together, these findings describe an inflammation-induced pathway for stimulating 
the regeneration of injured RGC axons. Because Zymosan is one of the earliest, most widely 
used, and most reliably effective regenerative stimuli in the visual system, and because 
obtaining and administering Zymosan and CPT-cAMP is straightforward and relatively low-
cost, I used Zymosan as the primary intrinsic stimulus for the majority of my optic nerve 




5.1.2  |  The hM3Dq DREADD receptor enhances the endogenous activity of RGCs 
 
 Evidence from developmental studies suggests that visual experience is required to 
establish sophisticated visual processing networks in the brain (Wiesel & Hubel 1963). A 
similar phenomenon has been observed with somatosensory stimulation, with experience-
dependent synaptic plasticity observed in the mouse barrel cortex (Trachtenberg et al. 2002). 
It follows that the stimulated activity of RGCs may therefore play a critical role in their 
growth, navigation, formation of synapses with central targets, and strengthening of synaptic 
connections. Cultured RGCs do not spontaneously extend axons, but will do so when 
exposed to electrical stimulation that mimics physiological levels of activity (Goldberg, 
Espinosa, et al. 2002). Conversely, blocking electrical activity with tetrodotoxin leads to 
RGC death in vitro (Lipton 1986). The retina contains a subpopulation of ipRGCs that 
express melanopsin, allowing them to respond directly to light stimulation (Provencio et al. 
2000; Foster et al. 1991). Infection of mouse RGCs with a virus carrying melanopsin resulted 
in an enhancement of axon regeneration after ONC (Li et al. 2016). Melanopsin 
overexpression enhanced the responsiveness of RGCs to light stimulation. Elevated levels of 
mTOR complex 1 (mTORC1) were observed in these cells, suggesting that electrical 
stimulation promotes RGC axon regeneration in an mTOR-dependent manner (Li et al. 
2016). This appears to suggest that artificially overexpressing melanopsin might promote 
regeneration of RGC axons in a manner similar to direct stimulation of mTOR pathways. 
However, it remains unknown whether other subtypes, rather than just ipRGCs, have the 
capacity to process opsin proteins. It is possible, for instance, that only ipRGCs possess the 
biomachinery required to recycle opsin photopigments, and that introducing melanopsin to 
other RGC subtypes would have a muted effect, if any, thereby limiting the long-term 
usefulness of an intervention that ultimately provides benefit to only a small fraction of the 
total RGC population. The study does, however, convincingly emphasize the potential link 
between elevating endogenous activity levels in RGCs and improving their capacity for 
regenerating their axons following injury. 
RGC activity can be chemogenetically increased by expressing designer receptors 
exclusively activated by designer drugs (DREADDs) such as hM3Dq (human M3 muscarinic 
DREADD receptor coupled to Gq) (Urban & Roth 2015). In the presence of the ligand 
clozapine-N-oxide (CNO), hM3Dq enhances the basal activity of neurons (Urban & Roth 
2015). Overexpression of virally-delivered hM3Dq in RGCs in conjunction with systemic 
delivery of CNO led to significant increases in axon regeneration after ONC (Lim et al. 
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2016). Intriguingly, exposing mice to high-contrast visual stimulation following ONC in the 
optic nerve of one eye and enucleation of the contralateral eye also promoted axon 
regeneration (Lim et al. 2016). These findings suggest that biased visual stimulation may be a 
useful non-invasive intervention to elevate RGC activity levels and promote axonal growth. 
Electrical stimulation therapy has already been applied to several ophthalmic diseases, 
including optic neuropathy and Best Vitelliform Macular Dystrophy, with improvements in 
visual acuity reported in several case studies (Fu et al. 2015). Transcorneal electrical 
stimulation also enhanced regeneration of RGC axons after ONC in rats (Miyake et al. 2007). 
In human patients with retinitis pigmentosa, a progressive neurodegenerative condition, 
RGCs in the central retina survive better than those in the periphery, possibly due to higher 
endogenous activity levels in the central retina (Santos et al. 1997). With these observations 
in mind, I chose to incorporate elevation of basal RGC activity via hM3Dq into my 
combinatorial therapy. 
 
5.1.3  |  shRNA against PTEN elevates mTOR activity  
 
One of the most common targets of CNS regeneration therapies is the phosphatase 
and tensin homolog (PTEN) gene. PTEN is an upstream inhibitor of mammalian target of 
rapamycin (mTOR), the hub of a signaling pathway that controls cell growth and protein 
synthesis (Lipton & Sahin 2014) (Figure 5.1). PTEN, acting through the phosphoinositide 3-
kinase (PI3K)-Akt-mTOR pathway, plays a central role in cell survival and proliferation (M. 
S. Song et al. 2012). Knocking down or suppressing PTEN activates the mTOR pathway, 
thereby promoting cell growth. Deletion of PTEN in a transgenic floxed mouse line led to 
enhanced survival and robust regeneration of RGC axons after optic nerve injury (Park et al. 
2008). PTEN deletion and elevation of mTOR activity have since been incorporated into 
many combinatorial therapies that successfully stimulated robust, long-distance RGC axon 
regeneration (Sun et al. 2011; de Lima et al. 2012; Kurimoto et al. 2010; Bei et al. 2016; Lim 
et al. 2016). However, many of these therapies use transgenic mice, which can require 
substantial investment of time and resources, and may ultimately be less clinically 
translatable. I chose to use a short hairpin RNA (shRNA) that silences PTEN, developed by 





Figure 5.1. The PI3K-Akt-mTOR pathway leads to cell survival and proliferation. 
Activation of PI3K catalyzes the conversion of PIP2 to PIP3. PIP3 then prompts 
phosphorylation of Akt, which leads to enhanced cell survival, growth, and proliferation via 
mTOR activation. The reverse reaction is catalyzed by PTEN, which converts PIP3 to PIP2. 
Feeding into the mTOR pathway, by activating PI3K or its subunits, or by suppressing 
PTEN, leads to greater survival and growth of the targeted cells. Figure adapted from 
(Dienstmann et al. 2014). 
 
5.1.4  |  The p110α subunit of PI3K elevates mTOR activity 
 
 PTEN dephosphorylates phosphatidylinositol-3,4,5-trisphosphate (PIP3), thereby 
reducing activation of PIP3’s downstream effectors 3-phosphoinositide-dependent kinase 
(PDK) and Akt (Maehama & Dixon 1998). PI3K catalyzes the reverse reaction (M. S. Song 
et al. 2012). Class IA PI3Ks consist of a p110 catalytic subunit that associates with a p85 
regulatory subunit (M. S. Song et al. 2012) (Figure 5.1). Among Class IA PI3Ks (p110α, 
p110β, and p110δ), those containing the p110α catalytic subunit are the most widely 
expressed. Extensive work conducted by Dr. Richard Eva demonstrates that inhibitors of 
p110α inhibit regeneration of axons in cultured mouse cortical neurons. With assistance from 
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Dr. Eva and Dr. Patrice Smith, I developed transgenic mice containing a cre-inducible 
hyperactive mutant (H1047K) form of the p110α subunit of PI3K. Preliminary studies 
performed by Dr. Patrice Smith using mice heterozygous for the p110α mutant suggested that 
hyperactive p110α may enhance RGC survival and axon regeneration. Therefore, I chose to 
evaluate the regenerative potential of homozygous p110α mutant mice. I also treated p110α 
mice with ChABC applied directly to the optic nerve lesion site to reduce the CSPG-mediated 
inhibition of axon growth within the glial scar. These studies, conducted with some assistance 
in dissections and data analysis from Dr. Joshua Cave and Dr. Amanda Barber, were 
designed to provide critical pilot data examining the effects of combined intrinsic and 
extrinsic therapies to promote axon regeneration in the optic nerve. 
 
5.1.5  |  Combining intrinsic and extrinsic stimuli 
 
 Experimental therapies that promote robust, long-distance axon regeneration in the 
optic nerve remain rare (de Lima et al. 2012; Lim et al. 2016; Kurimoto et al. 2010). I sought 
to integrate several of the intrinsic interventions described above with modification of glial 
scar CSPGs by ARSB (see Chapter 4). This combinatorial treatment included viral 
expression of hM3Dq and shPTEN in RGCs, as well as treatment with Zymosan, CPT-
cAMP, and ARSB following ONC. 
 
5.2  |  RESULTS 
 
5.2.1  |  Zymosan and CPT-cAMP promote axon regeneration 
 
 The pro-regenerative effects of Zymosan and CPT-cAMP were quantified previously 
(Figure 4.12). Intravitreal injection of Zymosan (12.5 μg/μL) and CPT-cAMP (50 mM) at 3 
d after ONC resulted in significantly (p = 0.0226) higher RGC axon regeneration at 14 dpc 
than injection of PBS (axons at 0.25 mm distal to the lesion [mean±SE]: 282±83.4 and 
42.3±11.1, respectively) (Figure 4.12). 
 
5.2.2  |  Enhancing electrical activity of RGCs with hM3Dq promotes axon regeneration 
 
 Endogenous levels of electrical activity in RGCs were elevated by viral expression of 
hM3Dq. In a pilot experiment, mouse eyes were injected intravitreally with 1 µL of AAV2-
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hSyn-HA-hM3Dq-mCherry (3.48×1012 genome copies (GC)/mL), and whole mount retinas 
were harvested at 14 days post injection. Expression of the hM3Dq-mCherry fusion protein 
was observed throughout the retina, indicating successful infection of RGCs (Figure 5.2a). 
To determine the effects of enhanced activity on RGC survival and axon regeneration, mice 
received either AAV2-hM3Dq or PBS control injection, followed by ONC at 14 d (Figure 
5.3a). The hM3Dq ligand CNO was injected intraperitoneally twice daily from 14 d to 28 d, 
at which point retinas and optic nerves were collected for analysis. Surviving RGCs were 
immunolabeled with the RBPMS antibody, which colocalized with mCherry (Figure 5.2c). 
RGC survival in hM3Dq-treated mice showed an increase vs. PBS controls that failed to 
reach statistical significance (p = 0.0532) (RGC survival as % of non-lesioned controls 
[mean±SE]: 17.2±1.73 and 9.11±1.78, respectively) (Figure 5.3b-c). Axon regeneration was 
significantly (p = 0.0164) enhanced in hM3Dq-treated mice (axons at 0.25 mm distal to the 
lesion [mean±SE]: 67.3±26.2 and 16.1±5.64, respectively) (Figure 5.3d-e). 
 
5.2.3  |  Stimulation of the mTOR pathway with PTEN shRNA promotes axon 
regeneration 
 
 Activation of the mTOR pathway was enhanced by intravitreal injection of a virus 
carrying shRNA against PTEN. Successful infection of RGCs in non-lesioned retinas was 
observed 14 days post injection of AAV2-shPTEN-GFP (1 µL, 6.52×1012 GC/mL) (Figure 
5.2b). To assess the ability of shPTEN to promote RGC survival and axon regeneration, 
intravitreal injection of AAV2-shPTEN or PBS was administered, followed by ONC at 14 d 
and collection of retinas and optic nerves at 28 d (Figure 5.3a). Surviving RBPMS+ RGCs 
colocalized with GFP (Figure 5.2d). RGC survival in shPTEN-treated mice was not 
significantly different (p = 0.8680) from PBS controls (RGC survival as % of non-lesioned 
controls [mean±SE]: 9.81±2.83 and 9.11±1.78, respectively) (Figure 5.3b-c). Axon 
regeneration was also slightly but not significantly (p = 0.1006) elevated (axons at 0.25 mm 






Figure 5.2. shPTEN and hM3Dq are expressed in virally infected retinal ganglion cells. 
(a, b) Micrographs showing the expression of shPTEN-GFP (green) and hM3Dq-mCherry 
(red) fusion proteins in the retinas of non-lesioned mice 14 d after intravitreal virus injection. 
(c, d) In lesioned mice, retinas collected at 14 dpc were immunolabeled with RBPMS, which 
colocalized with GFP and mCherry in surviving cells. (c’, d’) Insets showing co-labeled 









Figure 5.3 hM3Dq and shPTEN promote RGC survival and axon regeneration. (a) 
Experiment timeline. (b) Micrographs showing RBPMS+ immunolabeled RGCs from retinal 
whole mounts collected 14 d after ONC. Scale bar = 100 µm. (c) Graph showing 
quantification of RGC survival in hM3Dq- and shPTEN-treated and untreated mice expressed 
as % of cells versus non-lesioned control retinas. Statistical significance was determined by 
Student’s t-test. (d) Micrographs showing GAP-43-labeled optic nerves from mice injected 
with hM3Dq, shPTEN, or PBS. Arrows indicate lesion site. Scale bar = 200 µm, insets = 15 
µm. (e) Graph showing the number of regenerating axons at distances distal to the lesion site, 
displayed as mean±SEM. Statistical significance was determined by two-way ANOVA with 
Bonferroni post-hoc test for multiple comparisons. * p < 0.05. Blue asterisk indicates 




5.2.4  |  Hyperactive p110α promotes RGC survival and regeneration 
 
 The genotypes of wildtype mice and transgenic mice homozygous for the mutant 
hyperactive p110α subunit were confirmed by PCR. Genomic DNA was extracted from 
transgenic p110α mice and WT mice, and PCR was performed with the following primer 
pair: GGCTCAGTTGGGCTGTTTTG, forward; TCTGTGGGAAGTCTTGTCCC, reverse. 
The expected band (359 bp) was observed only in p110α mice (Figure 5.4). To determine the 
effects of enhancing mTOR pathway activation via hyperactive p110α, transgenic and 
wildtype mice were injected with AAV2-cre to induce expression of mutant p110α in the 
transgenic mice (Figure 5.5a). Both young (6-8 weeks) and aged (9-12 months) mice were 
included in each group, to evaluate whether age affects RGC survival or axon regeneration 
under these conditions. ONC was performed at 14 d, and retinas and optic nerves were 
collected at 42 d. RGC survival was significantly enhanced by p110α in both young mice (p = 
0.0139) (RGC survival as % of non-lesioned controls [mean±SE]: 10.7±0.67 in p110α vs. 
5.59±0.55 in WT) and old (p = 0.0075) mice (RGC survival as % of non-lesioned controls 
[mean±SE]: 12.8±1.10 in p110α vs. 4.53±0.67 in WT) (Figure 5.5b-c). Axon regeneration 
was significantly (p = 0.0234) elevated in young p110α mice vs. young WT controls (axons 
at 0.50 mm distal to the lesion [mean±SE]: 71.6±13.5 and 19.0±6.11, respectively) (Figure 
5.5d-e). However, aged p110α mice failed to show a significant increase versus WT controls 
(p = 0.0796) (48.9±21.1 axons). 
 After validating the efficacy of several intrinsic pro-regenerative stimuli, the 
effectiveness of a combined stimulus was assessed. mTOR pathway activity was elevated 
with hyperactive p110α, and an implant loaded with 5 μL ChABC (50 U/mL) was applied 
directly to the optic nerve lesion site to reduce extrinsic inhibition of axon regeneration. 
Transgenic p110α mice received intravitreal AAV2-cre or AAV2-eGFP, followed by ONC at 
14 d and either ChABC or PBS implant at 17 d. Nerves were collected at 42 d and stained 
with GAP-43 to detect regenerating axons (Figure 5.6a). As shown previously, p110α mice 
that received cre showed higher levels of axon regeneration than controls that did not receive 
cre (axons at 0.50 mm distal to the lesion [mean±SE]: 119±56.3 and 10.7±8.92, respectively) 
(Figure 5.6b-c). Axon regeneration in mice that received both cre and ChABC was higher 
than that of mice that received cre and PBS (axons at 0.50 mm distal to the lesion 
[mean±SE]: 217±119 and 119±56.3, respectively), although the difference was not 





Figure 5.4 Validation of hyperactive p110α genotype. DNA gel showing the products of a 
PCR reaction designed to isolate a sequence from the p110α mutant gene from transgenic 





Figure 5.5 Expression of hyperactive p110α promotes RGC survival and axon 
regeneration. (a) Experiment timeline. (b) Micrographs showing Brn3a immunolabeled 
RGCs in retinal whole mounts. Scale bar = 100 µm. (c) Graph showing quantification of 
RGC survival in young and aged p110α and wildtype mice expressed as % of cells versus 
non-lesioned control retinas. Statistical significance was determined by Student’s t-test. * p < 
0.05, ** p < 0.01. (d) Micrographs showing CTβ-labeled optic nerves from young p110α and 
wildtype mice. Arrows indicate lesion site. Scale bar = 100 µm. (e) Graph showing the 
number of regenerating axons at 0.5 mm distal to the lesion site, displayed as mean±SEM. 





Figure 5.6 ChABC enhances regeneration stimulated by hyperactive p110α. (a) 
Experiment timeline. (b) Micrographs showing GAP-43-labeled optic nerves from p110α 
mice injected with (i, iii) AAV2-cre or (v) AAV2-eGFP and treated with either (i) ChABC or 
(iii) PBS. Arrows indicate lesion site. Scale bar = 200 µm. Insets (ii, iv, vi) show GAP-43+ 
regenerating axons. Scale bar = 25 µm. (c) Graph showing the number of regenerating axons 
at 0.5 mm distal to the lesion site, displayed as mean±SEM. Statistical significance was 




5.2.5  |  Combination of intrinsic and extrinsic stimuli yields robust long-distance 
regeneration 
 
 I observed that combining intrinsic and extrinsic regenerative stimuli promotes RGC 
axon regeneration to a greater degree than either stimulus alone (Figure 4.13). The intrinsic 
stimuli characterized above activate distinctive, though occasionally overlapping, pathways. 
It was therefore hypothesized that combining several intrinsic stimuli in addition to reducing 
CSPG-mediated inhibition with ARSB might have an additive effect, leading to long-distance 
axon regeneration into and even beyond the optic chiasm. To test this, a combinatorial 
treatment was devised. Viruses containing hM3Dq and shPTEN were injected intravitreally, 
followed by ONC at 14 d, and intravitreal injection of Zymosan/CTP-cAMP and implantation 
of ARSB scaffolds at 17 d (Figure 5.7a). CNO was administered by intraperitoneal injection 
twice daily from 14 d to 42 d to activate the hM3Dq receptor. At 42 d, whole optic pathways 
were collected and stained with GAP-43. Robust regeneration of RGC axons was observed in 
mice receiving the combinatorial treatment (Figure 5.7b). GAP-43 axons were found 
entering the optic chiasm (Figure 5.7b-iii), and GFP+ axons were observed distally in the 
contralateral optic tract (Figure 5.7b-iv). GFP+ axons expressed GAP-43, indicating that 
GFP+ axons were genuinely regenerating axons rather than axons spared by an incomplete 
crush injury (Figure 5.8). When GAP-43+ labeled axons were compared to data from 
previous experiments (Figures 4.14, 4.17, 5.3), the combinatorial treatment revealed an 
enhancement of the number and distance of regenerating axons in comparison with individual 
treatments (Figure 5.7c). During development in mice, nearly all RGC axons cross at the 
optic chiasm into the contralateral optic tract. In the mice treated with the combinatorial 
therapy, however, misrouting of regenerating axons was observed at the optic chiasm (Figure 
5.9a-ii, b-ii), with GFP+ axons traveling not only into the contralateral optic tract (Figure 







Figure 5.7. Combining intrinsic and extrinsic stimuli promotes axon regeneration into 
the optic tract. (a) Experiment timeline. (b) Micrographs showing a representative optic 
pathway treated with the combined stimulus. (i) GFP+ axons in the optic pathway. Scale bar = 
500 µm. Insets show GFP+ axons in the (ii) optic nerve, (iii) optic chiasm, and (iv) 
contralateral optic tract. Scale bar = 25 µm. (c) Graph showing the number of GAP-43+ 
regenerating axons at distances distal to the lesion site, displayed as mean +/- SEM. Graph 






Figure 5.8. GFP+ regenerating axons express GAP-43. Micrographs show (i) co-
localization of shPTEN-GFP and GAP-43, (ii) GAP-43 alone, and (iii) shPTEN-GFP alone. 






Figure 5.9. Regenerating axons fail to navigate correctly at the optic chiasm. 
Micrographs showing GFP+ regenerating axons in the optic pathways (i) of two mice (a) and 
(b). In the optic chiasm (ii), axons lose their linearity and appear to navigate in multiple 
directions without a uniform path. Many axons correctly navigate to the contralateral optic 
tract (iii), but several aberrantly navigate to the ipsilateral optic tract (iv). Arrows indicate 
GFP+ regenerating axons. Scale bar = 500 µm, insets = 50 µm.  
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5.3  |  DISCUSSION 
 
 I characterized the effects of several intrinsic stimuli on RGC survival and axonal 
regeneration and found that combining these stimuli and simultaneously targeting CSPGs in 
the glial scar with ARSB led to a significant, additive enhancement of axonal regeneration. 
Regenerating axons were observed traversing the optic chiasm and entering the optic tract. 
These findings demonstrate the additive effects of activating discrete molecular pathways that 
support cell survival and regeneration. 
 
5.3.1  |  Intrinsic modifications of RGCs stimulate axonal regeneration 
 
 I showed that three classes of intrinsic manipulation—stimulation of inflammatory 
pathways, elevation of neuronal activity levels, and enhancement of mTOR pathway 
activation via PTEN suppression or PI3K hyperactivation—function both independently and 
in combination to enhance the regeneration of RGC axons after an ONC lesion. Of these, 
intravitreal injection of Zymosan and CPT-cAMP proved the most robust and reliable, 
although variation in experimental technique and the fact that studies were not run in parallel 
makes direct comparison inadvisable. My inclusion of Zymosan injection in a combined 
intrinsic/extrinsic therapy is described in Chapter 4. Here, I show that expanding this therapy 
to include hM3Dq and shPTEN viruses dramatically increases the number and length of 
regenerating RGC axons, resulting in robust, long-distance growth, with axons found deep in 
both the contralateral and ipsilateral optic tracts. 
 
Stimulation of inflammatory pathways 
 
 The discovery that lens injury stimulates axonal regeneration was among the earliest 
indicators that modulating factors intrinsic to RGCs could promote their survival and growth 
(Leon et al. 2000). Since then, numerous studies have sought to elucidate the underlying 
mechanisms by which ocular inflammation promotes the survival and axonal regeneration of 
RGCs. One important variable is timing. In rats, when Zymosan was injected at several time 
points following ONC, the 3 dpc time point showed the strongest pro-regenerative effect, 
with more than 1,000 GAP-43+ regenerating axons observed at 0.50 mm distal from the 
lesion site at 14 dpc, in comparison with ~750 axons when Zymsoan was injected at 0 dpc 
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and almost none when it was injected at 7 dpc (Yin et al. 2003). A study in mice found ~250 
axons at 0.50 mm at 14 dpc when Zymosan was injected at 0 dpc (Baldwin et al. 2015). My 
experiments in mice generally showed ~150-200 regenerating axons at 0.50 mm at 14 dpc 
when Zymosan was injected at 3 dpc. While direct comparisons with these other studies are 
not possible—due not only to the difference in species and injection time, respectively, but 
also to the fact that manual counting of axons often varies between observers, and therefore 
absolute values may be appreciably different in separate laboratories and even between 
studies from the same group—the regeneration I observed is of a similar order to that 
reported by others. 
The macrophage-secreted factor Ocm has been identified as a critical element of the 
inflammatory response that stimulates RGC growth (Yin et al. 2006; Yin et al. 2009). 
However, the precise signaling pathways within RGCs that control inflammation-induced 
regeneration remain under debate. It was reported that activation of the JAK/STAT3 pathway 
via repeated intravitreal injections of Pam(3)Cys, an agonist of toll-like receptor 2 (TLR2), 
transforms RGCs into a regenerative state and promotes axonal regeneration to an even 
greater degree than lens injury (Hauk et al. 2010). Pam(3)Cys stimulated higher levels of 
ciliary neurotrophic factor (CNTF) and GFAP expression in retinal glia, a phenomenon also 
observed after lens injury. In response to Pam(3)Cys administration, cultured RGCs exhibited 
elevated GAP-43 expression and extended longer neurites (Hauk et al. 2010). However, 
subsequent work demonstrated that administering a form of Zymosan specifically depleted of 
its ability to stimulate TLR2 while preserving stimulation of dectin-1 signaling (Ikeda et al. 
2008) nonetheless stimulated robust RGC axon regeneration (Baldwin et al. 2015). A similar 
phenomenon was observed in knockout mice that lacked MyD88, the downstream effector 
through which most TLR family members signal. Administering Zymosan in MyD88-/- mice 
promoted comparable regeneration to that observed in wildtype mice (Baldwin et al. 2015). 
This group then argued that TLR2 acts in a complementary manner with dectin-1, but that 
dectin-1 signaling is required for Zymosan-induced regeneration whereas TLR2 is not. This 
was demonstrated by administering intravitreal injections of curdlan, a form of β(1, 3)-glucan 
that signals through dectin-1, and observing that curdlan enhances axon regeneration via the 
dectin-1 downstream effector CARD9 (Baldwin et al. 2015). Precisely how dectin-1 or other 
signaling pathways transform RGCs into a regenerative state remains unknown. 
 The clinical relevance of inflammatory signaling to support neuronal growth and 
regeneration is ambiguous. On the one hand, Zymosan injection is most effective at a delay 
of 3 d after the initial ONC injury, suggesting that robust regeneration is possible even when 
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treatment is delayed (Yin et al. 2003). This observation was confirmed by my own findings. 
Similarly, it was observed that administering β-glucan 2 d after ONC was equally effective as 
administering it at the time of ONC, suggesting an extended therapeutic window (Baldwin et 
al. 2015). In clinical situations where axonal regeneration is desired, such as acute spinal cord 
injury or neurodegenerative diseases like glaucoma, interventions are rarely available 
immediately after an injury. Therefore, therapies that can be delivered after a significant 
delay are highly attractive. However, stimulating ocular inflammation to promote 
regeneration naturally produces a set of side effects, many of which are potentially damaging. 
For instance, intraspinal injections of Zymosan promoted regeneration of DRG axons, but the 
concurrent activation of macrophages also leads to toxicity that destroyed proximate axons 
(Gensel et al. 2009). Toxicity was similarly observed after Zymosan injections into the eye, 
generating symptoms reminiscent of experimental autoimmune uveitis (Baldwin et al. 2015). 
In my experiments, mouse eyes injected with Zymosan were visibly inflamed, with retinal 
folding and detachment, similar to the results reported by others (Baldwin et al. 2015). To 
maximize clinical relevance, therefore, future studies will likely need to expand our 
understanding of the specific signaling pathways downstream of inflammatory stimuli that 
modify RGCs and enable them to regenerate their axons, and target these pathways directly. 
 
Elevation of neuronal activity levels 
 
 I used an AAV2 vector carrying hM3Dq to elevate endogenous activity levels in 
RGCs and promote axonal regeneration. My pilot results showed a significant enhancement 
of regeneration, but not a significant enhancement of cell survival. The absence of a robust 
effect similar to that observed in previously published work (Lim et al. 2016)—which found 
>150 regenerating axons at 0.50 mm in comparison to my findings of <50 axons at this 
distance—likely derives from the small number of animals used (n = 5) and a failure to fully 
optimize all experimental conditions. Additionally, it must be acknowledged that 
electrophysiology was not performed to validate that hM3Dq was enhancing action potentials 
in RGCs. However, the fact that axon regeneration was improved suggests that hM3Dq was 
indeed elevating RGC activity and modifying the cells’ intrinsic state. Another possible 
explanation for the difference in magnitude in comparison with the previous study is the 
viruses used. I administered injections of AAV2-hSyn-HA-hM3Dq-mCherry, which 
generates a fusion protein, hM3Dq-mCherry, whereas Lim et al. used AAV2-hSyn-HA-
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hM3Dq-IRES-mCitrine. The internal ribosome entry site (IRES) element facilitates 
translation of two distinct proteins, meaning hM3Dq and mCitrine will be expressed 
independently in infected RGCs. In my case, the fusion of mCherry to the hM3Dq receptor is 
not expected to dramatically affect its function; however, it is impossible to rule out this 
possibility. 
 The mechanisms by which neural activity stimulates RGC growth and regeneration 
are not entirely characterized, but several key signaling pathways have been identified. 
Cultured RGCs exposed to physiological levels of electrical stimulation were observed to be 
more responsive to BDNF and other trophic factors (Goldberg, Espinosa, et al. 2002). When 
RGCs are depolarized or subjected to cAMP elevation, levels of the TrkB receptor, which 
binds BDNF, undergo an abrupt increase at the cell surface, indicating recruitment of TrkB 
from the intracellular space to the plasma membrane (Meyer-Franke et al. 1998). cAMP 
elevation also increases TrkB receptor gene expression (Deogracias et al. 2004). cAMP 
appears to be critical for activity-dependent enhancement of neuronal growth, as blocking 
adenylate cyclase, which lies upstream of cAMP, abolishes the positive effect of electrical 
stimulation (Goldberg, Espinosa, et al. 2002). Blocking cAMP’s downstream partner PKA 
has a similar effect (Meyer-Franke et al. 1995). cAMP has been shown to influence the 
functioning of NMDA receptors in RGCs (Dong et al. 2008). It is worth noting that cAMP 
potentiates the pro-regenerative effects of Zymosan and facilitates Ocm binding to the inner 
retina (Yin et al. 2006). This implies that elevated activity and inflammatory stimulation may 
function through partially overlapping pathways. In melanopsin-expressing ipRGCs, light 
activates a signaling pathway mediated by the GPCR Gq/11, which feeds into the mTOR 
pathway (Li et al. 2016). Silencing ipRGCs suppressed activation of mTOR and abolished the 
growth-enhancing effects of light stimulation (Li et al. 2016), suggesting that mTOR also 
overlaps with activity dependent signaling in RGCs. Future studies will need to determine 
whether different types of electrical activity stimulate different molecular pathways. It has 
already been demonstrated that the pattern of stimulation is critical (Corredor & Goldberg 
2009). Retinal prostheses have been designed to replace damaged or degenerated 
photoreceptors, and it seems clear that the patterns of activity produced by these devices 





Enhancement of mTOR pathway activation 
 
 I utilized two distinct stimuli to enhance mTOR activity in RGCs: suppression of 
PTEN with shRNA and activation of PI3K with transgenic mice expressing a hyperactive 
p110α subunit. In previously published studies, transgenic floxed PTEN-/- mice demonstrated 
significant increases in axon regeneration following cre injection (Park et al. 2008). The 
magnitude of these increases was enormous, with ~1,500 CTβ+ regenerating axons estimated 
at 0.50 mm distal from the lesion site at 14 dpc. There are several reasons why the levels of 
regeneration observed in our cohort of mice treated with shPTEN (~100 axons at 0.50 mm at 
14 dpc) did not match the magnitude of the effect seen previously. Firstly, as mentioned 
previously, comparison of absolute axon counts is generally unreliable due to differences in 
counting technique between observers; it is possible that my counts underestimate the 
magnitude of the effect, or that published reports overestimate theirs, or both. Secondly, my 
low animal number reduced the statistical power of the study. Any errors in the injection 
would thus be magnified; indeed, shPTEN-GFP expression did not appear equally robust in 
all animals. Retinas where shPTEN-GFP expression was high correlated with those that 
exhibited the strongest effect on axon regeneration, indicating that variable injection 
efficiency may underlie the somewhat diminished effect of the cohort overall. Additionally, 
cre-induced knockdown of PTEN in transgenic mice is likely to be more efficient and affect 
more RGCs than injections of shPTEN. Nonetheless, my shPTEN did appear to enhance 
regeneration, with a very strong effect observed in some of the experimental animals. 
 PTEN suppression elevates activation of the mTOR pathway, which has been 
repeatedly linked to gains in cell growth and proliferation. In species that naturally regenerate 
their axons, mTOR signaling has been shown to play an important role (Barber et al. 2017). 
These include Drosophila (Y. Song et al. 2012), C. elegans (Byrne et al. 2014), and zebrafish 
(Abe et al. 2010; Hirose et al. 2014). It has been suggested that suppressing PTEN may be 
less effective than directly activating its counterpart PI3K. I found that introducing a 
hyperactive mutant of p110α significantly enhanced the regeneration of severed RGC axons, 
and that this effect was enhanced by the application of ChABC to the lesion site. Ongoing 
work by Dr. Richard Eva aims to explore the complex role of PI3K and its product PIP3 in 
stimulating the mTOR pathway and boosting axonal growth and regeneration. Future studies 
will address this pathway in greater depth, evaluating the differences between p110α, which 
is expressed at low levels in adult RGCs, and p110δ, which is absent in adult RGCs but has 
been shown to play a pivotal role in the regeneration of sensory axons (Eickholt et al. 2007). 
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 mTOR activation seems to preferentially preserve α-RGCs (Duan et al. 2015). Even 
in the absence of intervention, α-RGCs are more likely than other RGCs to survive following 
an ONC injury (Duan et al. 2015). When mice were treated with AAV2-shPTEN, nearly all 
regenerating axons were from α-RGCs (Duan et al. 2015). α-RGCs selectively express the 
protein osteopontin (OPN) and receptors for insulin-like growth factor 1 (IGF-1). The same 
study found that administering OPN and IGF-1 yielded a regenerative effect comparable to 
that of shPTEN, indicating that directly targeting α-RGCs may be equivalent to enhancing 
mTOR activation by suppressing PTEN (Duan et al. 2015). 
 




RGCs can be classified into more than 30 subtypes by features such as morphology, 
gene expression, and physiology (Sanes & Masland 2015). With the increasing availability of 
molecular markers and transgenic mice with labeled subpopulations of RGCs, new findings 
are emerging that suggest different RGC subtypes respond to separate stimuli and exhibit 
differential survival and regeneration depending on the type of intervention used (Dhande & 
Huberman 2014). As described above, suppressing PTEN overwhelmingly favors survival of 
α-RGCs, which comprise roughly 6% of the total RGC population in healthy retinas, but 
account for more than 90% of regenerating cells after treatment with shPTEN (Duan et al. 
2015). However, in a related study, it was discovered that overexpressing the transcription 
factor Sox11 promoted RGC axon regeneration but simultaneously killed nearly all α-RGCs, 
providing evidence that α-RGCs are not the only regeneration competent subtype of RGCs 
(Norsworthy et al. 2017). Fascinatingly, mice with double knockout for PTEN and Sox11 had 
fewer total numbers of regenerating axons that PTEN knockout alone, and yet the axons that 
did regenerate grew longer distances than those in the PTEN-only control (Norsworthy et al. 
2017). These findings illustrate the complexity and diversity of RGCs and underline the 








In my comparison of p110α and WT mice, I found that p110α mice exhibited 
enhanced cell survival after ONC when compared with WT controls, but that only young (6-8 
weeks) p110α mice showed a significant elevation of axon regeneration, while aged (9-12 
months) p110α mice did not. This study emphasizes the widely observed phenomenon that 
the regenerative capacity of CNS neurons declines with age. In a similar study, PTEN 
deletion in aged mice failed to promote regeneration of injured spinal cord axons to the same 
degree as it did in young mice (Geoffroy et al. 2016). In cultured rat RGCs isolated from 
animals at different stages of development, embryo-derived cells exhibit substantially better 
growth potential than do cells from neonates (Goldberg, Espinosa, et al. 2002). Dramatic 
changes in gene expression occur after birth, and it has been proposed that neurons transform 
from an “axon outgrowth mode” to a “synapse formation and stabilization mode” at this time 
(He & Jin 2016). For instance, mTOR expression progressively declines over the course of 
development, rendering more advanced axons less capable of regeneration (Park et al. 2008; 
Belin et al. 2015). Intriguingly, PNS neurons do not show this age-related reduction of 
mTOR expression, perhaps explaining their sustained regenerative capacity in adulthood 
(Belin et al. 2015). Expression levels of kruppel-like factors (KLFs), which modulate the 
intrinsic growth potential of neurons, also drop in RGCs around birth (Moore et al. 2009). It 
has therefore been proposed that modifying epigenetic regulators, such as histone 
acetyltransferases, may enable neurons to more easily return to an active growth state similar 
to that observed during development (He & Jin 2016). 
It has been proposed that age affects not only the intrinsic state of neurons, but also 
their environment. In the brain, advancing age correlates with an increase in the ratio of 4S to 
6S GAG chains in endogenously expressed CSPGs (Foscarin et al. 2017). A similar shift was 
observed over the course of early development (Miyata et al. 2012). Future studies might 
evaluate whether injury-induced deposition of CSPGs follows a similar pattern. 
 




As I observed in my mice treated with the combinatorial therapy, strong pro-
regenerative stimuli can induce extensive axonal growth, but many of the regenerating axons 
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exhibit unusual growth paths and aberrant navigation at the optic chiasm. This phenomenon 
has been reported by other groups. One study used light sheet fluorescence microscopy 
(LSFM) to generate three-dimensional images of whole cleared optic nerves demonstrating 
that the regenerating axons of PTEN/SOCS3 knockout mice as well as PTEN knockout mice 
treated with Zymosan and CPT-cAMP both displayed highly irregular growth paths, often 
failing to decussate and enter the contralateral optic tract, instead traveling into the ipsilateral 
optic tract, contralateral optic nerve, or even back into the lesioned nerve from which they 
had originally extended (Luo et al. 2013). Some axons were found innervating the SCN, 
although the identity of these RGCs was unclear (Luo et al. 2013). A related study used the 
CNTFRα “super-agonist” DH-CNTF to stimulate long-distance regeneration of RGC axons, 
and observed axonal branching and misguidance at the optic chiasm (Pernet et al. 2013). 
Three-dimensional reconstructions of individual Thy1-YFP+ axons revealed that many RGC 
axons extend their axons over long distances even in the absence of a stimulus, undertaking 
tortuous, looping paths that fail to penetrate the lesion site (Bray et al. 2017). Axons that did 
cross the lesion following treatment with CNTF also exhibited complex branching and 
turning (Bray et al. 2017). These mixed results have led to an intense focus on defining 
rigorous methods for determining whether axons extending beyond the site of an optic nerve 
lesion are in fact evidence of regeneration, or if they may be surviving axons spared by an 
incomplete lesion (Fischer et al. 2017). More research is required to understand whether 
different stimuli lead to more or less efficient pathfinding in RGCs, and whether altering the 




 Even in cases where RGC axons regenerate long distances, it remains debated 
whether they have the capacity to form functional synapses and restore visual behavior. In 
one study, an optic tract transection was performed to limit the distance necessary for axons 
to travel from the lesion to their targets in the brain (Bei et al. 2016). Axons stimulated by co-
deletion of PTEN and SOCS3, or by overexpression of OPN, IGF-1, and CNTF, were 
observed forming functional synapses in the SC; however, this innervation did not result in 
restoration of visual behaviors (Bei et al. 2016). It was hypothesized that this failure was due 
to lack of remyelination of regenerated axons, rendering them unable to conduct action 
potentials. Correspondingly, administering voltage-gated potassium channel blockers restored 
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conduction in regenerated axons and led to a significant enhancement of visual acuity, 
suggesting that remyelination is a critical barrier for RGCs to restore visual function (Bei et 
al. 2016). Curiously, another study found that axons stimulated to regenerate by PTEN 
deletion and administration of Zymosan and CPT-cAMP displayed signs of spontaneous 
remyelination and reassembly of nodes of Ranvier, even in axonal regions distal from the 
lesion (Marin et al. 2016). Additional studies will be required to validate these findings and 
expand our understanding of whether and how regenerated axons remyelinate and form 
functional synapses in the brain. 
 
5.3.4  |  Summary 
 
 In this chapter, I have demonstrated the pro-regenerative effects of a diverse set of 
intrinsic stimuli, including inflammatory signaling, neural activity levels, and activation of 
the mTOR pathway. I combined these interventions with ARSB administered at the ONC 
lesion site and observed robust long-distance regeneration of RGC axons. I found, in 
agreement with the findings produced by other groups, persistent errors in pathfinding of 
regenerating axons, with growth cones entering the ipsilateral optic tract or contralateral optic 
nerve rather than decussating at the optic chiasm and extending into the contralateral optic 
tract. However, by demonstrating the effectiveness of a combinatorial stimulus that 
incorporates direct modification of the inhibitory extracellular matrix at the glial scar using a 
clinically safe enzyme, I have advanced the tools available for promoting RGC growth with 
more translatable methods. Future studies will need to examine the extent to which ARSB 
can be combined with intrinsic stimuli that do not produce high-risk side effects, and whether 





CHAPTER 6: CONCLUSIONS AND PERSPECTIVES 
 
 The objective of this thesis was to examine the dynamics of CSPG expression in the 
glial scar, and to investigate the potential of modifying CSPGs to enhance the regeneration of 
RGC axons after optic nerve injury. I found that selectively altering the sulfation pattern of 
GAG chains with the enzyme ARSB results in a robust and reliable increase in the number 
and distance of regenerating axons following optic nerve crush. ARSB is a human enzyme 
that has been approved for clinical use, making it a promising candidate for future 
combinatorial therapies that seek to promote regeneration of damaged CNS neurons in 
multiple contexts. 
 
6.1  |  OVERVIEW OF FINDINGS 
 
In Chapter 3, I described a surgical technique for delivering therapeutic enzymes to 
the mouse optic nerve. I demonstrated that the enzymes ARSB and ChABC remain active in 
vivo and successfully penetrate into the axon fibers of the optic nerve, and quantified the 
digestion products of ChABC to show that the enzyme was actively modifying CSPGs. This 
protocol should prove useful for future studies that seek to modify the ECM in the optic 
nerve, an approach often ignored in regeneration studies due to its technical difficulty. 
In Chapter 4, I showed comprehensive evidence that CSPGs, including the highly 
growth-inhibitory 4S GAGs, are upregulated within optic nerve and spinal cord lesions in 
mice and rats. I found that these changes were associated with reactive astrogliosis, and that 
injuring the optic nerve stimulates gliosis not only at the site of the lesion, but also in the 
ganglion cell layer of the retina. RGC axons fail to regenerate beyond the lesion site, a 
phenomenon that appears to be at least partially due to CSPGs, as I observed dystrophic axon 
endbulbs localized in proximity with high areas of CSPG deposition. I then used two CSPG-
targeting enzymes, ARSB and ChABC, to modify CSPGs in the lesioned optic nerve, and 
showed a significant enhancement of axon regeneration when enzymes were administered in 
conjunction with Zymosan/CPT-cAMP, a growth-promoting inflammatory stimulus (Figure 
6.1). Neither ARSB nor ChABC altered the formation of an astrocytic scar, although ChABC 
caused an elevation of Iba1 expression at the lesion site. ChABC also destroyed PNNs in the 
cortex, whereas ARSB left these structures intact. Together, these findings provide strong 
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evidence that modifying GAG chain sulfation with ARSB could be combined with existing or 
novel intrinsic pro-regenerative therapies to enhance their effectiveness without posing 
significant clinical risks. 
In Chapter 5, I assessed several potential intrinsic stimuli and characterized their 
effects on RGC survival and axon regeneration. These included inducing a sterile 
inflammatory response in the retina (Zymosan), elevating endogenous activity levels in RGCs 
(hM3Dq), and activating the PI3K-mTOR pathway (shPTEN and hyperactive p110α). I 
observed that these stimuli are mutually enhancing when combined, and found that a 
combinatorial treatment which included Zymosan/CPT-cAMP, shPTEN, hM3Dq, and ARSB 
stimulated robust, long-distance regeneration of RGC axons, with many axons crossing the 
optic chiasm and entering the contralateral optic tract. I noted that, unlike during 
development when extracellular guidance cues populate the optic pathway to facilitate axonal 
navigation, many regenerating axons in the adult mice exhibited aberrant pathfinding, with 
axons diverging at the optic chiasm and entering the ipsilateral optic tract. Modifying the 
extracellular matrix at the ONC lesion site significantly improved axonal regeneration, but 
the environment at the optic chiasm remains a key obstacle for regenerating axons before 
robust repair can be achieved. 
As of yet, no therapies aimed at stimulating repair of CNS axons have entered clinical 
trials. Several critical challenges remain before true translational treatments can be 
developed. These include limitations on the number of axons that regenerate even when long-
distance growth is observed, impaired navigation and pathfinding of regenerating axons, and 
the existence of risks and side effects from gene therapies and therapeutic agents introduced 
into the visual system. Resolving these issues will be vital before viable translational 




Figure 6.1. Summary of findings. Removing 4S groups from the non-reducing end of CS 
GAG chains with ARSB enhanced RGC axon regeneration in the presence of an intrinsic pro-
regenerative stimulus. Modification of the ECM alone, with ARSB or ChABC, was 
insufficient to stimulate regeneration. Intrinsic modification of RGCs with Zymosan and 
other stimuli combined in an additive fashion to collectively promote axon regeneration, 
especially in combination with ARSB. 
 
6.2  |   LONG-DISTANCE RGC AXON REGENERATION AND RECOVERY OF 
FUNCTIONAL VISION 
 
 During development, RGC axons extend from the retina through the optic nerve, 
where most decussate at the optic chiasm before traveling up the optic tract and synapsing at 
central targets including the SCN and the LGN in the thalamus. Recapitulating this growth 
pathway is the primary objective of regenerative therapies in the visual system. As strategies 
for inducing and sustaining RGC axon regeneration have improved, more studies have 
demonstrated long-distance growth of axons, including, in some cases, the establishment of 
connections in the brain and the recovery of functional visual behaviors. 
 In mice subjected to co-deletion of PTEN and SOCS3, regenerating axons were 
observed traversing the optic chiasm (Sun et al. 2011). A combinatorial treatment that 
included PTEN deletion and two injections of Zymosan and CPT-cAMP, many axons crossed 
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the chiasm into the optic tract and some, visualized with CTβ, were found in the ventral LGN 
(Kurimoto et al. 2010). The same treatment was later shown to promote regeneration of axons 
into the SCN, LGN, superior colliculus (SC), and medial terminal nucleus (MTN), and to 
restore some visual behaviors, although gains in visual function were not sustained (de Lima 
et al. 2012). It should be noted that the degree of innervation was very low, with just a 
handful (< 10) of axon terminals detected in some regions (de Lima et al. 2012), and yet these 
numbers were reported to be sufficient for restoring behaviors such as the optokinetic reflex 
(OKR), which relies on the innervation of dsRGCs into multiple brain regions, including the 
LGN, SC, and accessory optic system (AOS). It must also be noted that while observers in 
this study were blinded to the experimental conditions, they were not blinded to the direction 
of the rotating drum, providing an opportunity for false positive detection of the OKR, which 
the authors acknowledge (de Lima et al. 2012). They also report that mice from their 
treatment group that did not show histological reinnervation of target regions were excluded 
from the statistical analysis of the OKR. These caveats make the assertion that visual 
behaviors were rescued by PTEN/SOCS3 deletion somewhat problematic, and robust, 
unequivocal evidence of recovered visual function remains to be seen in virtually all of the 
treatments described here. 
 In another study, a combination of mTOR stimulation using constitutively active ras 
homolog enriched in brain 1 (cRheb1) alongside biased visual stimulation yielded 
regeneration of axons into the SCN, LGN, SC, MTN, pretectum, and olivary pretectal 
nucleus (OPN) (Lim et al. 2016). Using a transgenic mouse line that express GFP in cochlin+ 
RGCs, where most labeled RGCs are of the α-RGC subtype, the same group showed that α-
RGCs appear to navigate to appropriate target regions and avoid non-target regions, 
suggesting that subtype-specific pathfinding behavior is preserved in adult regenerating axons 
under these experimental conditions (Lim et al. 2016). The presence of regenerating axons in 
the ipsilateral optic tract was not quantified, as I and others have consistently observed, and 
images were not provided, making it difficult to definitively argue that misguidance did not 
occur. These mice also showed improvements in some behavioral measures of visual 
function, including the OKR and looming response, but not others, such as direct pupil 
response, consensual pupil response, and the visual cliff assay (Lim et al. 2016). It is worth 
noting, again, that the observer of the OKR was not blinded to the direction of rotation, 
allowing for possible false positive detection; additionally, in this study, while it is stated that 
the observer was blind to the experimental conditions when counting the number of 
regenerating axons, it is not stated that they were blinded to the experimental conditions 
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when performing behavioral studies. If this is indeed the case, it could undermine the 
reported findings, given the high degree of subjectivity in measuring the OKR. 
 
6.3  |  NAVIGATION OF REGENERATING AXONS 
 
While many experimental treatments, such as those mentioned above, have shown 
success in regenerating RGC axons, it remains the case that even in the best therapies, only a 
fraction of RGCs project their axons as far as the optic chiasm, with most stalling at various 
points along the optic nerve. Numerous groups have reported that regenerating RGC axons 
are prone to misguidance, turning back on themselves, forming branches, and/or 
demonstrating inadequate pathfinding at the optic chiasm (Figure 6.2), a key decision point 
in both development and regeneration states (Luo et al. 2013; Pernet et al. 2013; Berry et al. 
1999). The failure of axons to regenerate beyond the chiasm may be due in part to inhibitory 
cues in the microenvironment, including CSPGs (Wang et al. 2012; Burnside & Bradbury 
2014; Rodriguez-Grande et al. 2014; Deguchi et al. 2005). Pathfinding errors likely also arise 
from the lack of guidance cues in the adult visual pathway and/or from changes in the 
expression of their respective receptors on RGCs (Springer et al. 1990; Burnside & Bradbury 
2014). Some experiments have generated data implying that the chiasm itself is inherently 
inhibitory to retinal axons, or at least promotes their divergence. For instance, co-culture of 
retinal neurites with optic chiasm explants led to a reduction in neurite outgrowth (Wang et 
al. 1996). It is known that RGC axon bundles defasciculate at the optic nerve-chiasm junction 
and fasciculate at the optic chiasm-tract junction (Jeffery 2001; Plas et al. 2005). In my own 
data, I observed that regenerating axons which appeared more or less linear, or at least were 
traveling unidirectionally, within the optic nerve were far more disorganized upon entering 
the optic chiasm. Notably, cells near these junctions have been observed to express CSPGs 
(Reese et al. 1997; Leung et al. 2003), although I did not specifically observe that in my 
studies. Whether CSPGs or other inhibitory ECM proteins may prompt axon rearrangement 
at both ends of the optic chiasm remains to be seen. Regardless, improving our understanding 
of how the extracellular environment changes at these key transition points will prove 





Figure 6.2. RGC axon misguidance at the optic chiasm. (A) After optic nerve injury, 
regenerating RGC axons are prone to misguidance at various points along the optic pathway. 
Panel adapted from (Pernet & Schwab 2014). (B) Three-dimensional reconstruction of 
regenerating axon tracts at the optic chiasm using light sheet fluorescence microscopy shows 
irregular pathfinding of individual axons, with some crossing ipsilaterally, others 
contralaterally, and others migrating into the contralateral optic nerve or back into the nerve 
through which they originally grew. Panel adapted from (Luo et al. 2013). 
 
 Navigational challenges also affect how cells ultimately find their terminals in the 
brain, where RGCs must connect with one of several target regions (Figure 6.3). If RGC 
axons regenerate long distances but fail to synapse at the proper targets, it is possible—and 
indeed likely—that few beneficial outcomes will be observed. It should be acknowledged, 
however, that even a low number of functional synapses may provide meaningful therapeutic 
benefit in some cases. Studies have suggested that as little as 5-10% of the original 
population of axonal connections may be required for meaningful recovery of some visual 
functions (Bregman et al. 1995). Increased sensitivity to light/dark boundaries could improve 
quality of life for patients even if higher order visual functioning remains impaired. 
Additionally, different RGC subtypes appear to have different capacities to regenerate, and, 
as noted in previous chapters, certain stimuli promote preferential growth from some 
subpopulations over others. As the functions of these different subtypes become more well 
established, prioritizing the regeneration of certain cells to their proper targets will be an 
increasingly important priority. The navigational aptitude of different RGC subtypes has not 




Figure 6.3. Summary of barriers to regeneration of visual pathways. Before translational 
regenerative therapies can migrate into the clinic, several prominent challenges must be 
overcome. These include barriers to cell survival in the retina and regeneration through the 
optic nerve, navigation of growing axons, reinnervation of accurate targets in the brain, and 
restoration of functional visual circuits. Figure adapted from (Crair & Mason 2016).  
 
 Many of the most successful pro-regenerative stimuli activate oncogenic pathways or 
knock out tumor suppressor genes such as PTEN. Some have warned that these strategies 
may be clinically unviable, given the potential risks to human health (Barber et al. 2017). 
Discovering ways to mediate these risks may be one path forward; investing in therapies that 
draw from more clinically plausible solutions is another. So far, the experimental therapies 
that produce robust regeneration tend to combine multiple stimuli to achieve long-distance 
regeneration, potentially compounding these risk factors. Future research should prioritize 
therapies with lower barriers to use in human patients. 
 
6.4  |  TRANSLATIONAL POTENTIAL OF PRO-REGENERATIVE THERAPIES 
  
 The extent to which experimental therapies that promote RGC survival and axon 
regeneration in animal models will translate to human patients remains unknown. As noted 
above, the severity of many forms of blindness and visual impairment and the sensitivity of 
RGCs mean that even a small number of functional connections has the potential to provide 
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substantial gains in function and improvements in quality of life. However, many of the most 
successful interventions in animals are unlikely to be suitable for clinical use. Activating 
inflammatory pathways causes retinal folding and detachment (Baldwin et al. 2015). The role 
of PTEN in cell growth was first identified as a common mutation in cancers, including 
glioblastoma (Li et al. 1997). Forced expression of c-myc, another cancer-related gene, was 
also found to promote regeneration (Belin et al. 2015). Given the oncogenic risks associated 
with knocking out a tumor suppressor gene such as PTEN or overexpressing an oncogene 
such as Myc, their use in experimental therapies has been questioned (Barber et al. 2017). 
Future strategies will need to prioritize clinically safe treatments that promote regeneration 
without risking severe side effects. 
 My discovery that ARSB enhances the regeneration of RGC axons is an encouraging 
one for precisely this reason. ARSB, a human enzyme, is currently approved for clinical use 
and has been utilized as an enzyme replacement therapy for MPS VI for more than a decade. 
However, there are caveats. Firstly, delivering ARSB to the optic nerve in humans will 
naturally be far more challenging than doing so in mice or other animals. One of the benefits 
of many existing therapies for visual system pathologies is the ability to inject agents such as 
viruses or small molecules directly into the eye, where they diffuse through the vitreous 
humor and eventually reach the retina. Directly targeting the optic nerve would require 
surgery, which carries many risks. Similarly, it should be noted that the type of injury I used 
in my studies, optic nerve crush, is rarely seen in humans. Far more common in the visual 
system are neurodegenerative conditions such as glaucoma, which, while they are known to 
be associated with CSPG elevation, occur over a much longer time course and lack a specific 
lesion site. It is possible, then, that ARSB may be more applicable to acute injuries of the 
brain or spinal cord, where the glial scarring and focal CSPG expression are far more 
common. This is a promising direction for future research. Still, it remains possible that 
ARSB might improve outcomes in glaucoma or other related visual system pathologies, 
whether by alleviating 4S GAG deposition in the ganglion cell layer of the retina, or even by 
using gene therapy to engineer expression of ARSB by glial cells or by RGCs themselves. 
Regardless of the approach, it will be crucial to address features of the extracellular 
environment when designing therapies to stimulate regeneration of axons in the visual system 
or elsewhere in the CNS. As this thesis demonstrates, inhibitory features of the extracellular 
matrix are critical obstacles that prevent the effective extension of new axons, and therefore 
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